A Phase 3 interventional study of Niraparib and Dostarlimab (TSR-042) in Ovarian Neoplasms and Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma, sponsored by Tesaro, Inc.. Active, not recruiting at 182 sites in 19 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.
Among the 44 studies testing niraparib in Ovarian Neoplasms, this one has the largest enrollment, is one of 5 that started in 2018, is one of 7 in phase 3, reaches primary completion later than 2 of the 13 other live ones, and was the 13th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:
University of Miami · Sites in United States, Nigeria
Ages 18+ · Women only
MedSIR · Sites in Spain
Ages 18+ · Women only
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Sites in Italy
Ages 18+ · Women only
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 18+ · Women only
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+ · Women only
By country, each count listing its studies:
niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, niraparib is the treatment under test here. Read study by study →
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 22 · Phase 3 7 · Phase 4 5
First in 2008; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,400 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 41 across the 44 interventional studies. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tesaro, Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
31 studies in Ovarian Neoplasms by GlaxoSmithKline: 5 open now, 7 under way, 5 of them phase 3. Of 22 finished, 16 (73%) have results posted.
Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, this one has the largest enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2018, is one of 7 in phase 3, and was the 23rd registered.
GlaxoSmithKline’s Ovarian Neoplasms studies by the year they started, since 1997.
2 of the studies testing niraparib in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04641247GlaxoSmithKlineA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | 2026-12-28 |
| NCT06594679Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoA Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) | 2027-03-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies testing niraparib in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 31 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the unmet medical need of participants with advanced or metastatic ovarian cancer, this study design will enable investigators to provide participants with current SOC for ovarian cancer for the duration of the study. This is a global, multicenter, randomized, double-blind, controlled Phase 3 study that will primarily compare the progression-free survival (PFS) for participants receiving dostarlimab with SOC chemotherapy +/- bevacizumab followed by niraparib and dostarlimab maintenance +/- bevacizumab versus participants receiving SOC with chemotherapy followed by niraparib maintenance. This comparison will be investigated in participants of newly diagnosed stage III or IV advanced non-mucinous epithelial ovarian cancer participants and also to compare PFS of all participants with Stage III or IV high-grade non-mucinous epithelial ovarian cancer treated with platinum-based combination therapy, dostarlimab (TSR-042), and niraparib to SOC platinum-based combination therapy. The currently recommended SOC therapy for the first line treatment of Stage III or IV ovarian cancer is the combination of paclitaxel and carboplatin, with or without concurrent and maintenance bevacizumab. Participants will receive SOC during the chemotherapy Run-In period (cycle 1) before randomization to study treatment (cycle 2). Concurrent bevacizumab use must be determined prior to randomization at cycle 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive SOC (carboplatin+paclitaxel+/-bevacizumab) in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment with dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/-bevacizumab along with niraparib placebo and dostarlimab placebo
Drug: Standard of care · Drug: Dostarlimab-Placebo · Drug: Niraparib-Placebo
Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/- bevacizumab with niraparib and dostarlimab placebo
Drug: Niraparib · Drug: Standard of care · Drug: Dostarlimab-Placebo
Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab, and maintenance treatment of +/-bevacizumab with niraparib and dostarlimab
Drug: Niraparib · Drug: Dostarlimab (TSR-042) · Drug: Standard of care
Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)
Also known as: ZEJULA
Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.
Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.
Progression Free Survival (PFS)
Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documented progressive disease (PD) or death due to any cause, whichever occurs first by the Investigator assessment according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeter (mm).
Time frame: Up to approximately 316 weeks
Overall Survival (OS)
Overall Survival (OS) is defined as the time from the date of randomization to the date of death by any cause.
Time frame: Up to approximately 316 weeks
PFS Determined by Blinded Independent Central Review (BICR) Per RECIST v1.1 Criteria
Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documented progressive disease (PD) or death due to any cause, whichever occurs first determined by the BICR according to RECIST version 1.1. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
Time frame: Up to approximately 316 weeks
Time to First Subsequent Therapy (TFST)
Time to First Subsequent Therapy (TFST) is defined as the time from randomization until the start date of the first subsequent anticancer therapy or death by any cause, whichever occurs first. First subsequent anticancer therapy is defined as the earliest anticancer therapy on the follow-up anticancer therapy form.
Time frame: Up to approximately 316 weeks
Time to Second Subsequent Therapy (TSST)
Time to Second Subsequent Therapy (TSST) is defined as the time from the date of randomization to the start date of the second subsequent anticancer therapy or death of any cause, whichever occurs first. Second subsequent anticancer therapy is defined as an anticancer therapy with a start date after the first subsequent anticancer therapy and a recorded PD on first subsequent anticancer therapy, as captured on the follow-up anticancer therapy eCRF form.
Time frame: Up to approximately 316 weeks
Time to Second Progression (PFS2)
PFS2 is defined as the time from the date of randomization to the date of first Progressive Disease per Investigator's assessment after initiation of subsequent anticancer therapy or death due to any cause, whichever occurs first. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeter (mm).
Time frame: Up to approximately 316 weeks
Objective Response Rate (ORR)
Objective Response Rate (ORR) is defined as the percentage of participants with measurable disease at baseline achieving a best overall response (BOR) of complete response (CR) or partial response (PR) by Investigator assessment per RECIST v1.1 criteria for participants with measurable disease at baseline. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.
Time frame: Up to approximately 316 weeks
Duration of Response (DOR)
DOR is defined as the time from the first documented response (complete response (CR) OR partial response (PR) ) to the first documented disease progression per Investigator assessed RECIST v1.1 or death by any cause in participants with measurable disease at baseline who responded to treatment. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.
Time frame: Up to approximately 316 weeks
Disease Control Rate (DCR)
Disease Control Rate (DCR) is defined as the percentage of participants with measurable disease at baseline achieving a best overall response (BOR) of complete response (CR), partial response (PR) or stable disease (SD) by Investigator assessment per RECIST v1.1 criteria for participants with measurable disease at baseline. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions. SD defined as any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.
Time frame: Up to approximately 316 weeks
Number of Participants With Treatment Emergent Positive Antidrug Antibodies (ADAs) of Dostarlimab
Serum samples were collected for the analysis of Anti-drug antibody (ADAs) of dostarlimab.
Time frame: Up to approximately 316 weeks
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-5D-5L is a standardized, participant-rated health outcomes questionnaire covering five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each of dimensions, participant self-assigned score: 1 (no problems); 2 (slight problems); 3 (moderate problems); 4 (severe problems); 5 (extreme problems). VAS is collected separately and recorded from 0 (Worst imaginable health state) to 100 (Best imaginable health state). HUI values summarize how good or bad each health state is on a scale of 1 (full health) to 0 (worse health/dead). High HUI value indicates a good HRQoL. Baseline is defined as the latest, non-missing collected value, excluding end of treatment, safety follow-up, long term follow-up visits records and unscheduled visits after end of treatment (EOT).
Time frame: Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology.
Time frame: Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
The EORTC QLQ-OV28 supplements the QLQ-C30. It includes three functional scales (body image (BI), sexuality (S), attitude to disease/treatment(ATD)) and five symptom scales/items (abdominal/GI symptoms (AS), peripheral neuropathy (PN), hormonal/menopausal symptoms (MS), other chemotherapy side effects (CSE), and hair loss (HS)). Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much). Higher scores represent better functioning (better quality of life). For functional scales: improved (worsened) is defined as \>=10 points increase (decrease) from baseline. For symptom scales: improved (worsened) is defined as \>=10 points decrease (increase) from baseline. Baseline is defined as the latest, non-missing collected value, excluding end of treatment, safety follow-up, long term follow-up visits records and unscheduled visits after end of treatment.
Time frame: Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)
| Milestone | All Enrolled Participants | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1) | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|---|---|
| Started | 1400 | 0 | 0 | 0 |
| Completed | 1321 | 0 | 0 | 0 |
| Not completed | 79 | 0 | 0 | 0 |
| Withdrew: Adverse event | 10 | 0 | 0 | 0 |
| Withdrew: Disease progression per clinical criteria by investigator | 2 | 0 | 0 | 0 |
| Withdrew: Risk to patient | 3 | 0 | 0 | 0 |
| Withdrew: Severe noncompliance to protocol | 6 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 10 | 0 | 0 | 0 |
| Withdrew: Death | 10 | 0 | 0 | 0 |
| Withdrew: Other | 27 | 0 | 0 | 0 |
| Withdrew: Missing | 1 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 10 | 0 | 0 | 0 |
| Milestone | All Enrolled Participants | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1) | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|---|---|
| Started | 0 | 159 | 417 | 745 |
| Itt population | 0 | 193 | 385 | 753 |
| Completed | 0 | 129 | 371 | 645 |
| Not completed | 0 | 30 | 46 | 100 |
| Withdrew: Investigator decision | 0 | 1 | 5 | 3 |
| Withdrew: Adverse event | 0 | 7 | 11 | 25 |
| Withdrew: Progression/clinical progression | 0 | 7 | 14 | 15 |
| Withdrew: Risk to patient | 0 | 2 | 1 | 5 |
| Withdrew: Severe noncompliance to protocol | 0 | 2 | 2 | 8 |
| Withdrew: Withdrawal by subject | 0 | 9 | 11 | 29 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 1 | 1 | 5 |
| Withdrew: Other | 0 | 1 | 1 | 9 |
| Milestone | All Enrolled Participants | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1) | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|---|---|
| Started | 0 | 129 | 371 | 645 |
| Completed | 0 | 5 | 41 | 77 |
| Not completed | 0 | 124 | 330 | 568 |
| Withdrew: Ongoing | 0 | 3 | 23 | 42 |
| Withdrew: Adverse event | 0 | 6 | 24 | 91 |
| Withdrew: Thrombocytopenia platelet count not returned to >=100000 cells/ul w/in | 0 | 0 | 1 | 2 |
| Withdrew: Progression/clinical progression | 0 | 83 | 251 | 356 |
| Withdrew: Risk to patient | 0 | 2 | 1 | 2 |
| Withdrew: Severe noncompliance to protocol | 0 | 3 | 3 | 5 |
| Withdrew: Withdrawal by subject | 0 | 7 | 22 | 48 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 7 |
| Withdrew: Unblinded due to being randomized to arm 1 | 0 | 18 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 2 | 2 | 12 |
Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documented progressive disease (PD) or death due to any cause, whichever occurs first by the Investigator assessment according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeter (mm).
| Months | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| Progression Free Survival (PFS) | 19.19 (16.59 to 20.99) | 20.63 (19.22 to 22.77) |
Overall Survival (OS) is defined as the time from the date of randomization to the date of death by any cause.
| Months | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| Overall Survival (OS) | 45.37 (40.28 to 52.21) | 44.39 (41.17 to 47.54) |
Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documented progressive disease (PD) or death due to any cause, whichever occurs first determined by the BICR according to RECIST version 1.1. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
| Months | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| PFS Determined by Blinded Independent Central Review (BICR) Per RECIST v1.1 Criteria | 23.56 (20.14 to 27.40) | 25.89 (23.36 to 32.49) |
Time to First Subsequent Therapy (TFST) is defined as the time from randomization until the start date of the first subsequent anticancer therapy or death by any cause, whichever occurs first. First subsequent anticancer therapy is defined as the earliest anticancer therapy on the follow-up anticancer therapy form.
| Months | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| Time to First Subsequent Therapy (TFST) | 20.93 (17.58 to 22.67) | 20.86 (19.15 to 23.92) |
Time to Second Subsequent Therapy (TSST) is defined as the time from the date of randomization to the start date of the second subsequent anticancer therapy or death of any cause, whichever occurs first. Second subsequent anticancer therapy is defined as an anticancer therapy with a start date after the first subsequent anticancer therapy and a recorded PD on first subsequent anticancer therapy, as captured on the follow-up anticancer therapy eCRF form.
| Months | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| Time to Second Subsequent Therapy (TSST) | 33.97 (30.06 to 37.49) | 35.32 (32.46 to 38.31) |
PFS2 is defined as the time from the date of randomization to the date of first Progressive Disease per Investigator's assessment after initiation of subsequent anticancer therapy or death due to any cause, whichever occurs first. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeter (mm).
| Months | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| Time to Second Progression (PFS2) | 31.84 (28.65 to 35.09) | 32.69 (30.42 to 35.38) |
Objective Response Rate (ORR) is defined as the percentage of participants with measurable disease at baseline achieving a best overall response (BOR) of complete response (CR) or partial response (PR) by Investigator assessment per RECIST v1.1 criteria for participants with measurable disease at baseline. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.
| Percentage of participants | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| Objective Response Rate (ORR) | 88 (83.7 to 91.6) | 88.4 (85.5 to 90.9) |
DOR is defined as the time from the first documented response (complete response (CR) OR partial response (PR) ) to the first documented disease progression per Investigator assessed RECIST v1.1 or death by any cause in participants with measurable disease at baseline who responded to treatment. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.
| Months | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| Duration of Response (DOR) | 16.07 (13.86 to 18.40) | 18.27 (16.36 to 20.53) |
Disease Control Rate (DCR) is defined as the percentage of participants with measurable disease at baseline achieving a best overall response (BOR) of complete response (CR), partial response (PR) or stable disease (SD) by Investigator assessment per RECIST v1.1 criteria for participants with measurable disease at baseline. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions. SD defined as any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.
| Percentage of participants | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| Disease Control Rate (DCR) | 93.7 (90.2 to 96.2) | 93.6 (91.2 to 95.5) |
Serum samples were collected for the analysis of Anti-drug antibody (ADAs) of dostarlimab.
| Participants | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|
| Number of Participants With Treatment Emergent Positive Antidrug Antibodies (ADAs) of Dostarlimab | 17 |
EQ-5D-5L is a standardized, participant-rated health outcomes questionnaire covering five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each of dimensions, participant self-assigned score: 1 (no problems); 2 (slight problems); 3 (moderate problems); 4 (severe problems); 5 (extreme problems). VAS is collected separately and recorded from 0 (Worst imaginable health state) to 100 (Best imaginable health state). HUI values summarize how good or bad each health state is on a scale of 1 (full health) to 0 (worse health/dead). High HUI value indicates a good HRQoL. Baseline is defined as the latest, non-missing collected value, excluding end of treatment, safety follow-up, long term follow-up visits records and unscheduled visits after end of treatment (EOT).
| Scores on a scale | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| EQ-VAS, Cycle 4 Chemotherapy | 1.2 ± 18.33 | 0.1 ± 18.00 |
| EQ-VAS, Cycle 6 Chemotherapy | 4.6 ± 18.84 | 2.0 ± 18.69 |
| EQ-VAS, Cycle 1 Maintenance | 5.9 ± 19.99 | 3.2 ± 18.25 |
| EQ-VAS, Cycle 2 Maintenance | 6.9 ± 19.03 | 2.9 ± 19.52 |
| EQ-VAS, Cycle 3 Maintenance | 4.9 ± 20.42 | 4.9 ± 19.32 |
| EQ-VAS, Cycle 6 Maintenance | 5.1 ± 17.81 | 5.3 ± 18.80 |
| EQ-VAS, Cycle 9 Maintenance | 7.6 ± 19.74 | 6.6 ± 18.09 |
| EQ-VAS, Cycle 12 Maintenance | 9.6 ± 20.58 | 6.6 ± 17.59 |
| EQ-VAS, Cycle 15 Maintenance | 8.1 ± 23.56 | 6.6 ± 17.72 |
| EQ-VAS, Cycle 17 Maintenance | 14.8 ± 26.29 | 11.5 ± 19.81 |
| EQ-VAS, Cycle 23 Maintenance | 13.3 ± 22.95 | 10.4 ± 20.89 |
| EQ-VAS, Cycle 29 Maintenance | 12.5 ± 22.27 | 10.3 ± 19.06 |
| EQ-VAS, Cycle 35 Maintenance | 9.9 ± 19.00 | 10.4 ± 16.55 |
| EQ-VAS, Cycle 41 Maintenance | 9.8 ± 22.91 | 10.1 ± 18.96 |
| EQ-VAS, Cycle 47 Maintenance | 8.8 ± 21.16 | 10.9 ± 18.39 |
| EQ-VAS, Cycle 53 Maintenance | 8.5 ± 25.94 | 11.4 ± 18.65 |
| EQ-VAS, Cycle 59 Maintenance | 7.3 ± 25.15 | 10.7 ± 18.14 |
| EQ-VAS, Cycle 65 Maintenance | 2.5 ± 11.10 | 14.9 ± 19.55 |
| EQ-VAS, Cycle 71 Maintenance | 5.9 ± 10.78 | 13.0 ± 17.09 |
| EQ-VAS, Cycle 77 Maintenance | 9.3 ± 9.84 | 15.9 ± 18.65 |
| EQ-VAS, Cycle 83 Maintenance | 9.7 ± 6.35 | 19.3 ± 21.45 |
| EQ-VAS, Cycle 89 Maintenance | — | -5.0 ± NA |
| EQ-VAS, End of Treatment | 0.7 ± 21.93 | -0.1 ± 22.51 |
| EQ-VAS, Safety Follow-up | 3.5 ± 21.89 | -0.1 ± 21.45 |
| EQ-VAS, Long term Follow-up (LTFU) EOT + 3 months | 3.0 ± 21.47 | 2.7 ± 20.06 |
| EQ-VAS, LTFU-EOT + 9 months | 1.1 ± 18.14 | 2.4 ± 21.53 |
| EQ-VAS, LTFU-EOT + 15 months | 2.3 ± 21.57 | 4.3 ± 19.29 |
| EQ-VAS, LTFU-EOT + 21 months | 1.8 ± 19.39 | 1.8 ± 24.79 |
| EQ-VAS, LTFU-EOT + 27 months | 5.5 ± 15.87 | 5.0 ± 21.42 |
| EQ-VAS, LTFU-EOT + 33 months | 4.6 ± 21.75 | 9.2 ± 17.02 |
| EQ-VAS, LTFU-EOT + 39 months | 5.9 ± 22.38 | -1.9 ± 13.89 |
| EQ-VAS, LTFU-EOT + 45 months | 5.5 ± 19.23 | -4.7 ± 16.00 |
| EQ-VAS, LTFU-EOT + 51 months | 0.0 ± 0.0 | 3.6 ± 11.50 |
| EQ-VAS, LTFU-EOT + 57 months | 2.5 ± 3.54 | -12.0 ± NA |
| EQ-VAS, LTFU-EOT + 63 months | 0.0 ± NA | — |
| HUI, Cycle 4 Chemotherapy | -0.0033 ± 0.16847 | -0.0035 ± 0.19281 |
| HUI, Cycle 6 Chemotherapy | -0.0049 ± 0.18207 | -0.0065 ± 0.19647 |
| HUI, Cycle 1 Maintenance | 0.0034 ± 0.19324 | -0.0043 ± 0.20270 |
| HUI, Cycle 2 Maintenance | 0.0118 ± 0.18781 | 0.0036 ± 0.20052 |
| HUI, Cycle 3 Maintenance | -0.0015 ± 0.21441 | -0.0073 ± 0.21785 |
| HUI, Cycle 6 Maintenance | 0.0184 ± 0.21704 | 0.0029 ± 0.19389 |
| HUI, Cycle 9 Maintenance | 0.0281 ± 0.19001 | 0.0181 ± 0.20597 |
| HUI, Cycle 12 Maintenance | 0.0326 ± 0.21333 | 0.0177 ± 0.19577 |
| HUI, Cycle 15 Maintenance | 0.0379 ± 0.21060 | 0.0136 ± 0.18809 |
| HUI, Cycle 17 Maintenance | 0.0777 ± 0.23603 | 0.0545 ± 0.19913 |
| HUI, Cycle 23 Maintenance | 0.0353 ± 0.16562 | 0.0012 ± 0.22021 |
| HUI, Cycle 29 Maintenance | 0.0610 ± 0.23268 | 0.0058 ± 0.18551 |
| HUI, Cycle 35 Maintenance | 0.0295 ± 0.20956 | 0.0175 ± 0.19186 |
| HUI, Cycle 41 Maintenance | 0.0247 ± 0.23996 | 0.0084 ± 0.22003 |
| HUI, Cycle 47 Maintenance | 0.0251 ± 0.20478 | 0.0263 ± 0.19109 |
| HUI, Cycle 53 Maintenance | 0.0285 ± 0.17721 | -0.0270 ± 0.20412 |
| HUI, Cycle 59 Maintenance | 0.0156 ± 0.11589 | -0.0210 ± 0.19579 |
| HUI, Cycle 65 Maintenance | 0.0358 ± 0.10770 | -0.0302 ± 0.20843 |
| HUI, Cycle 71 Maintenance | 0.0604 ± 0.08941 | 0.0165 ± 0.11503 |
| HUI, Cycle 77 Maintenance | 0.0783 ± 0.06087 | 0.0193 ± 0.20537 |
| HUI, Cycle 83 Maintenance | 0.0200 ± 0.09952 | 0.0720 ± 0.08398 |
| HUI, Cycle 89 Maintenance | — | 0.0640 ± 0.09051 |
| HUI, End of Treatment | -0.0251 ± 0.22757 | -0.0310 ± 0.24320 |
| HUI, Safety Follow-up | -0.0326 ± 0.22131 | -0.0460 ± 0.23927 |
| HUI, LTFU- EOT + 3 months | -0.0439 ± 0.22896 | -0.0222 ± 0.22768 |
| HUI, LTFU-EOT + 9 months | -0.0723 ± 0.20713 | -0.0400 ± 0.23756 |
| HUI, LTFU-EOT + 15 months | -0.0323 ± 0.20492 | -0.0386 ± 0.22117 |
| HUI, LTFU-EOT + 21 months | -0.0370 ± 0.16768 | -0.0457 ± 0.26270 |
| HUI, LTFU-EOT + 27 months | -0.0407 ± 0.17664 | -0.0635 ± 0.23835 |
| HUI, LTFU-EOT + 33 months | -0.0547 ± 0.15663 | -0.0114 ± 0.23974 |
| HUI, LTFU-EOT + 39 months | -0.0374 ± 0.11831 | -0.0993 ± 0.24071 |
| HUI, LTFU-EOT + 45 months | -0.0568 ± 0.14026 | -0.0648 ± 0.23505 |
| HUI, LTFU-EOT + 51 months | 0.0000 ± NA | 0.0028 ± 0.18532 |
| HUI, LTFU-EOT + 57 months | -0.0780 ± 0.11031 | 0.0000 ± NA |
| HUI, LTFU-EOT + 63 months | 0.0000 ± NA | — |
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology.
| Participants | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| GHS/QoL, Cycle 4 Chemotherapy — Worsened | 70 | 148 |
| GHS/QoL, Cycle 4 Chemotherapy — Stable | 142 | 283 |
| GHS/QoL, Cycle 4 Chemotherapy — Improved | 71 | 116 |
| PF, Cycle 4 Chemotherapy — Worsened | 77 | 150 |
| PF, Cycle 4 Chemotherapy — Stable | 146 | 290 |
| PF, Cycle 4 Chemotherapy — Improved | 60 | 108 |
| RF, Cycle 4 Chemotherapy — Worsened | 95 | 183 |
| RF, Cycle 4 Chemotherapy — Stable | 104 | 207 |
| RF, Cycle 4 Chemotherapy — Improved | 84 | 157 |
| EF, Cycle 4 Chemotherapy — Worsened | 46 | 128 |
| EF, Cycle 4 Chemotherapy — Stable | 179 | 317 |
| EF, Cycle 4 Chemotherapy — Improved | 58 | 103 |
| CF, Cycle 4 Chemotherapy — Worsened | 93 | 174 |
| CF, Cycle 4 Chemotherapy — Stable | 149 | 272 |
| CF, Cycle 4 Chemotherapy — Improved | 41 | 102 |
| SF, Cycle 4 Chemotherapy — Worsened | 95 | 201 |
| SF, Cycle 4 Chemotherapy — Stable | 120 | 220 |
| SF, Cycle 4 Chemotherapy — Improved | 67 | 127 |
| Fatigue, Cycle 4 Chemotherapy — Worsened | 121 | 223 |
| Fatigue, Cycle 4 Chemotherapy — Stable | 79 | 155 |
| Fatigue, Cycle 4 Chemotherapy — Improved | 83 | 170 |
| N/V, Cycle 4 Chemotherapy — Worsened | 47 | 91 |
| N/V, Cycle 4 Chemotherapy — Stable | 191 | 363 |
| N/V, Cycle 4 Chemotherapy — Improved | 45 | 94 |
| Pain, Cycle 4 Chemotherapy — Worsened | 88 | 170 |
| Pain, Cycle 4 Chemotherapy — Stable | 107 | 224 |
| Pain, Cycle 4 Chemotherapy — Improved | 88 | 154 |
| Dyspnoea, Cycle 4 Chemotherapy — Worsened | 59 | 103 |
| Dyspnoea, Cycle 4 Chemotherapy — Stable | 179 | 346 |
| Dyspnoea, Cycle 4 Chemotherapy — Improved | 45 | 99 |
| Insomnia, Cycle 4 Chemotherapy — Worsened | 58 | 96 |
| Insomnia, Cycle 4 Chemotherapy — Stable | 147 | 319 |
| Insomnia, Cycle 4 Chemotherapy — Improved | 78 | 133 |
| AL, Cycle 4 Chemotherapy — Worsened | 53 | 111 |
| AL, Cycle 4 Chemotherapy — Stable | 163 | 322 |
| AL, Cycle 4 Chemotherapy — Improved | 67 | 115 |
| Constipation, Cycle 4 Chemotherapy — Worsened | 67 | 104 |
| Constipation, Cycle 4 Chemotherapy — Stable | 153 | 299 |
| Constipation, Cycle 4 Chemotherapy — Improved | 63 | 145 |
| Diarrhoea, Cycle 4 Chemotherapy — Worsened | 41 | 82 |
| Diarrhoea, Cycle 4 Chemotherapy — Stable | 196 | 373 |
| Diarrhoea, Cycle 4 Chemotherapy — Improved | 46 | 93 |
| FD, Cycle 4 Chemotherapy — Worsened | 28 | 98 |
| FD, Cycle 4 Chemotherapy — Stable | 214 | 380 |
| FD, Cycle 4 Chemotherapy — Improved | 41 | 68 |
| GHS/QoL, Cycle 6 Chemotherapy — Worsened | 66 | 147 |
| GHS/QoL, Cycle 6 Chemotherapy — Stable | 133 | 260 |
| GHS/QoL, Cycle 6 Chemotherapy — Improved | 74 | 147 |
| PF, Cycle 6 Chemotherapy — Worsened | 80 | 163 |
| PF, Cycle 6 Chemotherapy — Stable | 131 | 274 |
| PF, Cycle 6 Chemotherapy — Improved | 62 | 117 |
| RF, Cycle 6 Chemotherapy — Worsened | 78 | 195 |
| RF, Cycle 6 Chemotherapy — Stable | 104 | 189 |
| RF, Cycle 6 Chemotherapy — Improved | 91 | 169 |
| EF, Cycle 6 Chemotherapy — Worsened | 48 | 123 |
| EF, Cycle 6 Chemotherapy — Stable | 162 | 316 |
| EF, Cycle 6 Chemotherapy — Improved | 63 | 114 |
| CF, Cycle 6 Chemotherapy — Worsened | 92 | 199 |
| CF, Cycle 6 Chemotherapy — Stable | 144 | 260 |
| CF, Cycle 6 Chemotherapy — Improved | 37 | 94 |
| SF, Cycle 6 Chemotherapy — Worsened | 79 | 185 |
| SF, Cycle 6 Chemotherapy — Stable | 116 | 222 |
| SF, Cycle 6 Chemotherapy — Improved | 78 | 146 |
| Fatigue, Cycle 6 Chemotherapy — Worsened | 110 | 221 |
| Fatigue, Cycle 6 Chemotherapy — Stable | 71 | 163 |
| Fatigue, Cycle 6 Chemotherapy — Improved | 92 | 170 |
| N/V, Cycle 6 Chemotherapy — Worsened | 43 | 116 |
| N/V, Cycle 6 Chemotherapy — Stable | 182 | 340 |
| N/V, Cycle 6 Chemotherapy — Improved | 48 | 98 |
| Pain, Cycle 6 Chemotherapy — Worsened | 76 | 150 |
| Pain, Cycle 6 Chemotherapy — Stable | 99 | 220 |
| Pain, Cycle 6 Chemotherapy — Improved | 98 | 184 |
| Dyspnoea, Cycle 6 Chemotherapy — Worsened | 56 | 150 |
| Dyspnoea, Cycle 6 Chemotherapy — Stable | 174 | 316 |
| Dyspnoea, Cycle 6 Chemotherapy — Improved | 43 | 87 |
| Insomnia, Cycle 6 Chemotherapy — Worsened | 54 | 110 |
| Insomnia, Cycle 6 Chemotherapy — Stable | 135 | 301 |
| Insomnia, Cycle 6 Chemotherapy — Improved | 84 | 142 |
| AL, Cycle 6 Chemotherapy — Worsened | 44 | 113 |
| AL, Cycle 6 Chemotherapy — Stable | 162 | 288 |
| AL, Cycle 6 Chemotherapy — Improved | 67 | 153 |
| Constipation, Cycle 6 Chemotherapy — Worsened | 51 | 117 |
| Constipation, Cycle 6 Chemotherapy — Stable | 148 | 300 |
| Constipation, Cycle 6 Chemotherapy — Improved | 73 | 136 |
| Diarrhoea, Cycle 6 Chemotherapy — Worsened | 34 | 78 |
| Diarrhoea, Cycle 6 Chemotherapy — Stable | 193 | 388 |
| Diarrhoea, Cycle 6 Chemotherapy — Improved | 46 | 88 |
| FD, Cycle 6 Chemotherapy — Worsened | 35 | 91 |
| FD, Cycle 6 Chemotherapy — Stable | 203 | 395 |
| FD, Cycle 6 Chemotherapy — Improved | 35 | 66 |
| GHS/QoL, Cycle 1 Maintenance — Worsened | 50 | 135 |
| GHS/QoL, Cycle 1 Maintenance — Stable | 138 | 241 |
| GHS/QoL, Cycle 1 Maintenance — Improved | 78 | 126 |
| PF, Cycle 1 Maintenance — Worsened | 62 | 130 |
| PF, Cycle 1 Maintenance — Stable | 127 | 255 |
| PF, Cycle 1 Maintenance — Improved | 76 | 119 |
| RF, Cycle 1 Maintenance — Worsened | 73 | 144 |
| RF, Cycle 1 Maintenance — Stable | 100 | 186 |
| RF, Cycle 1 Maintenance — Improved | 93 | 172 |
| EF, Cycle 1 Maintenance — Worsened | 55 | 127 |
| EF, Cycle 1 Maintenance — Stable | 150 | 283 |
| EF, Cycle 1 Maintenance — Improved | 61 | 94 |
| CF, Cycle 1 Maintenance — Worsened | 96 | 181 |
| CF, Cycle 1 Maintenance — Stable | 132 | 246 |
| CF, Cycle 1 Maintenance — Improved | 38 | 77 |
| SF, Cycle 1 Maintenance — Worsened | 83 | 154 |
| SF, Cycle 1 Maintenance — Stable | 109 | 224 |
| SF, Cycle 1 Maintenance — Improved | 74 | 126 |
| Fatigue, Cycle 1 Maintenance — Worsened | 89 | 180 |
| Fatigue, Cycle 1 Maintenance — Stable | 71 | 145 |
| Fatigue, Cycle 1 Maintenance — Improved | 106 | 179 |
| N/V, Cycle 1 Maintenance — Worsened | 35 | 90 |
| N/V, Cycle 1 Maintenance — Stable | 178 | 317 |
| N/V, Cycle 1 Maintenance — Improved | 53 | 97 |
| Pain, Cycle 1 Maintenance — Worsened | 58 | 127 |
| Pain, Cycle 1 Maintenance — Stable | 104 | 186 |
| Pain, Cycle 1 Maintenance — Improved | 104 | 191 |
| Dyspnoea, Cycle 1 Maintenance — Worsened | 64 | 109 |
| Dyspnoea, Cycle 1 Maintenance — Stable | 159 | 297 |
| Dyspnoea, Cycle 1 Maintenance — Improved | 43 | 95 |
| Insomnia, Cycle 1 Maintenance — Worsened | 49 | 98 |
| Insomnia, Cycle 1 Maintenance — Stable | 143 | 253 |
| Insomnia, Cycle 1 Maintenance — Improved | 74 | 153 |
| AL, Cycle 1 Maintenance — Worsened | 40 | 86 |
| AL, Cycle 1 Maintenance — Stable | 154 | 285 |
| AL, Cycle 1 Maintenance — Improved | 72 | 132 |
| Constipation, Cycle 1 Maintenance — Worsened | 54 | 88 |
| Constipation, Cycle 1 Maintenance — Stable | 143 | 270 |
| Constipation, Cycle 1 Maintenance — Improved | 68 | 145 |
| Diarrhoea, Cycle 1 Maintenance — Worsened | 28 | 87 |
| Diarrhoea, Cycle 1 Maintenance — Stable | 189 | 338 |
| Diarrhoea, Cycle 1 Maintenance — Improved | 49 | 76 |
| FD, Cycle 1 Maintenance — Worsened | 33 | 74 |
| FD, Cycle 1 Maintenance — Stable | 195 | 361 |
| FD, Cycle 1 Maintenance — Improved | 38 | 68 |
| GHS/QoL, Cycle 2 Maintenance — Worsened | 47 | 118 |
| GHS/QoL, Cycle 2 Maintenance — Stable | 110 | 211 |
| GHS/QoL, Cycle 2 Maintenance — Improved | 74 | 117 |
| PF, Cycle 2 Maintenance — Worsened | 43 | 107 |
| PF, Cycle 2 Maintenance — Stable | 115 | 236 |
| PF, Cycle 2 Maintenance — Improved | 72 | 103 |
| RF, Cycle 2 Maintenance — Worsened | 58 | 139 |
| RF, Cycle 2 Maintenance — Stable | 83 | 151 |
| RF, Cycle 2 Maintenance — Improved | 89 | 155 |
| EF, Cycle 2 Maintenance — Worsened | 37 | 103 |
| EF, Cycle 2 Maintenance — Stable | 134 | 253 |
| EF, Cycle 2 Maintenance — Improved | 60 | 90 |
| CF, Cycle 2 Maintenance — Worsened | 78 | 160 |
| CF, Cycle 2 Maintenance — Stable | 117 | 208 |
| CF, Cycle 2 Maintenance — Improved | 36 | 78 |
| SF, Cycle 2 Maintenance — Worsened | 63 | 137 |
| SF, Cycle 2 Maintenance — Stable | 91 | 177 |
| SF, Cycle 2 Maintenance — Improved | 77 | 132 |
| Fatigue, Cycle 2 Maintenance — Worsened | 55 | 146 |
| Fatigue, Cycle 2 Maintenance — Stable | 68 | 138 |
| Fatigue, Cycle 2 Maintenance — Improved | 108 | 161 |
| N/V, Cycle 2 Maintenance — Worsened | 42 | 94 |
| N/V, Cycle 2 Maintenance — Stable | 144 | 266 |
| N/V, Cycle 2 Maintenance — Improved | 45 | 85 |
| Pain, Cycle 2 Maintenance — Worsened | 48 | 128 |
| Pain, Cycle 2 Maintenance — Stable | 88 | 159 |
| Pain, Cycle 2 Maintenance — Improved | 95 | 159 |
| Dyspnoea, Cycle 2 Maintenance — Worsened | 34 | 91 |
| Dyspnoea, Cycle 2 Maintenance — Stable | 155 | 277 |
| Dyspnoea, Cycle 2 Maintenance — Improved | 41 | 77 |
| Insomnia, Cycle 2 Maintenance — Worsened | 41 | 90 |
| Insomnia, Cycle 2 Maintenance — Stable | 115 | 220 |
| Insomnia, Cycle 2 Maintenance — Improved | 75 | 135 |
| AL, Cycle 2 Maintenance — Worsened | 29 | 90 |
| AL, Cycle 2 Maintenance — Stable | 134 | 250 |
| AL, Cycle 2 Maintenance — Improved | 67 | 105 |
| Constipation, Cycle 2 Maintenance — Worsened | 42 | 85 |
| Constipation, Cycle 2 Maintenance — Stable | 118 | 249 |
| Constipation, Cycle 2 Maintenance — Improved | 71 | 110 |
| Diarrhoea, Cycle 2 Maintenance — Worsened | 22 | 52 |
| Diarrhoea, Cycle 2 Maintenance — Stable | 160 | 315 |
| Diarrhoea, Cycle 2 Maintenance — Improved | 49 | 79 |
| FD, Cycle 2 Maintenance — Worsened | 26 | 71 |
| FD, Cycle 2 Maintenance — Stable | 175 | 316 |
| FD, Cycle 2 Maintenance — Improved | 30 | 59 |
| GHS/QoL, Cycle 3 Maintenance — Worsened | 56 | 146 |
| GHS/QoL, Cycle 3 Maintenance — Stable | 110 | 199 |
| GHS/QoL, Cycle 3 Maintenance — Improved | 76 | 112 |
| PF, Cycle 3 Maintenance — Worsened | 49 | 130 |
| PF, Cycle 3 Maintenance — Stable | 113 | 216 |
| PF, Cycle 3 Maintenance — Improved | 79 | 109 |
| RF, Cycle 3 Maintenance — Worsened | 68 | 146 |
| RF, Cycle 3 Maintenance — Stable | 85 | 163 |
| RF, Cycle 3 Maintenance — Improved | 88 | 147 |
| EF, Cycle 3 Maintenance — Worsened | 60 | 122 |
| EF, Cycle 3 Maintenance — Stable | 126 | 255 |
| EF, Cycle 3 Maintenance — Improved | 56 | 80 |
| CF, Cycle 3 Maintenance — Worsened | 83 | 183 |
| CF, Cycle 3 Maintenance — Stable | 120 | 193 |
| CF, Cycle 3 Maintenance — Improved | 39 | 81 |
| SF, Cycle 3 Maintenance — Worsened | 63 | 152 |
| SF, Cycle 3 Maintenance — Stable | 101 | 185 |
| SF, Cycle 3 Maintenance — Improved | 78 | 119 |
| Fatigue, Cycle 3 Maintenance — Worsened | 84 | 182 |
| Fatigue, Cycle 3 Maintenance — Stable | 51 | 119 |
| Fatigue, Cycle 3 Maintenance — Improved | 106 | 156 |
| N/V, Cycle 3 Maintenance — Worsened | 70 | 147 |
| N/V, Cycle 3 Maintenance — Stable | 122 | 241 |
| N/V, Cycle 3 Maintenance — Improved | 49 | 68 |
| Pain, Cycle 3 Maintenance — Worsened | 58 | 133 |
| Pain, Cycle 3 Maintenance — Stable | 95 | 167 |
| Pain, Cycle 3 Maintenance — Improved | 89 | 157 |
| Dyspnoea, Cycle 3 Maintenance — Worsened | 65 | 121 |
| Dyspnoea, Cycle 3 Maintenance — Stable | 136 | 258 |
| Dyspnoea, Cycle 3 Maintenance — Improved | 39 | 77 |
| Insomnia, Cycle 3 Maintenance — Worsened | 55 | 115 |
| Insomnia, Cycle 3 Maintenance — Stable | 117 | 221 |
| Insomnia, Cycle 3 Maintenance — Improved | 69 | 121 |
| AL, Cycle 3 Maintenance — Worsened | 45 | 124 |
| AL, Cycle 3 Maintenance — Stable | 129 | 229 |
| AL, Cycle 3 Maintenance — Improved | 66 | 104 |
| Constipation, Cycle 3 Maintenance — Worsened | 73 | 125 |
| Constipation, Cycle 3 Maintenance — Stable | 110 | 221 |
| Constipation, Cycle 3 Maintenance — Improved | 58 | 111 |
| Diarrhoea, Cycle 3 Maintenance — Worsened | 15 | 38 |
| Diarrhoea, Cycle 3 Maintenance — Stable | 177 | 329 |
| Diarrhoea, Cycle 3 Maintenance — Improved | 50 | 90 |
| FD, Cycle 3 Maintenance — Worsened | 31 | 68 |
| FD, Cycle 3 Maintenance — Stable | 171 | 327 |
| FD, Cycle 3 Maintenance — Improved | 40 | 60 |
| GHS/QoL, Cycle 6 Maintenance — Worsened | 30 | 89 |
| GHS/QoL, Cycle 6 Maintenance — Stable | 101 | 192 |
| GHS/QoL, Cycle 6 Maintenance — Improved | 70 | 129 |
| PF, Cycle 6 Maintenance — Worsened | 39 | 86 |
| PF, Cycle 6 Maintenance — Stable | 96 | 222 |
| PF, Cycle 6 Maintenance — Improved | 65 | 101 |
| RF, Cycle 6 Maintenance — Worsened | 52 | 100 |
| RF, Cycle 6 Maintenance — Stable | 75 | 171 |
| RF, Cycle 6 Maintenance — Improved | 74 | 139 |
| EF, Cycle 6 Maintenance — Worsened | 36 | 86 |
| EF, Cycle 6 Maintenance — Stable | 113 | 246 |
| EF, Cycle 6 Maintenance — Improved | 52 | 78 |
| CF, Cycle 6 Maintenance — Worsened | 68 | 134 |
| CF, Cycle 6 Maintenance — Stable | 95 | 201 |
| CF, Cycle 6 Maintenance — Improved | 38 | 75 |
| SF, Cycle 6 Maintenance — Worsened | 43 | 106 |
| SF, Cycle 6 Maintenance — Stable | 91 | 162 |
| SF, Cycle 6 Maintenance — Improved | 67 | 142 |
| Fatigue, Cycle 6 Maintenance — Worsened | 49 | 132 |
| Fatigue, Cycle 6 Maintenance — Stable | 59 | 110 |
| Fatigue, Cycle 6 Maintenance — Improved | 93 | 167 |
| N/V, Cycle 6 Maintenance — Worsened | 36 | 91 |
| N/V, Cycle 6 Maintenance — Stable | 126 | 247 |
| N/V, Cycle 6 Maintenance — Improved | 39 | 71 |
| Pain, Cycle 6 Maintenance — Worsened | 44 | 96 |
| Pain, Cycle 6 Maintenance — Stable | 85 | 161 |
| Pain, Cycle 6 Maintenance — Improved | 72 | 153 |
| Dyspnoea, Cycle 6 Maintenance — Worsened | 43 | 105 |
| Dyspnoea, Cycle 6 Maintenance — Stable | 125 | 240 |
| Dyspnoea, Cycle 6 Maintenance — Improved | 33 | 63 |
| Insomnia, Cycle 6 Maintenance — Worsened | 43 | 88 |
| Insomnia, Cycle 6 Maintenance — Stable | 99 | 211 |
| Insomnia, Cycle 6 Maintenance — Improved | 59 | 110 |
| AL, Cycle 6 Maintenance — Worsened | 29 | 68 |
| AL, Cycle 6 Maintenance — Stable | 111 | 232 |
| AL, Cycle 6 Maintenance — Improved | 61 | 108 |
| Constipation, Cycle 6 Maintenance — Worsened | 62 | 106 |
| Constipation, Cycle 6 Maintenance — Stable | 89 | 207 |
| Constipation, Cycle 6 Maintenance — Improved | 49 | 93 |
| Diarrhoea, Cycle 6 Maintenance — Worsened | 8 | 45 |
| Diarrhoea, Cycle 6 Maintenance — Stable | 152 | 293 |
| Diarrhoea, Cycle 6 Maintenance — Improved | 41 | 71 |
| FD, Cycle 6 Maintenance — Worsened | 21 | 50 |
| FD, Cycle 6 Maintenance — Stable | 145 | 299 |
| FD, Cycle 6 Maintenance — Improved | 35 | 60 |
| GHS/QoL, Cycle 9 Maintenance — Worsened | 22 | 76 |
| GHS/QoL, Cycle 9 Maintenance — Stable | 100 | 167 |
| GHS/QoL, Cycle 9 Maintenance — Improved | 68 | 127 |
| PF, Cycle 9 Maintenance — Worsened | 30 | 80 |
| PF, Cycle 9 Maintenance — Stable | 91 | 192 |
| PF, Cycle 9 Maintenance — Improved | 69 | 96 |
| RF, Cycle 9 Maintenance — Worsened | 41 | 84 |
| RF, Cycle 9 Maintenance — Stable | 71 | 140 |
| RF, Cycle 9 Maintenance — Improved | 78 | 145 |
| EF, Cycle 9 Maintenance — Worsened | 29 | 70 |
| EF, Cycle 9 Maintenance — Stable | 105 | 220 |
| EF, Cycle 9 Maintenance — Improved | 56 | 80 |
| CF, Cycle 9 Maintenance — Worsened | 57 | 113 |
| CF, Cycle 9 Maintenance — Stable | 102 | 183 |
| CF, Cycle 9 Maintenance — Improved | 31 | 74 |
| SF, Cycle 9 Maintenance — Worsened | 37 | 82 |
| SF, Cycle 9 Maintenance — Stable | 88 | 168 |
| SF, Cycle 9 Maintenance — Improved | 65 | 120 |
| Fatigue, Cycle 9 Maintenance — Worsened | 52 | 101 |
| Fatigue, Cycle 9 Maintenance — Stable | 47 | 105 |
| Fatigue, Cycle 9 Maintenance — Improved | 91 | 164 |
| N/V, Cycle 9 Maintenance — Worsened | 35 | 65 |
| N/V, Cycle 9 Maintenance — Stable | 114 | 234 |
| N/V, Cycle 9 Maintenance — Improved | 41 | 71 |
| Pain, Cycle 9 Maintenance — Worsened | 36 | 99 |
| Pain, Cycle 9 Maintenance — Stable | 77 | 145 |
| Pain, Cycle 9 Maintenance — Improved | 77 | 126 |
| Dyspnoea, Cycle 9 Maintenance — Worsened | 37 | 73 |
| Dyspnoea, Cycle 9 Maintenance — Stable | 119 | 223 |
| Dyspnoea, Cycle 9 Maintenance — Improved | 34 | 74 |
| Insomnia, Cycle 9 Maintenance — Worsened | 46 | 73 |
| Insomnia, Cycle 9 Maintenance — Stable | 81 | 184 |
| Insomnia, Cycle 9 Maintenance — Improved | 63 | 112 |
| AL, Cycle 9 Maintenance — Worsened | 14 | 58 |
| AL, Cycle 9 Maintenance — Stable | 121 | 199 |
| AL, Cycle 9 Maintenance — Improved | 55 | 113 |
| Constipation, Cycle 9 Maintenance — Worsened | 62 | 89 |
| Constipation, Cycle 9 Maintenance — Stable | 83 | 189 |
| Constipation, Cycle 9 Maintenance — Improved | 44 | 91 |
| Diarrhoea, Cycle 9 Maintenance — Worsened | 15 | 36 |
| Diarrhoea, Cycle 9 Maintenance — Stable | 138 | 264 |
| Diarrhoea, Cycle 9 Maintenance — Improved | 36 | 69 |
| FD, Cycle 9 Maintenance — Worsened | 18 | 42 |
| FD, Cycle 9 Maintenance — Stable | 145 | 276 |
| FD, Cycle 9 Maintenance — Improved | 27 | 51 |
| GHS/QoL, Cycle 12 Maintenance — Worsened | 23 | 64 |
| GHS/QoL, Cycle 12 Maintenance — Stable | 69 | 141 |
| GHS/QoL, Cycle 12 Maintenance — Improved | 70 | 111 |
| PF, Cycle 12 Maintenance — Worsened | 22 | 60 |
| PF, Cycle 12 Maintenance — Stable | 82 | 167 |
| PF, Cycle 12 Maintenance — Improved | 57 | 87 |
| RF, Cycle 12 Maintenance — Worsened | 29 | 57 |
| RF, Cycle 12 Maintenance — Stable | 68 | 127 |
| RF, Cycle 12 Maintenance — Improved | 64 | 129 |
| EF, Cycle 12 Maintenance — Worsened | 31 | 69 |
| EF, Cycle 12 Maintenance — Stable | 82 | 181 |
| EF, Cycle 12 Maintenance — Improved | 49 | 65 |
| CF, Cycle 12 Maintenance — Worsened | 50 | 106 |
| CF, Cycle 12 Maintenance — Stable | 86 | 154 |
| CF, Cycle 12 Maintenance — Improved | 26 | 55 |
| SF, Cycle 12 Maintenance — Worsened | 27 | 74 |
| SF, Cycle 12 Maintenance — Stable | 69 | 123 |
| SF, Cycle 12 Maintenance — Improved | 66 | 117 |
| Fatigue, Cycle 12 Maintenance — Worsened | 39 | 87 |
| Fatigue, Cycle 12 Maintenance — Stable | 42 | 88 |
| Fatigue, Cycle 12 Maintenance — Improved | 80 | 140 |
| N/V, Cycle 12 Maintenance — Worsened | 21 | 62 |
| N/V, Cycle 12 Maintenance — Stable | 105 | 190 |
| N/V, Cycle 12 Maintenance — Improved | 35 | 62 |
| Pain, Cycle 12 Maintenance — Worsened | 33 | 100 |
| Pain, Cycle 12 Maintenance — Stable | 71 | 97 |
| Pain, Cycle 12 Maintenance — Improved | 58 | 119 |
| Dyspnoea, Cycle 12 Maintenance — Worsened | 27 | 57 |
| Dyspnoea, Cycle 12 Maintenance — Stable | 107 | 197 |
| Dyspnoea, Cycle 12 Maintenance — Improved | 26 | 60 |
| Insomnia, Cycle 12 Maintenance — Worsened | 28 | 69 |
| Insomnia, Cycle 12 Maintenance — Stable | 80 | 161 |
| Insomnia, Cycle 12 Maintenance — Improved | 53 | 84 |
| AL, Cycle 12 Maintenance — Worsened | 12 | 49 |
| AL, Cycle 12 Maintenance — Stable | 99 | 173 |
| AL, Cycle 12 Maintenance — Improved | 50 | 92 |
| Constipation, Cycle 12 Maintenance — Worsened | 38 | 90 |
| Constipation, Cycle 12 Maintenance — Stable | 79 | 150 |
| Constipation, Cycle 12 Maintenance — Improved | 44 | 74 |
| Diarrhoea, Cycle 12 Maintenance — Worsened | 12 | 42 |
| Diarrhoea, Cycle 12 Maintenance — Stable | 119 | 221 |
| Diarrhoea, Cycle 12 Maintenance — Improved | 31 | 53 |
| FD, Cycle 12 Maintenance — Worsened | 17 | 41 |
| FD, Cycle 12 Maintenance — Stable | 126 | 222 |
| FD, Cycle 12 Maintenance — Improved | 19 | 50 |
| GHS/QoL, Cycle 15 Maintenance — Worsened | 26 | 60 |
| GHS/QoL, Cycle 15 Maintenance — Stable | 67 | 142 |
| GHS/QoL, Cycle 15 Maintenance — Improved | 60 | 85 |
| PF, Cycle 15 Maintenance — Worsened | 24 | 63 |
| PF, Cycle 15 Maintenance — Stable | 67 | 137 |
| PF, Cycle 15 Maintenance — Improved | 60 | 85 |
| RF, Cycle 15 Maintenance — Worsened | 25 | 60 |
| RF, Cycle 15 Maintenance — Stable | 60 | 108 |
| RF, Cycle 15 Maintenance — Improved | 68 | 118 |
| EF, Cycle 15 Maintenance — Worsened | 37 | 59 |
| EF, Cycle 15 Maintenance — Stable | 78 | 160 |
| EF, Cycle 15 Maintenance — Improved | 37 | 68 |
| CF, Cycle 15 Maintenance — Worsened | 54 | 111 |
| CF, Cycle 15 Maintenance — Stable | 78 | 120 |
| CF, Cycle 15 Maintenance — Improved | 21 | 56 |
| SF, Cycle 15 Maintenance — Worsened | 27 | 61 |
| SF, Cycle 15 Maintenance — Stable | 70 | 121 |
| SF, Cycle 15 Maintenance — Improved | 56 | 105 |
| Fatigue, Cycle 15 Maintenance — Worsened | 38 | 81 |
| Fatigue, Cycle 15 Maintenance — Stable | 40 | 74 |
| Fatigue, Cycle 15 Maintenance — Improved | 75 | 132 |
| N/V, Cycle 15 Maintenance — Worsened | 29 | 47 |
| N/V, Cycle 15 Maintenance — Stable | 92 | 179 |
| N/V, Cycle 15 Maintenance — Improved | 32 | 59 |
| Pain, Cycle 15 Maintenance — Worsened | 38 | 71 |
| Pain, Cycle 15 Maintenance — Stable | 58 | 102 |
| Pain, Cycle 15 Maintenance — Improved | 57 | 114 |
| Dyspnoea, Cycle 15 Maintenance — Worsened | 28 | 59 |
| Dyspnoea, Cycle 15 Maintenance — Stable | 95 | 172 |
| Dyspnoea, Cycle 15 Maintenance — Improved | 29 | 56 |
| Insomnia, Cycle 15 Maintenance — Worsened | 37 | 65 |
| Insomnia, Cycle 15 Maintenance — Stable | 73 | 128 |
| Insomnia, Cycle 15 Maintenance — Improved | 43 | 93 |
| AL, Cycle 15 Maintenance — Worsened | 13 | 29 |
| AL, Cycle 15 Maintenance — Stable | 89 | 164 |
| AL, Cycle 15 Maintenance — Improved | 50 | 92 |
| Constipation, Cycle 15 Maintenance — Worsened | 38 | 66 |
| Constipation, Cycle 15 Maintenance — Stable | 76 | 147 |
| Constipation, Cycle 15 Maintenance — Improved | 39 | 73 |
| Diarrhoea, Cycle 15 Maintenance — Worsened | 12 | 29 |
| Diarrhoea, Cycle 15 Maintenance — Stable | 116 | 200 |
| Diarrhoea, Cycle 15 Maintenance — Improved | 25 | 58 |
| FD, Cycle 15 Maintenance — Worsened | 16 | 47 |
| FD, Cycle 15 Maintenance — Stable | 116 | 195 |
| FD, Cycle 15 Maintenance — Improved | 20 | 44 |
| GHS/QoL, Cycle 17 Maintenance — Worsened | 4 | 13 |
| GHS/QoL, Cycle 17 Maintenance — Stable | 24 | 33 |
| GHS/QoL, Cycle 17 Maintenance — Improved | 12 | 39 |
| PF, Cycle 17 Maintenance — Worsened | 7 | 13 |
| PF, Cycle 17 Maintenance — Stable | 20 | 38 |
| PF, Cycle 17 Maintenance — Improved | 13 | 34 |
| RF, Cycle 17 Maintenance — Worsened | 10 | 20 |
| RF, Cycle 17 Maintenance — Stable | 14 | 24 |
| RF, Cycle 17 Maintenance — Improved | 16 | 41 |
| EF, Cycle 17 Maintenance — Worsened | 4 | 15 |
| EF, Cycle 17 Maintenance — Stable | 20 | 50 |
| EF, Cycle 17 Maintenance — Improved | 16 | 20 |
| CF, Cycle 17 Maintenance — Worsened | 13 | 32 |
| CF, Cycle 17 Maintenance — Stable | 21 | 42 |
| CF, Cycle 17 Maintenance — Improved | 6 | 11 |
| SF, Cycle 17 Maintenance — Worsened | 6 | 22 |
| SF, Cycle 17 Maintenance — Stable | 20 | 29 |
| SF, Cycle 17 Maintenance — Improved | 14 | 34 |
| Fatigue, Cycle 17 Maintenance — Worsened | 6 | 20 |
| Fatigue, Cycle 17 Maintenance — Stable | 14 | 27 |
| Fatigue, Cycle 17 Maintenance — Improved | 20 | 38 |
| N/V, Cycle 17 Maintenance — Worsened | 8 | 17 |
| N/V, Cycle 17 Maintenance — Stable | 22 | 42 |
| N/V, Cycle 17 Maintenance — Improved | 10 | 26 |
| Pain, Cycle 17 Maintenance — Worsened | 8 | 23 |
| Pain, Cycle 17 Maintenance — Stable | 13 | 26 |
| Pain, Cycle 17 Maintenance — Improved | 19 | 36 |
| Dyspnoea, Cycle 17 Maintenance — Worsened | 6 | 19 |
| Dyspnoea, Cycle 17 Maintenance — Stable | 25 | 49 |
| Dyspnoea, Cycle 17 Maintenance — Improved | 9 | 17 |
| Insomnia, Cycle 17 Maintenance — Worsened | 8 | 18 |
| Insomnia, Cycle 17 Maintenance — Stable | 19 | 38 |
| Insomnia, Cycle 17 Maintenance — Improved | 13 | 29 |
| AL, Cycle 17 Maintenance — Worsened | 6 | 6 |
| AL, Cycle 17 Maintenance — Stable | 27 | 51 |
| AL, Cycle 17 Maintenance — Improved | 7 | 28 |
| Constipation, Cycle 17 Maintenance — Worsened | 6 | 19 |
| Constipation, Cycle 17 Maintenance — Stable | 22 | 39 |
| Constipation, Cycle 17 Maintenance — Improved | 12 | 27 |
| Diarrhoea, Cycle 17 Maintenance — Worsened | 7 | 10 |
| Diarrhoea, Cycle 17 Maintenance — Stable | 24 | 60 |
| Diarrhoea, Cycle 17 Maintenance — Improved | 9 | 15 |
| FD, Cycle 17 Maintenance — Worsened | 7 | 11 |
| FD, Cycle 17 Maintenance — Stable | 26 | 59 |
| FD, Cycle 17 Maintenance — Improved | 7 | 15 |
| GHS/QoL, Cycle 23 Maintenance — Worsened | 9 | 16 |
| GHS/QoL, Cycle 23 Maintenance — Stable | 27 | 37 |
| GHS/QoL, Cycle 23 Maintenance — Improved | 19 | 49 |
| PF, Cycle 23 Maintenance — Worsened | 10 | 17 |
| PF, Cycle 23 Maintenance — Stable | 29 | 45 |
| PF, Cycle 23 Maintenance — Improved | 16 | 38 |
| RF, Cycle 23 Maintenance — Worsened | 12 | 21 |
| RF, Cycle 23 Maintenance — Stable | 23 | 33 |
| RF, Cycle 23 Maintenance — Improved | 20 | 45 |
| EF, Cycle 23 Maintenance — Worsened | 10 | 19 |
| EF, Cycle 23 Maintenance — Stable | 33 | 57 |
| EF, Cycle 23 Maintenance — Improved | 12 | 25 |
| CF, Cycle 23 Maintenance — Worsened | 15 | 37 |
| CF, Cycle 23 Maintenance — Stable | 28 | 48 |
| CF, Cycle 23 Maintenance — Improved | 12 | 17 |
| SF, Cycle 23 Maintenance — Worsened | 12 | 24 |
| SF, Cycle 23 Maintenance — Stable | 31 | 35 |
| SF, Cycle 23 Maintenance — Improved | 12 | 43 |
| Fatigue, Cycle 23 Maintenance — Worsened | 10 | 25 |
| Fatigue, Cycle 23 Maintenance — Stable | 15 | 27 |
| Fatigue, Cycle 23 Maintenance — Improved | 30 | 49 |
| N/V, Cycle 23 Maintenance — Worsened | 8 | 15 |
| N/V, Cycle 23 Maintenance — Stable | 36 | 63 |
| N/V, Cycle 23 Maintenance — Improved | 11 | 23 |
| Pain, Cycle 23 Maintenance — Worsened | 13 | 22 |
| Pain, Cycle 23 Maintenance — Stable | 19 | 39 |
| Pain, Cycle 23 Maintenance — Improved | 23 | 40 |
| Dyspnoea, Cycle 23 Maintenance — Worsened | 7 | 15 |
| Dyspnoea, Cycle 23 Maintenance — Stable | 37 | 62 |
| Dyspnoea, Cycle 23 Maintenance — Improved | 11 | 23 |
| Insomnia, Cycle 23 Maintenance — Worsened | 10 | 20 |
| Insomnia, Cycle 23 Maintenance — Stable | 27 | 43 |
| Insomnia, Cycle 23 Maintenance — Improved | 18 | 39 |
| AL, Cycle 23 Maintenance — Worsened | 6 | 12 |
| AL, Cycle 23 Maintenance — Stable | 40 | 58 |
| AL, Cycle 23 Maintenance — Improved | 9 | 30 |
| Constipation, Cycle 23 Maintenance — Worsened | 8 | 27 |
| Constipation, Cycle 23 Maintenance — Stable | 34 | 49 |
| Constipation, Cycle 23 Maintenance — Improved | 13 | 23 |
| Diarrhoea, Cycle 23 Maintenance — Worsened | 4 | 9 |
| Diarrhoea, Cycle 23 Maintenance — Stable | 41 | 70 |
| Diarrhoea, Cycle 23 Maintenance — Improved | 10 | 22 |
| FD, Cycle 23 Maintenance — Worsened | 7 | 18 |
| FD, Cycle 23 Maintenance — Stable | 42 | 65 |
| FD, Cycle 23 Maintenance — Improved | 6 | 18 |
| GHS/QoL, Cycle 29 Maintenance — Worsened | 5 | 21 |
| GHS/QoL, Cycle 29 Maintenance — Stable | 27 | 37 |
| GHS/QoL, Cycle 29 Maintenance — Improved | 20 | 40 |
| PF, Cycle 29 Maintenance 20 — Worsened | 4 | 17 |
| PF, Cycle 29 Maintenance 20 — Stable | 29 | 50 |
| PF, Cycle 29 Maintenance 20 — Improved | 19 | 30 |
| RF, Cycle 29 Maintenance — Worsened | 5 | 20 |
| RF, Cycle 29 Maintenance — Stable | 22 | 40 |
| RF, Cycle 29 Maintenance — Improved | 25 | 37 |
| EF, Cycle 29 Maintenance — Worsened | 5 | 21 |
| EF, Cycle 29 Maintenance — Stable | 32 | 58 |
| EF, Cycle 29 Maintenance — Improved | 15 | 19 |
| CF, Cycle 29 Maintenance — Worsened | 11 | 35 |
| CF, Cycle 29 Maintenance — Stable | 29 | 46 |
| CF, Cycle 29 Maintenance — Improved | 12 | 17 |
| SF, Cycle 29 Maintenance — Worsened | 12 | 24 |
| SF, Cycle 29 Maintenance — Stable | 20 | 37 |
| SF, Cycle 29 Maintenance — Improved | 20 | 37 |
| Fatigue, Cycle 29 Maintenance — Worsened | 10 | 24 |
| Fatigue, Cycle 29 Maintenance — Stable | 17 | 22 |
| Fatigue, Cycle 29 Maintenance — Improved | 25 | 51 |
| N/V, Cycle 29 Maintenance — Worsened | 4 | 9 |
| N/V, Cycle 29 Maintenance — Stable | 37 | 64 |
| N/V, Cycle 29 Maintenance — Improved | 11 | 24 |
| Pain, Cycle 29 Maintenance — Worsened | 10 | 27 |
| Pain, Cycle 29 Maintenance — Stable | 20 | 43 |
| Pain, Cycle 29 Maintenance — Improved | 21 | 28 |
| Dyspnoea, Cycle 29 Maintenance — Worsened | 9 | 17 |
| Dyspnoea, Cycle 29 Maintenance — Stable | 30 | 66 |
| Dyspnoea, Cycle 29 Maintenance — Improved | 12 | 13 |
| Insomnia, Cycle 29 Maintenance — Worsened | 14 | 24 |
| Insomnia, Cycle 29 Maintenance — Stable | 24 | 47 |
| Insomnia, Cycle 29 Maintenance — Improved | 14 | 26 |
| AL, Cycle 29 Maintenance — Worsened | 4 | 8 |
| AL, Cycle 29 Maintenance — Stable | 37 | 58 |
| AL, Cycle 29 Maintenance — Improved | 11 | 30 |
| Constipation, Cycle 29 Maintenance — Worsened | 5 | 19 |
| Constipation, Cycle 29 Maintenance — Stable | 29 | 60 |
| Constipation, Cycle 29 Maintenance — Improved | 18 | 18 |
| Diarrhoea, Cycle 29 Maintenance — Worsened | 3 | 6 |
| Diarrhoea, Cycle 29 Maintenance — Stable | 39 | 76 |
| Diarrhoea, Cycle 29 Maintenance — Improved | 10 | 16 |
| FD, Cycle 29 Maintenance — Worsened | 2 | 13 |
| FD, Cycle 29 Maintenance — Stable | 42 | 66 |
| FD, Cycle 29 Maintenance — Improved | 8 | 19 |
| GHS/QoL, Cycle 35 Maintenance — Worsened | 4 | 17 |
| GHS/QoL, Cycle 35 Maintenance — Stable | 24 | 38 |
| GHS/QoL, Cycle 35 Maintenance — Improved | 16 | 34 |
| PF, Cycle 35 Maintenance — Worsened | 9 | 19 |
| PF, Cycle 35 Maintenance — Stable | 19 | 45 |
| PF, Cycle 35 Maintenance — Improved | 16 | 26 |
| RF, Cycle 35 Maintenance — Worsened | 6 | 22 |
| RF, Cycle 35 Maintenance — Stable | 21 | 35 |
| RF, Cycle 35 Maintenance — Improved | 17 | 32 |
| EF, Cycle 35 Maintenance — Worsened | 8 | 16 |
| EF, Cycle 35 Maintenance — Stable | 24 | 51 |
| EF, Cycle 35 Maintenance — Improved | 12 | 22 |
| CF, Cycle 35 Maintenance — Worsened | 15 | 29 |
| CF, Cycle 35 Maintenance — Stable | 23 | 43 |
| CF, Cycle 35 Maintenance — Improved | 6 | 17 |
| SF, Cycle 35 Maintenance — Worsened | 11 | 18 |
| SF, Cycle 35 Maintenance — Stable | 21 | 29 |
| SF, Cycle 35 Maintenance — Improved | 12 | 42 |
| Fatigue, Cycle 35 Maintenance — Worsened | 10 | 25 |
| Fatigue, Cycle 35 Maintenance — Stable | 10 | 23 |
| Fatigue, Cycle 35 Maintenance — Improved | 24 | 41 |
| N/V, Cycle 35 Maintenance — Worsened | 6 | 17 |
| N/V, Cycle 35 Maintenance — Stable | 33 | 53 |
| N/V, Cycle 35 Maintenance — Improved | 5 | 18 |
| Pain, Cycle 35 Maintenance — Worsened | 6 | 30 |
| Pain, Cycle 35 Maintenance — Stable | 19 | 33 |
| Pain, Cycle 35 Maintenance — Improved | 19 | 27 |
| Dyspnoea, Cycle 35 Maintenance — Worsened | 8 | 21 |
| Dyspnoea, Cycle 35 Maintenance — Stable | 30 | 57 |
| Dyspnoea, Cycle 35 Maintenance — Improved | 6 | 11 |
| Insomnia, Cycle 35 Maintenance — Worsened | 15 | 22 |
| Insomnia, Cycle 35 Maintenance — Stable | 20 | 41 |
| Insomnia, Cycle 35 Maintenance — Improved | 9 | 26 |
| AL, Cycle 35 Maintenance — Worsened | 3 | 7 |
| AL, Cycle 35 Maintenance — Stable | 36 | 51 |
| AL, Cycle 35 Maintenance — Improved | 5 | 29 |
| Constipation, Cycle 35 Maintenance — Worsened | 5 | 19 |
| Constipation, Cycle 35 Maintenance — Stable | 27 | 48 |
| Constipation, Cycle 35 Maintenance — Improved | 12 | 20 |
| Diarrhoea, Cycle 35 Maintenance — Worsened | 4 | 8 |
| Diarrhoea, Cycle 35 Maintenance — Stable | 35 | 69 |
| Diarrhoea, Cycle 35 Maintenance — Improved | 5 | 11 |
| FD, Cycle 35 Maintenance — Worsened | 6 | 15 |
| FD, Cycle 35 Maintenance — Stable | 30 | 53 |
| FD, Cycle 35 Maintenance — Improved | 8 | 21 |
| GHS/QoL, Cycle 41 Maintenance — Worsened | 10 | 22 |
| GHS/QoL, Cycle 41 Maintenance — Stable | 26 | 46 |
| GHS/QoL, Cycle 41 Maintenance — Improved | 22 | 39 |
| PF, Cycle 41 Maintenance — Worsened | 5 | 26 |
| PF, Cycle 41 Maintenance — Stable | 32 | 54 |
| PF, Cycle 41 Maintenance — Improved | 21 | 26 |
| RF, Cycle 41 Maintenance — Worsened | 9 | 29 |
| RF, Cycle 41 Maintenance — Stable | 25 | 38 |
| RF, Cycle 41 Maintenance — Improved | 24 | 39 |
| EF, Cycle 41 Maintenance — Worsened | 10 | 23 |
| EF, Cycle 41 Maintenance — Stable | 35 | 55 |
| EF, Cycle 41 Maintenance — Improved | 13 | 29 |
| CF, Cycle 41 Maintenance — Worsened | 23 | 42 |
| CF, Cycle 41 Maintenance — Stable | 25 | 46 |
| CF, Cycle 41 Maintenance — Improved | 10 | 19 |
| SF, Cycle 41 Maintenance — Worsened | 13 | 28 |
| SF, Cycle 41 Maintenance — Stable | 25 | 38 |
| SF, Cycle 41 Maintenance — Improved | 20 | 41 |
| Fatigue, Cycle 41 Maintenance — Worsened | 11 | 35 |
| Fatigue, Cycle 41 Maintenance — Stable | 17 | 27 |
| Fatigue, Cycle 41 Maintenance — Improved | 30 | 44 |
| N/V, Cycle 41 Maintenance — Worsened | 8 | 17 |
| N/V, Cycle 41 Maintenance — Stable | 39 | 66 |
| N/V, Cycle 41 Maintenance — Improved | 11 | 24 |
| Pain, Cycle 41 Maintenance — Worsened | 11 | 35 |
| Pain, Cycle 41 Maintenance — Stable | 23 | 41 |
| Pain, Cycle 41 Maintenance — Improved | 24 | 31 |
| Dyspnoea, Cycle 41 Maintenance — Worsened | 8 | 26 |
| Dyspnoea, Cycle 41 Maintenance — Stable | 39 | 71 |
| Dyspnoea, Cycle 41 Maintenance — Improved | 11 | 10 |
| Insomnia, Cycle 41 Maintenance — Worsened | 16 | 30 |
| Insomnia, Cycle 41 Maintenance — Stable | 25 | 52 |
| Insomnia, Cycle 41 Maintenance — Improved | 17 | 25 |
| AL, Cycle 41 Maintenance — Worsened | 9 | 14 |
| AL, Cycle 41 Maintenance — Stable | 38 | 60 |
| AL, Cycle 41 Maintenance — Improved | 11 | 33 |
| Constipation, Cycle 41 Maintenance — Worsened | 12 | 28 |
| Constipation, Cycle 41 Maintenance — Stable | 33 | 47 |
| Constipation, Cycle 41 Maintenance — Improved | 13 | 32 |
| Diarrhoea, Cycle 41 Maintenance — Worsened | 5 | 5 |
| Diarrhoea, Cycle 41 Maintenance — Stable | 44 | 85 |
| Diarrhoea, Cycle 41 Maintenance — Improved | 9 | 17 |
| FD, Cycle 41 Maintenance — Worsened | 8 | 18 |
| FD, Cycle 41 Maintenance — Stable | 42 | 69 |
| FD, Cycle 41 Maintenance — Improved | 8 | 20 |
| GHS/QoL, Cycle 47 Maintenance — Worsened | 5 | 16 |
| GHS/QoL, Cycle 47 Maintenance — Stable | 26 | 41 |
| GHS/QoL, Cycle 47 Maintenance — Improved | 17 | 32 |
| PF, Cycle 47 Maintenance — Worsened | 4 | 17 |
| PF, Cycle 47 Maintenance — Stable | 30 | 49 |
| PF, Cycle 47 Maintenance — Improved | 14 | 21 |
| RF, Cycle 47 Maintenance — Worsened | 8 | 17 |
| RF, Cycle 47 Maintenance — Stable | 23 | 38 |
| RF, Cycle 47 Maintenance — Improved | 17 | 32 |
| EF, Cycle 47 Maintenance — Worsened | 4 | 17 |
| EF, Cycle 47 Maintenance — Stable | 29 | 48 |
| EF, Cycle 47 Maintenance — Improved | 15 | 24 |
| CF, Cycle 47 Maintenance — Worsened | 18 | 28 |
| CF, Cycle 47 Maintenance — Stable | 24 | 48 |
| CF, Cycle 47 Maintenance — Improved | 6 | 13 |
| SF, Cycle 47 Maintenance — Worsened | 5 | 17 |
| SF, Cycle 47 Maintenance — Stable | 27 | 38 |
| SF, Cycle 47 Maintenance — Improved | 16 | 34 |
| Fatigue, Cycle 47 Maintenance — Worsened | 7 | 27 |
| Fatigue, Cycle 47 Maintenance — Stable | 11 | 21 |
| Fatigue, Cycle 47 Maintenance — Improved | 30 | 40 |
| N/V, Cycle 47 Maintenance — Worsened | 9 | 14 |
| N/V, Cycle 47 Maintenance — Stable | 32 | 57 |
| N/V, Cycle 47 Maintenance — Improved | 7 | 18 |
| Pain, Cycle 47 Maintenance — Worsened | 11 | 25 |
| Pain, Cycle 47 Maintenance — Stable | 18 | 39 |
| Pain, Cycle 47 Maintenance — Improved | 19 | 25 |
| Dyspnoea, Cycle 47 Maintenance — Worsened | 6 | 20 |
| Dyspnoea, Cycle 47 Maintenance — Stable | 34 | 58 |
| Dyspnoea, Cycle 47 Maintenance — Improved | 8 | 11 |
| Insomnia, Cycle 47 Maintenance — Worsened | 11 | 25 |
| Insomnia, Cycle 47 Maintenance — Stable | 23 | 39 |
| Insomnia, Cycle 47 Maintenance — Improved | 14 | 25 |
| AL, Cycle 47 Maintenance — Worsened | 2 | 12 |
| AL, Cycle 47 Maintenance — Stable | 37 | 48 |
| AL, Cycle 47 Maintenance — Improved | 9 | 29 |
| Constipation, Cycle 47 Maintenance — Worsened | 13 | 21 |
| Constipation, Cycle 47 Maintenance — Stable | 25 | 44 |
| Constipation, Cycle 47 Maintenance — Improved | 10 | 24 |
| Diarrhoea, Cycle 47 Maintenance — Worsened | 6 | 8 |
| Diarrhoea, Cycle 47 Maintenance — Stable | 35 | 66 |
| Diarrhoea, Cycle 47 Maintenance — Improved | 7 | 15 |
| FD, Cycle 47 Maintenance — Worsened | 6 | 16 |
| FD, Cycle 47 Maintenance — Stable | 37 | 57 |
| FD, Cycle 47 Maintenance — Improved | 5 | 16 |
| GHS/QoL, Cycle 53 Maintenance — Worsened | 3 | 12 |
| GHS/QoL, Cycle 53 Maintenance — Stable | 11 | 18 |
| GHS/QoL, Cycle 53 Maintenance — Improved | 12 | 24 |
| PF, Cycle 53 Maintenance — Worsened | 4 | 11 |
| PF, Cycle 53 Maintenance — Stable | 11 | 31 |
| PF, Cycle 53 Maintenance — Improved | 11 | 12 |
| RF, Cycle 53 Maintenance — Worsened | 5 | 16 |
| RF, Cycle 53 Maintenance — Stable | 11 | 22 |
| RF, Cycle 53 Maintenance — Improved | 10 | 16 |
| EF, Cycle 53 Maintenance — Worsened | 3 | 15 |
| EF, Cycle 53 Maintenance — Stable | 17 | 23 |
| EF, Cycle 53 Maintenance — Improved | 6 | 16 |
| CF, Cycle 53 Maintenance — Worsened | 10 | 19 |
| CF, Cycle 53 Maintenance — Stable | 13 | 25 |
| CF, Cycle 53 Maintenance — Improved | 3 | 10 |
| SF, Cycle 53 Maintenance — Worsened | 7 | 11 |
| SF, Cycle 53 Maintenance — Stable | 12 | 23 |
| SF, Cycle 53 Maintenance — Improved | 7 | 20 |
| Fatigue, Cycle 53 Maintenance — Worsened | 3 | 14 |
| Fatigue, Cycle 53 Maintenance — Stable | 7 | 18 |
| Fatigue, Cycle 53 Maintenance — Improved | 16 | 22 |
| N/V, Cycle 53 Maintenance — Worsened | 3 | 7 |
| N/V, Cycle 53 Maintenance — Stable | 19 | 36 |
| N/V, Cycle 53 Maintenance — Improved | 4 | 11 |
| Pain, Cycle 53 Maintenance — Worsened | 4 | 14 |
| Pain, Cycle 53 Maintenance — Stable | 12 | 27 |
| Pain, Cycle 53 Maintenance — Improved | 10 | 13 |
| Dyspnoea, Cycle 53 Maintenance — Worsened | 3 | 12 |
| Dyspnoea, Cycle 53 Maintenance — Stable | 18 | 35 |
| Dyspnoea, Cycle 53 Maintenance — Improved | 5 | 7 |
| Insomnia, Cycle 53 Maintenance — Worsened | 8 | 12 |
| Insomnia, Cycle 53 Maintenance — Stable | 13 | 29 |
| Insomnia, Cycle 53 Maintenance — Improved | 5 | 13 |
| AL, Cycle 53 Maintenance — Worsened | 2 | 7 |
| AL, Cycle 53 Maintenance — Stable | 22 | 32 |
| AL, Cycle 53 Maintenance — Improved | 2 | 15 |
| Constipation, Cycle 53 Maintenance — Worsened | 7 | 9 |
| Constipation, Cycle 53 Maintenance — Stable | 14 | 30 |
| Constipation, Cycle 53 Maintenance — Improved | 5 | 15 |
| Diarrhoea, Cycle 53 Maintenance — Worsened | 2 | 5 |
| Diarrhoea, Cycle 53 Maintenance — Stable | 20 | 43 |
| Diarrhoea, Cycle 53 Maintenance — Improved | 4 | 6 |
| FD, Cycle 53 Maintenance — Worsened | 6 | 10 |
| FD, Cycle 53 Maintenance — Stable | 16 | 36 |
| FD, Cycle 53 Maintenance — Improved | 4 | 8 |
| GHS/QoL, Cycle 59 Maintenance — Worsened | 1 | 3 |
| GHS/QoL, Cycle 59 Maintenance — Stable | 11 | 12 |
| GHS/QoL, Cycle 59 Maintenance — Improved | 6 | 21 |
| PF, Cycle 59 Maintenance — Worsened | 3 | 9 |
| PF, Cycle 59 Maintenance — Stable | 8 | 18 |
| PF, Cycle 59 Maintenance — Improved | 7 | 9 |
| RF, Cycle 59 Maintenance — Worsened | 3 | 8 |
| RF, Cycle 59 Maintenance — Stable | 8 | 18 |
| RF, Cycle 59 Maintenance — Improved | 7 | 10 |
| EF, Cycle 59 Maintenance — Worsened | 4 | 6 |
| EF, Cycle 59 Maintenance — Stable | 11 | 18 |
| EF, Cycle 59 Maintenance — Improved | 3 | 12 |
| CF, Cycle 59 Maintenance — Worsened | 5 | 13 |
| CF, Cycle 59 Maintenance — Stable | 11 | 14 |
| CF, Cycle 59 Maintenance — Improved | 2 | 9 |
| SF, Cycle 59 Maintenance — Worsened | 4 | 6 |
| SF, Cycle 59 Maintenance — Stable | 10 | 12 |
| SF, Cycle 59 Maintenance — Improved | 4 | 18 |
| Fatigue, Cycle 59 Maintenance — Worsened | 4 | 7 |
| Fatigue, Cycle 59 Maintenance — Stable | 8 | 10 |
| Fatigue, Cycle 59 Maintenance — Improved | 6 | 19 |
| N/V, Cycle 59 Maintenance — Worsened | 4 | 6 |
| N/V, Cycle 59 Maintenance — Stable | 12 | 21 |
| N/V, Cycle 59 Maintenance — Improved | 2 | 9 |
| Pain, Cycle 59 Maintenance — Worsened | 1 | 6 |
| Pain, Cycle 59 Maintenance — Stable | 10 | 21 |
| Pain, Cycle 59 Maintenance — Improved | 7 | 9 |
| Dyspnoea, Cycle 59 Maintenance — Worsened | 2 | 9 |
| Dyspnoea, Cycle 59 Maintenance — Stable | 12 | 24 |
| Dyspnoea, Cycle 59 Maintenance — Improved | 4 | 3 |
| Insomnia, Cycle 59 Maintenance — Worsened | 6 | 6 |
| Insomnia, Cycle 59 Maintenance — Stable | 10 | 15 |
| Insomnia, Cycle 59 Maintenance — Improved | 2 | 15 |
| AL, Cycle 59 Maintenance — Worsened | 1 | 3 |
| AL, Cycle 59 Maintenance — Stable | 16 | 21 |
| AL, Cycle 59 Maintenance — Improved | 1 | 12 |
| Constipation, Cycle 59 Maintenance — Worsened | 5 | 8 |
| Constipation, Cycle 59 Maintenance — Stable | 12 | 20 |
| Constipation, Cycle 59 Maintenance — Improved | 1 | 8 |
| Diarrhoea, Cycle 59 Maintenance — Worsened | 1 | 2 |
| Diarrhoea, Cycle 59 Maintenance — Stable | 14 | 29 |
| Diarrhoea, Cycle 59 Maintenance — Improved | 3 | 5 |
| FD, Cycle 59 Maintenance — Worsened | 3 | 4 |
| FD, Cycle 59 Maintenance — Stable | 11 | 22 |
| FD, Cycle 59 Maintenance — Improved | 4 | 10 |
| GHS/QoL, Cycle 65 Maintenance — Worsened | 1 | 3 |
| GHS/QoL, Cycle 65 Maintenance — Stable | 7 | 7 |
| GHS/QoL, Cycle 65 Maintenance — Improved | 4 | 17 |
| PF, Cycle 65 Maintenance — Worsened | 1 | 10 |
| PF, Cycle 65 Maintenance — Stable | 6 | 12 |
| PF, Cycle 65 Maintenance — Improved | 5 | 5 |
| RF, Cycle 65 Maintenance — Worsened | 2 | 7 |
| RF, Cycle 65 Maintenance — Stable | 4 | 11 |
| RF, Cycle 65 Maintenance — Improved | 6 | 9 |
| EF, Cycle 65 Maintenance — Worsened | 0 | 3 |
| EF, Cycle 65 Maintenance — Stable | 8 | 16 |
| EF, Cycle 65 Maintenance — Improved | 4 | 8 |
| CF, Cycle 65 Maintenance — Worsened | 3 | 8 |
| CF, Cycle 65 Maintenance — Stable | 7 | 13 |
| CF, Cycle 65 Maintenance — Improved | 2 | 6 |
| SF, Cycle 65 Maintenance — Worsened | 4 | 6 |
| SF, Cycle 65 Maintenance — Stable | 4 | 8 |
| SF, Cycle 65 Maintenance — Improved | 4 | 13 |
| Fatigue, Cycle 65 Maintenance — Worsened | 1 | 7 |
| Fatigue, Cycle 65 Maintenance — Stable | 5 | 8 |
| Fatigue, Cycle 65 Maintenance — Improved | 6 | 12 |
| N/V, Cycle 65 Maintenance — Worsened | 1 | 2 |
| N/V, Cycle 65 Maintenance — Stable | 9 | 19 |
| N/V, Cycle 65 Maintenance — Improved | 2 | 6 |
| Pain, Cycle 65 Maintenance — Worsened | 2 | 8 |
| Pain, Cycle 65 Maintenance — Stable | 7 | 11 |
| Pain, Cycle 65 Maintenance — Improved | 3 | 8 |
| Dyspnoea, Cycle 65 Maintenance — Worsened | 2 | 10 |
| Dyspnoea, Cycle 65 Maintenance — Stable | 9 | 15 |
| Dyspnoea, Cycle 65 Maintenance — Improved | 1 | 2 |
| Insomnia, Cycle 65 Maintenance — Worsened | 3 | 7 |
| Insomnia, Cycle 65 Maintenance — Stable | 7 | 15 |
| Insomnia, Cycle 65 Maintenance — Improved | 2 | 5 |
| AL, Cycle 65 Maintenance — Worsened | 0 | 1 |
| AL, Cycle 65 Maintenance — Stable | 11 | 17 |
| AL, Cycle 65 Maintenance — Improved | 1 | 9 |
| Constipation, Cycle 65 Maintenance — Worsened | 6 | 6 |
| Constipation, Cycle 65 Maintenance — Stable | 5 | 17 |
| Constipation, Cycle 65 Maintenance — Improved | 1 | 4 |
| Diarrhoea, Cycle 65 Maintenance — Worsened | 1 | 1 |
| Diarrhoea, Cycle 65 Maintenance — Stable | 10 | 22 |
| Diarrhoea, Cycle 65 Maintenance — Improved | 1 | 4 |
| FD, Cycle 65 Maintenance — Worsened | 1 | 5 |
| FD, Cycle 65 Maintenance — Stable | 8 | 15 |
| FD, Cycle 65 Maintenance — Improved | 3 | 6 |
| GHS/QoL, Cycle 71 Maintenance — Worsened | 0 | 1 |
| GHS/QoL, Cycle 71 Maintenance — Stable | 3 | 5 |
| GHS/QoL, Cycle 71 Maintenance — Improved | 5 | 8 |
| PF, Cycle 71 Maintenance — Worsened | 1 | 4 |
| PF, Cycle 71 Maintenance — Stable | 4 | 9 |
| PF, Cycle 71 Maintenance — Improved | 3 | 1 |
| RF, Cycle 71 Maintenance — Worsened | 0 | 4 |
| RF, Cycle 71 Maintenance — Stable | 4 | 6 |
| RF, Cycle 71 Maintenance — Improved | 4 | 4 |
| EF, Cycle 71 Maintenance — Worsened | 1 | 3 |
| EF, Cycle 71 Maintenance — Stable | 6 | 9 |
| EF, Cycle 71 Maintenance — Improved | 1 | 2 |
| CF, Cycle 71 Maintenance — Worsened | 3 | 3 |
| CF, Cycle 71 Maintenance — Stable | 5 | 9 |
| CF, Cycle 71 Maintenance — Improved | 0 | 2 |
| SF, Cycle 71 Maintenance — Worsened | 2 | 4 |
| SF, Cycle 71 Maintenance — Stable | 2 | 4 |
| SF, Cycle 71 Maintenance — Improved | 4 | 6 |
| Fatigue, Cycle 71 Maintenance — Worsened | 0 | 3 |
| Fatigue, Cycle 71 Maintenance — Stable | 3 | 4 |
| Fatigue, Cycle 71 Maintenance — Improved | 5 | 7 |
| N/V, Cycle 71 Maintenance — Worsened | 1 | 1 |
| N/V, Cycle 71 Maintenance — Stable | 5 | 10 |
| N/V, Cycle 71 Maintenance — Improved | 2 | 3 |
| Pain, Cycle 71 Maintenance — Worsened | 0 | 2 |
| Pain, Cycle 71 Maintenance — Stable | 4 | 9 |
| Pain, Cycle 71 Maintenance — Improved | 4 | 3 |
| Dyspnoea, Cycle 71 Maintenance — Worsened | 0 | 1 |
| Dyspnoea, Cycle 71 Maintenance — Stable | 7 | 12 |
| Dyspnoea, Cycle 71 Maintenance — Improved | 1 | 1 |
| Insomnia, Cycle 71 Maintenance — Worsened | 2 | 3 |
| Insomnia, Cycle 71 Maintenance — Stable | 4 | 8 |
| Insomnia, Cycle 71 Maintenance — Improved | 2 | 3 |
| AL, Cycle 71 Maintenance — Worsened | 0 | 2 |
| AL, Cycle 71 Maintenance — Stable | 6 | 6 |
| AL, Cycle 71 Maintenance — Improved | 2 | 6 |
| Constipation, Cycle 71 Maintenance — Worsened | 2 | 4 |
| Constipation, Cycle 71 Maintenance — Stable | 4 | 9 |
| Constipation, Cycle 71 Maintenance — Improved | 2 | 1 |
| Diarrhoea, Cycle 71 Maintenance — Worsened | 0 | 0 |
| Diarrhoea, Cycle 71 Maintenance — Stable | 7 | 11 |
| Diarrhoea, Cycle 71 Maintenance — Improved | 1 | 3 |
| FD, Cycle 71 Maintenance — Worsened | 1 | 2 |
| FD, Cycle 71 Maintenance — Stable | 4 | 12 |
| FD, Cycle 71 Maintenance — Improved | 3 | 0 |
| GHS/QoL, Cycle 77 Maintenance — Worsened | 0 | 0 |
| GHS/QoL, Cycle 77 Maintenance — Stable | 2 | 3 |
| GHS/QoL, Cycle 77 Maintenance — Improved | 2 | 8 |
| PF, Cycle 77 Maintenance — Worsened | 0 | 2 |
| PF, Cycle 77 Maintenance — Stable | 2 | 5 |
| PF, Cycle 77 Maintenance — Improved | 2 | 4 |
| RF, Cycle 77 Maintenance — Worsened | 0 | 2 |
| RF, Cycle 77 Maintenance — Stable | 1 | 4 |
| RF, Cycle 77 Maintenance — Improved | 3 | 5 |
| EF, Cycle 77 Maintenance — Worsened | 1 | 1 |
| EF, Cycle 77 Maintenance — Stable | 2 | 8 |
| EF, Cycle 77 Maintenance — Improved | 1 | 2 |
| CF, Cycle 77 Maintenance — Worsened | 2 | 2 |
| CF, Cycle 77 Maintenance — Stable | 1 | 3 |
| CF, Cycle 77 Maintenance — Improved | 1 | 6 |
| SF, Cycle 77 Maintenance — Worsened | 1 | 2 |
| SF, Cycle 77 Maintenance — Stable | 1 | 2 |
| SF, Cycle 77 Maintenance — Improved | 2 | 7 |
| Fatigue, Cycle 77 Maintenance — Worsened | 0 | 5 |
| Fatigue, Cycle 77 Maintenance — Stable | 1 | 2 |
| Fatigue, Cycle 77 Maintenance — Improved | 3 | 4 |
| N/V, Cycle 77 Maintenance — Worsened | 0 | 2 |
| N/V, Cycle 77 Maintenance — Stable | 3 | 7 |
| N/V, Cycle 77 Maintenance — Improved | 1 | 2 |
| Pain, Cycle 77 Maintenance — Worsened | 0 | 1 |
| Pain, Cycle 77 Maintenance — Stable | 3 | 5 |
| Pain, Cycle 77 Maintenance — Improved | 1 | 5 |
| Dyspnoea, Cycle 77 Maintenance — Worsened | 0 | 3 |
| Dyspnoea, Cycle 77 Maintenance — Stable | 3 | 7 |
| Dyspnoea, Cycle 77 Maintenance — Improved | 1 | 1 |
| Insomnia, Cycle 77 Maintenance — Worsened | 0 | 5 |
| Insomnia, Cycle 77 Maintenance — Stable | 3 | 4 |
| Insomnia, Cycle 77 Maintenance — Improved | 1 | 2 |
| AL, Cycle 77 Maintenance — Worsened | 1 | 3 |
| AL, Cycle 77 Maintenance — Stable | 2 | 4 |
| AL, Cycle 77 Maintenance — Improved | 1 | 4 |
| Constipation, Cycle 77 Maintenance — Worsened | 1 | 1 |
| Constipation, Cycle 77 Maintenance — Stable | 3 | 8 |
| Constipation, Cycle 77 Maintenance — Improved | 0 | 2 |
| Diarrhoea, Cycle 77 Maintenance — Worsened | 0 | 0 |
| Diarrhoea, Cycle 77 Maintenance — Stable | 3 | 8 |
| Diarrhoea, Cycle 77 Maintenance — Improved | 1 | 3 |
| FD, Cycle 77 Maintenance — Worsened | 1 | 1 |
| FD, Cycle 77 Maintenance — Stable | 2 | 10 |
| FD, Cycle 77 Maintenance — Improved | 1 | 0 |
| GHS/QoL, Cycle 83 Maintenance — Worsened | 0 | 0 |
| GHS/QoL, Cycle 83 Maintenance — Stable | 1 | 1 |
| GHS/QoL, Cycle 83 Maintenance — Improved | 2 | 5 |
| PF, Cycle 83 Maintenance — Worsened | 1 | 2 |
| PF, Cycle 83 Maintenance — Stable | 1 | 1 |
| PF, Cycle 83 Maintenance — Improved | 1 | 3 |
| RF, Cycle 83 Maintenance — Worsened | 0 | 1 |
| RF, Cycle 83 Maintenance — Stable | 2 | 2 |
| RF, Cycle 83 Maintenance — Improved | 1 | 3 |
| EF, Cycle 83 Maintenance — Worsened | 0 | 2 |
| EF, Cycle 83 Maintenance — Stable | 3 | 3 |
| EF, Cycle 83 Maintenance — Improved | 0 | 1 |
| CF, Cycle 83 Maintenance — Worsened | 1 | 1 |
| CF, Cycle 83 Maintenance — Stable | 2 | 3 |
| CF, Cycle 83 Maintenance — Improved | 0 | 2 |
| SF, Cycle 83 Maintenance — Worsened | 1 | 1 |
| SF, Cycle 83 Maintenance — Stable | 1 | 1 |
| SF, Cycle 83 Maintenance — Improved | 1 | 4 |
| Fatigue, Cycle 83 Maintenance — Worsened | 0 | 1 |
| Fatigue, Cycle 83 Maintenance — Stable | 0 | 1 |
| Fatigue, Cycle 83 Maintenance — Improved | 3 | 4 |
| N/V, Cycle 83 Maintenance — Worsened | 1 | 0 |
| N/V, Cycle 83 Maintenance — Stable | 2 | 4 |
| N/V, Cycle 83 Maintenance — Improved | 0 | 2 |
| Pain, Cycle 83 Maintenance — Worsened | 0 | 1 |
| Pain, Cycle 83 Maintenance — Stable | 2 | 2 |
| Pain, Cycle 83 Maintenance — Improved | 1 | 3 |
| Dyspnoea, Cycle 83 Maintenance — Worsened | 0 | 3 |
| Dyspnoea, Cycle 83 Maintenance — Stable | 2 | 3 |
| Dyspnoea, Cycle 83 Maintenance — Improved | 1 | 0 |
| Insomnia, Cycle 83 Maintenance — Worsened | 0 | 2 |
| Insomnia, Cycle 83 Maintenance — Stable | 3 | 3 |
| Insomnia, Cycle 83 Maintenance — Improved | 0 | 1 |
| AL, Cycle 83 Maintenance — Worsened | 0 | 1 |
| AL, Cycle 83 Maintenance — Stable | 3 | 2 |
| AL, Cycle 83 Maintenance — Improved | 0 | 3 |
| Constipation, Cycle 83 Maintenance — Worsened | 2 | 0 |
| Constipation, Cycle 83 Maintenance — Stable | 0 | 6 |
| Constipation, Cycle 83 Maintenance — Improved | 1 | 0 |
| Diarrhoea, Cycle 83 Maintenance — Worsened | 0 | 0 |
| Diarrhoea, Cycle 83 Maintenance — Stable | 3 | 5 |
| Diarrhoea, Cycle 83 Maintenance — Improved | 0 | 1 |
| FD, Cycle 83 Maintenance — Worsened | 1 | 0 |
| FD, Cycle 83 Maintenance — Stable | 1 | 5 |
| FD, Cycle 83 Maintenance — Improved | 1 | 1 |
| GHS/QoL, Cycle 89 Maintenance — Worsened | 0 | 0 |
| GHS/QoL, Cycle 89 Maintenance — Stable | 0 | 0 |
| GHS/QoL, Cycle 89 Maintenance — Improved | 0 | 2 |
| PF, Cycle 89 Maintenance — Worsened | 0 | 0 |
| PF, Cycle 89 Maintenance — Stable | 0 | 0 |
| PF, Cycle 89 Maintenance — Improved | 0 | 2 |
| RF, Cycle 89 Maintenance — Worsened | 0 | 0 |
| RF, Cycle 89 Maintenance — Stable | 0 | 2 |
| RF, Cycle 89 Maintenance — Improved | 0 | 0 |
| EF, Cycle 89 Maintenance — Worsened | 0 | 0 |
| EF, Cycle 89 Maintenance — Stable | 0 | 2 |
| EF, Cycle 89 Maintenance — Improved | 0 | 0 |
| CF, Cycle 89 Maintenance — Worsened | 0 | 0 |
| CF, Cycle 89 Maintenance — Stable | 0 | 1 |
| CF, Cycle 89 Maintenance — Improved | 0 | 1 |
| SF, Cycle 89 Maintenance — Worsened | 0 | 0 |
| SF, Cycle 89 Maintenance — Stable | 0 | 1 |
| SF, Cycle 89 Maintenance — Improved | 0 | 1 |
| Fatigue, Cycle 89 Maintenance — Worsened | 0 | 0 |
| Fatigue, Cycle 89 Maintenance — Stable | 0 | 0 |
| Fatigue, Cycle 89 Maintenance — Improved | 0 | 2 |
| N/V, Cycle 89 Maintenance — Worsened | 0 | 0 |
| N/V, Cycle 89 Maintenance — Stable | 0 | 1 |
| N/V, Cycle 89 Maintenance — Improved | 0 | 1 |
| Pain, Cycle 89 Maintenance — Worsened | 0 | 0 |
| Pain, Cycle 89 Maintenance — Stable | 0 | 1 |
| Pain, Cycle 89 Maintenance — Improved | 0 | 1 |
| Dyspnoea, Cycle 89 Maintenance — Worsened | 0 | 0 |
| Dyspnoea, Cycle 89 Maintenance — Stable | 0 | 2 |
| Dyspnoea, Cycle 89 Maintenance — Improved | 0 | 0 |
| Insomnia, Cycle 89 Maintenance — Worsened | 0 | 0 |
| Insomnia, Cycle 89 Maintenance — Stable | 0 | 2 |
| Insomnia, Cycle 89 Maintenance — Improved | 0 | 0 |
| AL, Cycle 89 Maintenance — Worsened | 0 | 0 |
| AL, Cycle 89 Maintenance — Stable | 0 | 0 |
| AL, Cycle 89 Maintenance — Improved | 0 | 2 |
| Constipation, Cycle 89 Maintenance — Worsened | 0 | 0 |
| Constipation, Cycle 89 Maintenance — Stable | 0 | 2 |
| Constipation, Cycle 89 Maintenance — Improved | 0 | 0 |
| Diarrhoea, Cycle 89 Maintenance — Worsened | 0 | 0 |
| Diarrhoea, Cycle 89 Maintenance — Stable | 0 | 2 |
| Diarrhoea, Cycle 89 Maintenance — Improved | 0 | 0 |
| FD, Cycle 89 Maintenance — Worsened | 0 | 0 |
| FD, Cycle 89 Maintenance — Stable | 0 | 1 |
| FD, Cycle 89 Maintenance — Improved | 0 | 1 |
| GHS/QoL, End of treatment (EOT) — Worsened | 50 | 111 |
| GHS/QoL, End of treatment (EOT) — Stable | 81 | 150 |
| GHS/QoL, End of treatment (EOT) — Improved | 53 | 84 |
| PF, EOT — Worsened | 44 | 84 |
| PF, EOT — Stable | 80 | 161 |
| PF, EOT — Improved | 59 | 97 |
| RF, EOT — Worsened | 57 | 102 |
| RF, EOT — Stable | 64 | 115 |
| RF, EOT — Improved | 62 | 125 |
| EF, EOT — Worsened | 67 | 133 |
| EF, EOT — Stable | 92 | 161 |
| EF, EOT — Improved | 25 | 51 |
| CF, EOT — Worsened | 68 | 127 |
| CF, EOT — Stable | 92 | 155 |
| CF, EOT — Improved | 24 | 63 |
| SF, EOT — Worsened | 58 | 119 |
| SF, EOT — Stable | 68 | 118 |
| SF, EOT — Improved | 58 | 108 |
| Fatigue, EOT — Worsened | 66 | 124 |
| Fatigue, EOT — Stable | 45 | 80 |
| Fatigue, EOT — Improved | 73 | 140 |
| N/V, EOT — Worsened | 38 | 72 |
| N/V, EOT — Stable | 117 | 204 |
| N/V, EOT — Improved | 29 | 68 |
| Pain, EOT — Worsened | 66 | 95 |
| Pain, EOT — Stable | 50 | 140 |
| Pain, EOT — Improved | 68 | 110 |
| Dyspnoea, EOT — Worsened | 47 | 97 |
| Dyspnoea, EOT — Stable | 109 | 185 |
| Dyspnoea, EOT — Improved | 28 | 60 |
| Insomnia, EOT — Worsened | 47 | 91 |
| Insomnia, EOT — Stable | 81 | 160 |
| Insomnia, EOT — Improved | 56 | 93 |
| AL, EOT — Worsened | 40 | 74 |
| AL, EOT — Stable | 94 | 188 |
| AL, EOT — Improved | 49 | 81 |
| Constipation, EOT — Worsened | 44 | 73 |
| Constipation, EOT — Stable | 89 | 172 |
| Constipation, EOT — Improved | 50 | 98 |
| Diarrhoea, EOT — Worsened | 24 | 61 |
| Diarrhoea, EOT — Stable | 127 | 225 |
| Diarrhoea, EOT — Improved | 33 | 59 |
| FD, EOT — Worsened | 28 | 59 |
| FD, EOT — Stable | 130 | 239 |
| FD, EOT — Improved | 25 | 45 |
| GHS/QoL, Safety Follow-up — Worsened | 36 | 97 |
| GHS/QoL, Safety Follow-up — Stable | 71 | 130 |
| GHS/QoL, Safety Follow-up — Improved | 39 | 63 |
| PF, Safety Follow-up — Worsened | 40 | 80 |
| PF, Safety Follow-up — Stable | 66 | 129 |
| PF, Safety Follow-up — Improved | 40 | 78 |
| RF, Safety Follow-up — Worsened | 46 | 99 |
| RF, Safety Follow-up — Stable | 55 | 87 |
| RF, Safety Follow-up — Improved | 45 | 102 |
| EF, Safety Follow-up — Worsened | 44 | 107 |
| EF, Safety Follow-up — Stable | 72 | 147 |
| EF, Safety Follow-up — Improved | 30 | 36 |
| CF, Safety Follow-up — Worsened | 56 | 112 |
| CF, Safety Follow-up — Stable | 69 | 119 |
| CF, Safety Follow-up — Improved | 21 | 59 |
| SF, Safety Follow-up — Worsened | 42 | 105 |
| SF, Safety Follow-up — Stable | 59 | 105 |
| SF, Safety Follow-up — Improved | 45 | 80 |
| Fatigue, Safety Follow-up — Worsened | 54 | 109 |
| Fatigue, Safety Follow-up — Stable | 31 | 75 |
| Fatigue, Safety Follow-up — Improved | 61 | 106 |
| N/V, Safety Follow-up — Worsened | 34 | 65 |
| N/V, Safety Follow-up — Stable | 92 | 169 |
| N/V, Safety Follow-up — Improved | 20 | 56 |
| Pain, Safety Follow-up — Worsened | 50 | 108 |
| Pain, Safety Follow-up — Stable | 47 | 101 |
| Pain, Safety Follow-up — Improved | 49 | 81 |
| Dyspnoea, Safety Follow-up — Worsened | 36 | 84 |
| Dyspnoea, Safety Follow-up — Stable | 91 | 158 |
| Dyspnoea, Safety Follow-up — Improved | 19 | 48 |
| Insomnia, Safety Follow-up — Worsened | 22 | 79 |
| Insomnia, Safety Follow-up — Stable | 75 | 132 |
| Insomnia, Safety Follow-up — Improved | 49 | 79 |
| AL, Safety Follow-up — Worsened | 28 | 74 |
| AL, Safety Follow-up — Stable | 81 | 140 |
| AL, Safety Follow-up — Improved | 37 | 75 |
| Constipation, Safety Follow-up — Worsened | 32 | 56 |
| Constipation, Safety Follow-up — Stable | 72 | 153 |
| Constipation, Safety Follow-up — Improved | 41 | 81 |
| Diarrhoea, Safety Follow-up — Worsened | 21 | 58 |
| Diarrhoea, Safety Follow-up — Stable | 97 | 184 |
| Diarrhoea, Safety Follow-up — Improved | 27 | 48 |
| FD, Safety Follow-up — Worsened | 19 | 46 |
| FD, Safety Follow-up — Stable | 114 | 199 |
| FD, Safety Follow-up — Improved | 12 | 42 |
| GHS/QoL, LTFU (EOT + 3 months) — Worsened | 39 | 84 |
| GHS/QoL, LTFU (EOT + 3 months) — Stable | 53 | 97 |
| GHS/QoL, LTFU (EOT + 3 months) — Improved | 43 | 69 |
| PF, LTFU (EOT + 3 months) — Worsened | 42 | 80 |
| PF, LTFU (EOT + 3 months) — Stable | 66 | 100 |
| PF, LTFU (EOT + 3 months) — Improved | 27 | 70 |
| RF, LTFU (EOT + 3 months) — Worsened | 52 | 70 |
| RF, LTFU (EOT + 3 months) — Stable | 42 | 84 |
| RF, LTFU (EOT + 3 months) — Improved | 41 | 95 |
| EF, LTFU (EOT + 3 months) — Worsened | 30 | 76 |
| EF, LTFU (EOT + 3 months) — Stable | 76 | 129 |
| EF, LTFU (EOT + 3 months) — Improved | 29 | 45 |
| CF, LTFU (EOT + 3 months) — Worsened | 55 | 96 |
| CF, LTFU (EOT + 3 months) — Stable | 64 | 110 |
| CF, LTFU (EOT + 3 months) — Improved | 16 | 44 |
| SF, LTFU (EOT + 3 months) — Worsened | 48 | 80 |
| SF, LTFU (EOT + 3 months) — Stable | 51 | 91 |
| SF, LTFU (EOT + 3 months) — Improved | 36 | 79 |
| Fatigue, LTFU (EOT + 3 months) — Worsened | 52 | 98 |
| Fatigue, LTFU (EOT + 3 months) — Stable | 28 | 58 |
| Fatigue, LTFU (EOT + 3 months) — Improved | 55 | 94 |
| N/V, LTFU (EOT + 3 months) — Worsened | 20 | 45 |
| N/V, LTFU (EOT + 3 months) — Stable | 88 | 155 |
| N/V, LTFU (EOT + 3 months) — Improved | 27 | 50 |
| Pain, LTFU (EOT + 3 months) — Worsened | 41 | 89 |
| Pain, LTFU (EOT + 3 months) — Stable | 42 | 87 |
| Pain, LTFU (EOT + 3 months) — Improved | 52 | 74 |
| Dyspnoea, LTFU (EOT + 3 months) — Worsened | 33 | 71 |
| Dyspnoea, LTFU (EOT + 3 months) — Stable | 84 | 141 |
| Dyspnoea, LTFU (EOT + 3 months) — Improved | 18 | 38 |
| Insomnia, LTFU (EOT + 3 months) — Worsened | 28 | 58 |
| Insomnia, LTFU (EOT + 3 months) — Stable | 66 | 111 |
| Insomnia, LTFU (EOT + 3 months) — Improved | 40 | 81 |
| AL, LTFU (EOT + 3 months) — Worsened | 25 | 48 |
| AL, LTFU (EOT + 3 months) — Stable | 75 | 130 |
| AL, LTFU (EOT + 3 months) — Improved | 35 | 71 |
| Constipation, LTFU (EOT + 3 months) — Worsened | 25 | 53 |
| Constipation, LTFU (EOT + 3 months) — Stable | 64 | 128 |
| Constipation, LTFU (EOT + 3 months) — Improved | 45 | 69 |
| Diarrhoea, LTFU (EOT + 3 months) — Worsened | 20 | 52 |
| Diarrhoea, LTFU (EOT + 3 months) — Stable | 89 | 157 |
| Diarrhoea, LTFU (EOT + 3 months) — Improved | 26 | 41 |
| FD, LTFU (EOT + 3 months) — Worsened | 24 | 43 |
| FD, LTFU (EOT + 3 months) — Stable | 90 | 169 |
| FD, LTFU (EOT + 3 months) — Improved | 21 | 38 |
| GHS/QoL, LTFU (EOT + 9 months) — Worsened | 24 | 60 |
| GHS/QoL, LTFU (EOT + 9 months) — Stable | 53 | 77 |
| GHS/QoL, LTFU (EOT + 9 months) — Improved | 29 | 47 |
| PF, LTFU (EOT + 9 months) — Worsened | 32 | 56 |
| PF, LTFU (EOT + 9 months) — Stable | 59 | 83 |
| PF, LTFU (EOT + 9 months) — Improved | 14 | 45 |
| RF, LTFU (EOT + 9 months) — Worsened | 37 | 63 |
| RF, LTFU (EOT + 9 months) — Stable | 37 | 59 |
| RF, LTFU (EOT + 9 months) — Improved | 32 | 62 |
| EF, LTFU (EOT + 9 months) — Worsened | 31 | 53 |
| EF, LTFU (EOT + 9 months) — Stable | 57 | 97 |
| EF, LTFU (EOT + 9 months) — Improved | 18 | 34 |
| CF, LTFU (EOT + 9 months) — Worsened | 42 | 65 |
| CF, LTFU (EOT + 9 months) — Stable | 55 | 89 |
| CF, LTFU (EOT + 9 months) — Improved | 9 | 30 |
| SF, LTFU (EOT + 9 months) — Worsened | 40 | 62 |
| SF, LTFU (EOT + 9 months) — Stable | 37 | 69 |
| SF, LTFU (EOT + 9 months) — Improved | 29 | 53 |
| Fatigue, LTFU (EOT + 9 months) — Worsened | 43 | 73 |
| Fatigue, LTFU (EOT + 9 months) — Stable | 22 | 46 |
| Fatigue, LTFU (EOT + 9 months) — Improved | 41 | 64 |
| N/V, LTFU (EOT + 9 months) — Worsened | 21 | 40 |
| N/V, LTFU (EOT + 9 months) — Stable | 68 | 112 |
| N/V, LTFU (EOT + 9 months) — Improved | 17 | 31 |
| Pain, LTFU (EOT + 9 months) — Worsened | 33 | 70 |
| Pain, LTFU (EOT + 9 months) — Stable | 46 | 59 |
| Pain, LTFU (EOT + 9 months) — Improved | 27 | 55 |
| Dyspnoea, LTFU (EOT + 9 months) — Worsened | 34 | 48 |
| Dyspnoea, LTFU (EOT + 9 months) — Stable | 59 | 103 |
| Dyspnoea, LTFU (EOT + 9 months) — Improved | 13 | 31 |
| Insomnia, LTFU (EOT + 9 months) — Worsened | 24 | 44 |
| Insomnia, LTFU (EOT + 9 months) — Stable | 55 | 82 |
| Insomnia, LTFU (EOT + 9 months) — Improved | 27 | 57 |
| AL, LTFU (EOT + 9 months) — Worsened | 21 | 45 |
| AL, LTFU (EOT + 9 months) — Stable | 59 | 93 |
| AL, LTFU (EOT + 9 months) — Improved | 25 | 44 |
| Constipation, LTFU (EOT + 9 months) — Worsened | 23 | 43 |
| Constipation, LTFU (EOT + 9 months) — Stable | 50 | 85 |
| Constipation, LTFU (EOT + 9 months) — Improved | 33 | 54 |
| Diarrhoea, LTFU (EOT + 9 months) — Worsened | 21 | 35 |
| Diarrhoea, LTFU (EOT + 9 months) — Stable | 65 | 122 |
| Diarrhoea, LTFU (EOT + 9 months) — Improved | 20 | 27 |
| FD, LTFU (EOT + 9 months) — Worsened | 18 | 26 |
| FD, LTFU (EOT + 9 months) — Stable | 67 | 129 |
| FD, LTFU (EOT + 9 months) — Improved | 21 | 28 |
| GHS/QoL, LTFU (EOT + 15 months) — Worsened | 23 | 48 |
| GHS/QoL, LTFU (EOT + 15 months) — Stable | 34 | 66 |
| GHS/QoL, LTFU (EOT + 15 months) — Improved | 19 | 39 |
| PF, LTFU (EOT + 15 months) — Worsened | 23 | 44 |
| PF, LTFU (EOT + 15 months) — Stable | 38 | 71 |
| PF, LTFU (EOT + 15 months) — Improved | 13 | 39 |
| RF, LTFU (EOT + 15 months) — Worsened | 29 | 46 |
| RF, LTFU (EOT + 15 months) — Stable | 22 | 66 |
| RF, LTFU (EOT + 15 months) — Improved | 25 | 42 |
| EF, LTFU (EOT + 15 months) — Worsened | 23 | 40 |
| EF, LTFU (EOT + 15 months) — Stable | 42 | 86 |
| EF, LTFU (EOT + 15 months) — Improved | 11 | 28 |
| CF, LTFU (EOT + 15 months) — Worsened | 23 | 55 |
| CF, LTFU (EOT + 15 months) — Stable | 43 | 70 |
| CF, LTFU (EOT + 15 months) — Improved | 10 | 29 |
| SF, LTFU (EOT + 15 months) — Worsened | 31 | 51 |
| SF, LTFU (EOT + 15 months) — Stable | 23 | 58 |
| SF, LTFU (EOT + 15 months) — Improved | 22 | 44 |
| Fatigue, LTFU (EOT + 15 months) — Worsened | 29 | 63 |
| Fatigue, LTFU (EOT + 15 months) — Stable | 14 | 39 |
| Fatigue, LTFU (EOT + 15 months) — Improved | 33 | 52 |
| N/V, LTFU (EOT + 15 months) — Worsened | 19 | 30 |
| N/V, LTFU (EOT + 15 months) — Stable | 49 | 101 |
| N/V, LTFU (EOT + 15 months) — Improved | 8 | 23 |
| Pain, LTFU (EOT + 15 months) — Worsened | 21 | 61 |
| Pain, LTFU (EOT + 15 months) — Stable | 30 | 54 |
| Pain, LTFU (EOT + 15 months) — Improved | 25 | 39 |
| Dyspnoea, LTFU (EOT + 15 months) — Worsened | 24 | 47 |
| Dyspnoea, LTFU (EOT + 15 months) — Stable | 43 | 82 |
| Dyspnoea, LTFU (EOT + 15 months) — Improved | 9 | 25 |
| Insomnia, LTFU (EOT + 15 months) — Worsened | 19 | 35 |
| Insomnia, LTFU (EOT + 15 months) — Stable | 32 | 71 |
| Insomnia, LTFU (EOT + 15 months) — Improved | 24 | 48 |
| AL, LTFU (EOT + 15 months) — Worsened | 13 | 27 |
| AL, LTFU (EOT + 15 months) — Stable | 40 | 87 |
| AL, LTFU (EOT + 15 months) — Improved | 23 | 39 |
| Constipation, LTFU (EOT + 15 months) — Worsened | 20 | 32 |
| Constipation, LTFU (EOT + 15 months) — Stable | 35 | 73 |
| Constipation, LTFU (EOT + 15 months) — Improved | 21 | 49 |
| Diarrhoea, LTFU (EOT + 15 months) — Worsened | 12 | 23 |
| Diarrhoea, LTFU (EOT + 15 months) — Stable | 52 | 103 |
| Diarrhoea, LTFU (EOT + 15 months) — Improved | 12 | 28 |
| FD, LTFU (EOT + 15 months) — Worsened | 9 | 26 |
| FD, LTFU (EOT + 15 months) — Stable | 54 | 105 |
| FD, LTFU (EOT + 15 months) — Improved | 13 | 22 |
| GHS/QoL, LTFU (EOT + 21 months) — Worsened | 19 | 36 |
| GHS/QoL, LTFU (EOT + 21 months) — Stable | 14 | 37 |
| GHS/QoL, LTFU (EOT + 21 months) — Improved | 15 | 26 |
| PF, LTFU (EOT + 21 months) — Worsened | 15 | 33 |
| PF, LTFU (EOT + 21 months) — Stable | 25 | 41 |
| PF, LTFU (EOT + 21 months) — Improved | 8 | 24 |
| RF, LTFU (EOT + 21 months) — Worsened | 15 | 35 |
| RF, LTFU (EOT + 21 months) — Stable | 16 | 30 |
| RF, LTFU (EOT + 21 months) — Improved | 17 | 34 |
| EF, LTFU (EOT + 21 months) — Worsened | 16 | 27 |
| EF, LTFU (EOT + 21 months) — Stable | 28 | 44 |
| EF, LTFU (EOT + 21 months) — Improved | 4 | 28 |
| CF, LTFU (EOT + 21 months) — Worsened | 18 | 40 |
| CF, LTFU (EOT + 21 months) — Stable | 24 | 39 |
| CF, LTFU (EOT + 21 months) — Improved | 6 | 20 |
| SF, LTFU (EOT + 21 months) — Worsened | 13 | 43 |
| SF, LTFU (EOT + 21 months) — Stable | 20 | 32 |
| SF, LTFU (EOT + 21 months) — Improved | 15 | 24 |
| Fatigue, LTFU (EOT + 21 months) — Worsened | 22 | 42 |
| Fatigue, LTFU (EOT + 21 months) — Stable | 9 | 26 |
| Fatigue, LTFU (EOT + 21 months) — Improved | 17 | 31 |
| N/V, LTFU (EOT + 21 months) — Worsened | 13 | 23 |
| N/V, LTFU (EOT + 21 months) — Stable | 28 | 61 |
| N/V, LTFU (EOT + 21 months) — Improved | 7 | 15 |
| Pain, LTFU (EOT + 21 months) — Worsened | 16 | 34 |
| Pain, LTFU (EOT + 21 months) — Stable | 14 | 34 |
| Pain, LTFU (EOT + 21 months) — Improved | 18 | 31 |
| Dyspnoea, LTFU (EOT + 21 months) — Worsened | 18 | 27 |
| Dyspnoea, LTFU (EOT + 21 months) — Stable | 24 | 58 |
| Dyspnoea, LTFU (EOT + 21 months) — Improved | 6 | 14 |
| Insomnia, LTFU (EOT + 21 months) — Worsened | 14 | 25 |
| Insomnia, LTFU (EOT + 21 months) — Stable | 22 | 41 |
| Insomnia, LTFU (EOT + 21 months) — Improved | 12 | 33 |
| AL, LTFU (EOT + 21 months) — Worsened | 11 | 21 |
| AL, LTFU (EOT + 21 months) — Stable | 24 | 56 |
| AL, LTFU (EOT + 21 months) — Improved | 13 | 22 |
| Constipation, LTFU (EOT + 21 months) — Worsened | 8 | 27 |
| Constipation, LTFU (EOT + 21 months) — Stable | 22 | 45 |
| Constipation, LTFU (EOT + 21 months) — Improved | 18 | 27 |
| Diarrhoea, LTFU (EOT + 21 months) — Worsened | 12 | 17 |
| Diarrhoea, LTFU (EOT + 21 months) — Stable | 32 | 62 |
| Diarrhoea, LTFU (EOT + 21 months) — Improved | 4 | 20 |
| FD, LTFU (EOT + 21 months) — Worsened | 5 | 18 |
| FD, LTFU (EOT + 21 months) — Stable | 33 | 68 |
| FD, LTFU (EOT + 21 months) — Improved | 9 | 13 |
| GHS/QoL, LTFU (EOT + 27 months) — Worsened | 9 | 17 |
| GHS/QoL, LTFU (EOT + 27 months) — Stable | 15 | 32 |
| GHS/QoL, LTFU (EOT + 27 months) — Improved | 12 | 21 |
| PF, LTFU (EOT + 27 months) — Worsened | 13 | 22 |
| PF, LTFU (EOT + 27 months) — Stable | 16 | 32 |
| PF, LTFU (EOT + 27 months) — Improved | 7 | 16 |
| RF, LTFU (EOT + 27 months) — Worsened | 9 | 20 |
| RF, LTFU (EOT + 27 months) — Stable | 13 | 22 |
| RF, LTFU (EOT + 27 months) — Improved | 14 | 28 |
| EF, LTFU (EOT + 27 months) — Worsened | 9 | 20 |
| EF, LTFU (EOT + 27 months) — Stable | 21 | 31 |
| EF, LTFU (EOT + 27 months) — Improved | 6 | 19 |
| CF, LTFU (EOT + 27 months) — Worsened | 12 | 27 |
| CF, LTFU (EOT + 27 months) — Stable | 16 | 28 |
| CF, LTFU (EOT + 27 months) — Improved | 8 | 15 |
| SF, LTFU (EOT + 27 months) — Worsened | 14 | 28 |
| SF, LTFU (EOT + 27 months) — Stable | 11 | 21 |
| SF, LTFU (EOT + 27 months) — Improved | 11 | 21 |
| Fatigue, LTFU (EOT + 27 months) — Worsened | 14 | 25 |
| Fatigue, LTFU (EOT + 27 months) — Stable | 7 | 18 |
| Fatigue, LTFU (EOT + 27 months) — Improved | 15 | 27 |
| N/V, LTFU (EOT + 27 months) — Worsened | 7 | 12 |
| N/V, LTFU (EOT + 27 months) — Stable | 25 | 46 |
| N/V, LTFU (EOT + 27 months) — Improved | 4 | 12 |
| Pain, LTFU (EOT + 27 months) — Worsened | 9 | 28 |
| Pain, LTFU (EOT + 27 months) — Stable | 13 | 18 |
| Pain, LTFU (EOT + 27 months) — Improved | 14 | 24 |
| Dyspnoea, LTFU (EOT + 27 months) — Worsened | 11 | 17 |
| Dyspnoea, LTFU (EOT + 27 months) — Stable | 19 | 43 |
| Dyspnoea, LTFU (EOT + 27 months) — Improved | 6 | 10 |
| Insomnia, LTFU (EOT + 27 months) — Worsened | 8 | 16 |
| Insomnia, LTFU (EOT + 27 months) — Stable | 18 | 31 |
| Insomnia, LTFU (EOT + 27 months) — Improved | 10 | 23 |
| AL, LTFU (EOT + 27 months) — Worsened | 9 | 13 |
| AL, LTFU (EOT + 27 months) — Stable | 16 | 44 |
| AL, LTFU (EOT + 27 months) — Improved | 11 | 13 |
| Constipation, LTFU (EOT + 27 months) — Worsened | 5 | 15 |
| Constipation, LTFU (EOT + 27 months) — Stable | 17 | 33 |
| Constipation, LTFU (EOT + 27 months) — Improved | 14 | 22 |
| Diarrhoea, LTFU (EOT + 27 months) — Worsened | 8 | 12 |
| Diarrhoea, LTFU (EOT + 27 months) — Stable | 25 | 43 |
| Diarrhoea, LTFU (EOT + 27 months) — Improved | 3 | 15 |
| FD, LTFU (EOT + 27 months) — Worsened | 4 | 11 |
| FD, LTFU (EOT + 27 months) — Stable | 25 | 49 |
| FD, LTFU (EOT + 27 months) — Improved | 7 | 10 |
| GHS/QoL, LTFU (EOT + 33 months) — Worsened | 4 | 8 |
| GHS/QoL, LTFU (EOT + 33 months) — Stable | 6 | 20 |
| GHS/QoL, LTFU (EOT + 33 months) — Improved | 6 | 10 |
| PF, LTFU (EOT + 33 months) — Worsened | 5 | 10 |
| PF, LTFU (EOT + 33 months) — Stable | 9 | 14 |
| PF, LTFU (EOT + 33 months) — Improved | 2 | 15 |
| RF, LTFU (EOT + 33 months) — Worsened | 4 | 12 |
| RF, LTFU (EOT + 33 months) — Stable | 8 | 13 |
| RF, LTFU (EOT + 33 months) — Improved | 4 | 14 |
| EF, LTFU (EOT + 33 months) — Worsened | 5 | 4 |
| EF, LTFU (EOT + 33 months) — Stable | 8 | 24 |
| EF, LTFU (EOT + 33 months) — Improved | 3 | 10 |
| CF, LTFU (EOT + 33 months) — Worsened | 5 | 15 |
| CF, LTFU (EOT + 33 months) — Stable | 9 | 15 |
| CF, LTFU (EOT + 33 months) — Improved | 2 | 8 |
| SF, LTFU (EOT + 33 months) — Worsened | 5 | 14 |
| SF, LTFU (EOT + 33 months) — Stable | 6 | 15 |
| SF, LTFU (EOT + 33 months) — Improved | 5 | 9 |
| Fatigue, LTFU (EOT + 33 months) — Worsened | 5 | 11 |
| Fatigue, LTFU (EOT + 33 months) — Stable | 2 | 12 |
| Fatigue, LTFU (EOT + 33 months) — Improved | 9 | 16 |
| N/V, LTFU (EOT + 33 months) — Worsened | 4 | 7 |
| N/V, LTFU (EOT + 33 months) — Stable | 11 | 24 |
| N/V, LTFU (EOT + 33 months) — Improved | 1 | 8 |
| Pain, LTFU (EOT + 33 months) — Worsened | 2 | 16 |
| Pain, LTFU (EOT + 33 months) — Stable | 7 | 10 |
| Pain, LTFU (EOT + 33 months) — Improved | 7 | 13 |
| Dyspnoea, LTFU (EOT + 33 months) — Worsened | 5 | 10 |
| Dyspnoea, LTFU (EOT + 33 months) — Stable | 9 | 21 |
| Dyspnoea, LTFU (EOT + 33 months) — Improved | 2 | 8 |
| Insomnia, LTFU (EOT + 33 months) — Worsened | 3 | 6 |
| Insomnia, LTFU (EOT + 33 months) — Stable | 9 | 15 |
| Insomnia, LTFU (EOT + 33 months) — Improved | 4 | 17 |
| AL, LTFU (EOT + 33 months) — Worsened | 6 | 3 |
| AL, LTFU (EOT + 33 months) — Stable | 7 | 28 |
| AL, LTFU (EOT + 33 months) — Improved | 3 | 8 |
| Constipation, LTFU (EOT + 33 months) — Worsened | 2 | 10 |
| Constipation, LTFU (EOT + 33 months) — Stable | 7 | 19 |
| Constipation, LTFU (EOT + 33 months) — Improved | 7 | 10 |
| Diarrhoea, LTFU (EOT + 33 months) — Worsened | 5 | 3 |
| Diarrhoea, LTFU (EOT + 33 months) — Stable | 10 | 26 |
| Diarrhoea, LTFU (EOT + 33 months) — Improved | 1 | 9 |
| FD, LTFU (EOT + 33 months) — Worsened | 2 | 6 |
| FD, LTFU (EOT + 33 months) — Stable | 10 | 26 |
| FD, LTFU (EOT + 33 months) — Improved | 4 | 6 |
| GHS/QoL, LTFU (EOT + 39 months) — Worsened | 3 | 7 |
| GHS/QoL, LTFU (EOT + 39 months) — Stable | 3 | 14 |
| GHS/QoL, LTFU (EOT + 39 months) — Improved | 5 | 6 |
| PF, LTFU (EOT + 39 months) — Worsened | 2 | 7 |
| PF, LTFU (EOT + 39 months) — Stable | 6 | 12 |
| PF, LTFU (EOT + 39 months) — Improved | 3 | 8 |
| RF, LTFU (EOT + 39 months) — Worsened | 0 | 6 |
| RF, LTFU (EOT + 39 months) — Stable | 7 | 12 |
| RF, LTFU (EOT + 39 months) — Improved | 4 | 9 |
| EF, LTFU (EOT + 39 months) — Worsened | 2 | 8 |
| EF, LTFU (EOT + 39 months) — Stable | 7 | 16 |
| EF, LTFU (EOT + 39 months) — Improved | 2 | 3 |
| CF, LTFU (EOT + 39 months) — Worsened | 4 | 12 |
| CF, LTFU (EOT + 39 months) — Stable | 5 | 7 |
| CF, LTFU (EOT + 39 months) — Improved | 2 | 8 |
| SF, LTFU (EOT + 39 months) — Worsened | 1 | 9 |
| SF, LTFU (EOT + 39 months) — Stable | 4 | 12 |
| SF, LTFU (EOT + 39 months) — Improved | 6 | 6 |
| Fatigue, LTFU (EOT + 39 months) — Worsened | 1 | 10 |
| Fatigue, LTFU (EOT + 39 months) — Stable | 3 | 6 |
| Fatigue, LTFU (EOT + 39 months) — Improved | 7 | 11 |
| N/V, LTFU (EOT + 39 months) — Worsened | 3 | 5 |
| N/V, LTFU (EOT + 39 months) — Stable | 8 | 19 |
| N/V, LTFU (EOT + 39 months) — Improved | 0 | 3 |
| Pain, LTFU (EOT + 39 months) — Worsened | 4 | 10 |
| Pain, LTFU (EOT + 39 months) — Stable | 4 | 8 |
| Pain, LTFU (EOT + 39 months) — Improved | 3 | 9 |
| Dyspnoea, LTFU (EOT + 39 months) — Worsened | 5 | 9 |
| Dyspnoea, LTFU (EOT + 39 months) — Stable | 3 | 15 |
| Dyspnoea, LTFU (EOT + 39 months) — Improved | 3 | 3 |
| Insomnia, LTFU (EOT + 39 months) — Worsened | 5 | 5 |
| Insomnia, LTFU (EOT + 39 months) — Stable | 3 | 9 |
| Insomnia, LTFU (EOT + 39 months) — Improved | 3 | 13 |
| AL, LTFU (EOT + 39 months) — Worsened | 1 | 2 |
| AL, LTFU (EOT + 39 months) — Stable | 7 | 20 |
| AL, LTFU (EOT + 39 months) — Improved | 3 | 5 |
| Constipation, LTFU (EOT + 39 months) — Worsened | 2 | 10 |
| Constipation, LTFU (EOT + 39 months) — Stable | 5 | 10 |
| Constipation, LTFU (EOT + 39 months) — Improved | 4 | 7 |
| Diarrhoea, LTFU (EOT + 39 months) — Worsened | 2 | 6 |
| Diarrhoea, LTFU (EOT + 39 months) — Stable | 8 | 16 |
| Diarrhoea, LTFU (EOT + 39 months) — Improved | 1 | 5 |
| FD, LTFU (EOT + 39 months) — Worsened | 3 | 5 |
| FD, LTFU (EOT + 39 months) — Stable | 6 | 18 |
| FD, LTFU (EOT + 39 months) — Improved | 2 | 4 |
| GHS/QoL, LTFU (EOT + 45 months) — Worsened | 1 | 4 |
| GHS/QoL, LTFU (EOT + 45 months) — Stable | 1 | 8 |
| GHS/QoL, LTFU (EOT + 45 months) — Improved | 2 | 3 |
| PF, LTFU (EOT + 45 months) — Worsened | 1 | 3 |
| PF, LTFU (EOT + 45 months) — Stable | 2 | 8 |
| PF, LTFU (EOT + 45 months) — Improved | 1 | 4 |
| RF, LTFU (EOT + 45 months) — Worsened | 0 | 2 |
| RF, LTFU (EOT + 45 months) — Stable | 4 | 8 |
| RF, LTFU (EOT + 45 months) — Improved | 0 | 5 |
| EF, LTFU (EOT + 45 months) — Worsened | 0 | 4 |
| EF, LTFU (EOT + 45 months) — Stable | 3 | 8 |
| EF, LTFU (EOT + 45 months) — Improved | 1 | 3 |
| CF, LTFU (EOT + 45 months) — Worsened | 0 | 4 |
| CF, LTFU (EOT + 45 months) — Stable | 4 | 7 |
| CF, LTFU (EOT + 45 months) — Improved | 0 | 4 |
| SF, LTFU (EOT + 45 months) — Worsened | 0 | 3 |
| SF, LTFU (EOT + 45 months) — Stable | 2 | 8 |
| SF, LTFU (EOT + 45 months) — Improved | 2 | 4 |
| Fatigue, LTFU (EOT + 45 months) — Worsened | 1 | 5 |
| Fatigue, LTFU (EOT + 45 months) — Stable | 1 | 4 |
| Fatigue, LTFU (EOT + 45 months) — Improved | 2 | 6 |
| N/V, LTFU (EOT + 45 months) — Worsened | 0 | 2 |
| N/V, LTFU (EOT + 45 months) — Stable | 4 | 11 |
| N/V, LTFU (EOT + 45 months) — Improved | 0 | 2 |
| Pain, LTFU (EOT + 45 months) — Worsened | 1 | 5 |
| Pain, LTFU (EOT + 45 months) — Stable | 1 | 6 |
| Pain, LTFU (EOT + 45 months) — Improved | 2 | 4 |
| Dyspnoea, LTFU (EOT + 45 months) — Worsened | 1 | 3 |
| Dyspnoea, LTFU (EOT + 45 months) — Stable | 2 | 9 |
| Dyspnoea, LTFU (EOT + 45 months) — Improved | 1 | 3 |
| Insomnia, LTFU (EOT + 45 months) — Worsened | 2 | 5 |
| Insomnia, LTFU (EOT + 45 months) — Stable | 1 | 2 |
| Insomnia, LTFU (EOT + 45 months) — Improved | 1 | 8 |
| AL, LTFU (EOT + 45 months) — Worsened | 0 | 1 |
| AL, LTFU (EOT + 45 months) — Stable | 2 | 12 |
| AL, LTFU (EOT + 45 months) — Improved | 2 | 2 |
| Constipation, LTFU (EOT + 45 months) — Worsened | 1 | 5 |
| Constipation, LTFU (EOT + 45 months) — Stable | 1 | 7 |
| Constipation, LTFU (EOT + 45 months) — Improved | 2 | 3 |
| Diarrhoea, LTFU (EOT + 45 months) — Worsened | 0 | 5 |
| Diarrhoea, LTFU (EOT + 45 months) — Stable | 3 | 7 |
| Diarrhoea, LTFU (EOT + 45 months) — Improved | 1 | 3 |
| FD, LTFU (EOT + 45 months) — Worsened | 1 | 2 |
| FD, LTFU (EOT + 45 months) — Stable | 1 | 11 |
| FD, LTFU (EOT + 45 months) — Improved | 2 | 2 |
| GHS/QoL, LTFU (EOT + 51 months) — Worsened | 0 | 0 |
| GHS/QoL, LTFU (EOT + 51 months) — Stable | 2 | 4 |
| GHS/QoL, LTFU (EOT + 51 months) — Improved | 0 | 1 |
| PF, LTFU (EOT + 51 months) — Worsened | 1 | 1 |
| PF, LTFU (EOT + 51 months) — Stable | 1 | 3 |
| PF, LTFU (EOT + 51 months) — Improved | 0 | 1 |
| RF, LTFU (EOT + 51 months) — Worsened | 0 | 0 |
| RF, LTFU (EOT + 51 months) — Stable | 1 | 2 |
| RF, LTFU (EOT + 51 months) — Improved | 1 | 3 |
| EF, LTFU (EOT + 51 months) — Worsened | 0 | 1 |
| EF, LTFU (EOT + 51 months) — Stable | 1 | 2 |
| EF, LTFU (EOT + 51 months) — Improved | 1 | 2 |
| CF, LTFU (EOT + 51 months) — Worsened | 0 | 1 |
| CF, LTFU (EOT + 51 months) — Stable | 2 | 2 |
| CF, LTFU (EOT + 51 months) — Improved | 0 | 2 |
| SF, LTFU (EOT + 51 months) — Worsened | 0 | 1 |
| SF, LTFU (EOT + 51 months) — Stable | 1 | 3 |
| SF, LTFU (EOT + 51 months) — Improved | 1 | 1 |
| Fatigue, LTFU (EOT + 51 months) — Worsened | 0 | 1 |
| Fatigue, LTFU (EOT + 51 months) — Stable | 1 | 0 |
| Fatigue, LTFU (EOT + 51 months) — Improved | 1 | 4 |
| N/V, LTFU (EOT + 51 months) — Worsened | 0 | 0 |
| N/V, LTFU (EOT + 51 months) — Stable | 2 | 5 |
| N/V, LTFU (EOT + 51 months) — Improved | 0 | 0 |
| Pain, LTFU (EOT + 51 months) — Worsened | 0 | 0 |
| Pain, LTFU (EOT + 51 months) — Stable | 1 | 2 |
| Pain, LTFU (EOT + 51 months) — Improved | 1 | 3 |
| Dyspnoea, LTFU (EOT + 51 months) — Worsened | 1 | 0 |
| Dyspnoea, LTFU (EOT + 51 months) — Stable | 1 | 4 |
| Dyspnoea, LTFU (EOT + 51 months) — Improved | 0 | 1 |
| Insomnia, LTFU (EOT + 51 months) — Worsened | 0 | 1 |
| Insomnia, LTFU (EOT + 51 months) — Stable | 1 | 3 |
| Insomnia, LTFU (EOT + 51 months) — Improved | 1 | 1 |
| AL, LTFU (EOT + 51 months) — Worsened | 0 | 0 |
| AL, LTFU (EOT + 51 months) — Stable | 1 | 4 |
| AL, LTFU (EOT + 51 months) — Improved | 1 | 1 |
| Constipation, LTFU (EOT + 51 months) — Worsened | 0 | 2 |
| Constipation, LTFU (EOT + 51 months) — Stable | 1 | 2 |
| Constipation, LTFU (EOT + 51 months) — Improved | 1 | 1 |
| Diarrhoea, LTFU (EOT + 51 months) — Worsened | 0 | 1 |
| Diarrhoea, LTFU (EOT + 51 months) — Stable | 1 | 3 |
| Diarrhoea, LTFU (EOT + 51 months) — Improved | 1 | 1 |
| FD, LTFU (EOT + 51 months) — Worsened | 0 | 0 |
| FD, LTFU (EOT + 51 months) — Stable | 0 | 3 |
| FD, LTFU (EOT + 51 months) — Improved | 2 | 2 |
| GHS/QoL, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| GHS/QoL, LTFU (EOT + 57 months) — Stable | 2 | 1 |
| GHS/QoL, LTFU (EOT + 57 months) — Improved | 0 | 0 |
| PF, LTFU (EOT + 57 months) — Worsened | 1 | 0 |
| PF, LTFU (EOT + 57 months) — Stable | 1 | 1 |
| PF, LTFU (EOT + 57 months) — Improved | 0 | 0 |
| RF, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| RF, LTFU (EOT + 57 months) — Stable | 2 | 0 |
| RF, LTFU (EOT + 57 months) — Improved | 0 | 1 |
| EF, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| EF, LTFU (EOT + 57 months) — Stable | 2 | 0 |
| EF, LTFU (EOT + 57 months) — Improved | 0 | 1 |
| CF, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| CF, LTFU (EOT + 57 months) — Stable | 2 | 1 |
| CF, LTFU (EOT + 57 months) — Improved | 0 | 0 |
| SF, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| SF, LTFU (EOT + 57 months) — Stable | 1 | 1 |
| SF, LTFU (EOT + 57 months) — Improved | 1 | 0 |
| Fatigue, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| Fatigue, LTFU (EOT + 57 months) — Stable | 1 | 1 |
| Fatigue, LTFU (EOT + 57 months) — Improved | 1 | 0 |
| N/V, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| N/V, LTFU (EOT + 57 months) — Stable | 2 | 1 |
| N/V, LTFU (EOT + 57 months) — Improved | 0 | 0 |
| Pain, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| Pain, LTFU (EOT + 57 months) — Stable | 1 | 0 |
| Pain, LTFU (EOT + 57 months) — Improved | 1 | 1 |
| Dyspnoea, LTFU (EOT + 57 months) — Worsened | 1 | 0 |
| Dyspnoea, LTFU (EOT + 57 months) — Stable | 1 | 1 |
| Dyspnoea, LTFU (EOT + 57 months) — Improved | 0 | 0 |
| Insomnia, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| Insomnia, LTFU (EOT + 57 months) — Stable | 1 | 1 |
| Insomnia, LTFU (EOT + 57 months) — Improved | 1 | 0 |
| AL, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| AL, LTFU (EOT + 57 months) — Stable | 1 | 1 |
| AL, LTFU (EOT + 57 months) — Improved | 1 | 0 |
| Constipation, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| Constipation, LTFU (EOT + 57 months) — Stable | 1 | 0 |
| Constipation, LTFU (EOT + 57 months) — Improved | 1 | 1 |
| Diarrhoea, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| Diarrhoea, LTFU (EOT + 57 months) — Stable | 1 | 0 |
| Diarrhoea, LTFU (EOT + 57 months) — Improved | 1 | 1 |
| FD, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| FD, LTFU (EOT + 57 months) — Stable | 0 | 1 |
| FD, LTFU (EOT + 57 months) — Improved | 2 | 0 |
| GHS/QoL, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| GHS/QoL, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| GHS/QoL, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| PF, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| PF, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| PF, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| RF, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| RF, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| RF, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| EF, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| EF, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| EF, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| CF, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| CF, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| CF, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| SF, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| SF, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| SF, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| Fatigue, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| Fatigue, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| Fatigue, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| N/V, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| N/V, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| N/V, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| Pain, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| Pain, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| Pain, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| Dyspnoea, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| Dyspnoea, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| Dyspnoea, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| Insomnia, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| Insomnia, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| Insomnia, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| AL, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| AL, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| AL, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| Constipation, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| Constipation, LTFU (EOT + 63 months) — Stable | 0 | 0 |
| Constipation, LTFU (EOT + 63 months) — Improved | 1 | 0 |
| Diarrhoea, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| Diarrhoea, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| Diarrhoea, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| FD, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| FD, LTFU (EOT + 63 months) — Stable | 0 | 0 |
| FD, LTFU (EOT + 63 months) — Improved | 1 | 0 |
The EORTC QLQ-OV28 supplements the QLQ-C30. It includes three functional scales (body image (BI), sexuality (S), attitude to disease/treatment(ATD)) and five symptom scales/items (abdominal/GI symptoms (AS), peripheral neuropathy (PN), hormonal/menopausal symptoms (MS), other chemotherapy side effects (CSE), and hair loss (HS)). Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much). Higher scores represent better functioning (better quality of life). For functional scales: improved (worsened) is defined as \>=10 points increase (decrease) from baseline. For symptom scales: improved (worsened) is defined as \>=10 points decrease (increase) from baseline. Baseline is defined as the latest, non-missing collected value, excluding end of treatment, safety follow-up, long term follow-up visits records and unscheduled visits after end of treatment.
| Participants | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|
| BI, Cycle 4 Chemotherapy — Worsened | 89 | 214 |
| BI, Cycle 4 Chemotherapy — Stable | 108 | 189 |
| BI, Cycle 4 Chemotherapy — Improved | 73 | 131 |
| S, Cycle 4 Chemotherapy — Worsened | 30 | 59 |
| S, Cycle 4 Chemotherapy — Stable | 188 | 390 |
| S, Cycle 4 Chemotherapy — Improved | 51 | 77 |
| ATD, Cycle 4 Chemotherapy — Worsened | 103 | 205 |
| ATD, Cycle 4 Chemotherapy — Stable | 91 | 148 |
| ATD, Cycle 4 Chemotherapy — Improved | 76 | 181 |
| AS, Cycle 4 Chemotherapy — Worsened | 40 | 81 |
| AS, Cycle 4 Chemotherapy — Stable | 166 | 325 |
| AS, Cycle 4 Chemotherapy — Improved | 70 | 129 |
| PN, Cycle 4 Chemotherapy — Worsened | 151 | 316 |
| PN, Cycle 4 Chemotherapy — Stable | 68 | 135 |
| PN, Cycle 4 Chemotherapy — Improved | 57 | 84 |
| MS, Cycle 4 Chemotherapy — Worsened | 68 | 153 |
| MS, Cycle 4 Chemotherapy — Stable | 135 | 255 |
| MS, Cycle 4 Chemotherapy — Improved | 73 | 127 |
| CSE, Cycle 4 Chemotherapy — Worsened | 88 | 168 |
| CSE, Cycle 4 Chemotherapy — Stable | 145 | 278 |
| CSE, Cycle 4 Chemotherapy — Improved | 43 | 89 |
| HS, Cycle 4 Chemotherapy — Worsened | 92 | 176 |
| HS, Cycle 4 Chemotherapy — Stable | 81 | 139 |
| HS, Cycle 4 Chemotherapy — Improved | 100 | 219 |
| BI, Cycle 6 Chemotherapy — Worsened | 99 | 216 |
| BI, Cycle 6 Chemotherapy — Stable | 97 | 168 |
| BI, Cycle 6 Chemotherapy — Improved | 70 | 148 |
| S, Cycle 6 Chemotherapy — Worsened | 29 | 71 |
| S, Cycle 6 Chemotherapy — Stable | 184 | 368 |
| S, Cycle 6 Chemotherapy — Improved | 48 | 86 |
| ATD, Cycle 6 Chemotherapy — Worsened | 87 | 218 |
| ATD, Cycle 6 Chemotherapy — Stable | 81 | 132 |
| ATD, Cycle 6 Chemotherapy — Improved | 97 | 182 |
| AS, Cycle 6 Chemotherapy — Worsened | 32 | 66 |
| AS, Cycle 6 Chemotherapy — Stable | 148 | 312 |
| AS, Cycle 6 Chemotherapy — Improved | 87 | 156 |
| PN, Cycle 6 Chemotherapy — Worsened | 175 | 371 |
| PN, Cycle 6 Chemotherapy — Stable | 50 | 99 |
| PN, Cycle 6 Chemotherapy — Improved | 42 | 63 |
| MS, Cycle 6 Chemotherapy — Worsened | 71 | 161 |
| MS, Cycle 6 Chemotherapy — Stable | 113 | 240 |
| MS, Cycle 6 Chemotherapy — Improved | 83 | 132 |
| CSE, Cycle 6 Chemotherapy — Worsened | 77 | 173 |
| CSE, Cycle 6 Chemotherapy — Stable | 144 | 279 |
| CSE, Cycle 6 Chemotherapy — Improved | 46 | 80 |
| HS, Cycle 6 Chemotherapy — Worsened | 106 | 181 |
| HS, Cycle 6 Chemotherapy — Stable | 60 | 121 |
| HS, Cycle 6 Chemotherapy — Improved | 100 | 230 |
| BI, Cycle 1 Maintenance — Worsened | 95 | 187 |
| BI, Cycle 1 Maintenance — Stable | 92 | 165 |
| BI, Cycle 1 Maintenance — Improved | 75 | 142 |
| S, Cycle 1 Maintenance — Worsened | 29 | 63 |
| S, Cycle 1 Maintenance — Stable | 172 | 337 |
| S, Cycle 1 Maintenance — Improved | 53 | 85 |
| ATD, Cycle 1 Maintenance — Worsened | 104 | 181 |
| ATD, Cycle 1 Maintenance — Stable | 73 | 143 |
| ATD, Cycle 1 Maintenance — Improved | 85 | 170 |
| AS, Cycle 1 Maintenance — Worsened | 25 | 55 |
| AS, Cycle 1 Maintenance — Stable | 152 | 284 |
| AS, Cycle 1 Maintenance — Improved | 85 | 157 |
| PN, Cycle 1 Maintenance — Worsened | 173 | 358 |
| PN, Cycle 1 Maintenance — Stable | 49 | 73 |
| PN, Cycle 1 Maintenance — Improved | 40 | 64 |
| MS, Cycle 1 Maintenance — Worsened | 68 | 127 |
| MS, Cycle 1 Maintenance — Stable | 115 | 239 |
| MS, Cycle 1 Maintenance — Improved | 79 | 130 |
| CSE, Cycle 1 Maintenance — Worsened | 66 | 162 |
| CSE, Cycle 1 Maintenance — Stable | 151 | 235 |
| CSE, Cycle 1 Maintenance — Improved | 45 | 98 |
| HS, Cycle 1 Maintenance — Worsened | 89 | 145 |
| HS, Cycle 1 Maintenance — Stable | 56 | 117 |
| HS, Cycle 1 Maintenance — Improved | 115 | 232 |
| BI, Cycle 2 Maintenance — Worsened | 74 | 162 |
| BI, Cycle 2 Maintenance — Stable | 85 | 143 |
| BI, Cycle 2 Maintenance — Improved | 68 | 124 |
| S, Cycle 2 Maintenance — Worsened | 16 | 53 |
| S, Cycle 2 Maintenance — Stable | 166 | 290 |
| S, Cycle 2 Maintenance — Improved | 38 | 74 |
| ATD, Cycle 2 Maintenance — Worsened | 75 | 156 |
| ATD, Cycle 2 Maintenance — Stable | 54 | 103 |
| ATD, Cycle 2 Maintenance — Improved | 98 | 169 |
| AS, Cycle 2 Maintenance — Worsened | 19 | 35 |
| AS, Cycle 2 Maintenance — Stable | 127 | 260 |
| AS, Cycle 2 Maintenance — Improved | 82 | 136 |
| PN, Cycle 2 Maintenance — Worsened | 128 | 277 |
| PN, Cycle 2 Maintenance — Stable | 57 | 79 |
| PN, Cycle 2 Maintenance — Improved | 43 | 74 |
| MS, Cycle 2 Maintenance — Worsened | 52 | 129 |
| MS, Cycle 2 Maintenance — Stable | 106 | 186 |
| MS, Cycle 2 Maintenance — Improved | 70 | 115 |
| CSE, Cycle 2 Maintenance — Worsened | 54 | 115 |
| CSE, Cycle 2 Maintenance — Stable | 125 | 229 |
| CSE, Cycle 2 Maintenance — Improved | 49 | 86 |
| HS, Cycle 2 Maintenance — Worsened | 48 | 85 |
| HS, Cycle 2 Maintenance — Stable | 57 | 100 |
| HS, Cycle 2 Maintenance — Improved | 119 | 243 |
| BI, Cycle 3 Maintenance — Worsened | 70 | 159 |
| BI, Cycle 3 Maintenance — Stable | 88 | 147 |
| BI, Cycle 3 Maintenance — Improved | 74 | 135 |
| S, Cycle 3 Maintenance — Worsened | 24 | 55 |
| S, Cycle 3 Maintenance — Stable | 161 | 291 |
| S, Cycle 3 Maintenance — Improved | 41 | 78 |
| ATD, Cycle 3 Maintenance — Worsened | 71 | 161 |
| ATD, Cycle 3 Maintenance — Stable | 55 | 109 |
| ATD, Cycle 3 Maintenance — Improved | 106 | 171 |
| AS, Cycle 3 Maintenance — Worsened | 38 | 56 |
| AS, Cycle 3 Maintenance — Stable | 123 | 246 |
| AS, Cycle 3 Maintenance — Improved | 72 | 140 |
| PN, Cycle 3 Maintenance — Worsened | 129 | 285 |
| PN, Cycle 3 Maintenance — Stable | 53 | 91 |
| PN, Cycle 3 Maintenance — Improved | 50 | 66 |
| MS, Cycle 3 Maintenance — Worsened | 69 | 144 |
| MS, Cycle 3 Maintenance — Stable | 92 | 193 |
| MS, Cycle 3 Maintenance — Improved | 71 | 105 |
| CSE, Cycle 3 Maintenance — Worsened | 54 | 110 |
| CSE, Cycle 3 Maintenance — Stable | 118 | 242 |
| CSE, Cycle 3 Maintenance — Improved | 60 | 90 |
| HS, Cycle 3 Maintenance — Worsened | 32 | 54 |
| HS, Cycle 3 Maintenance — Stable | 66 | 96 |
| HS, Cycle 3 Maintenance — Improved | 134 | 290 |
| BI, Cycle 6 Maintenance — Worsened | 54 | 126 |
| BI, Cycle 6 Maintenance — Stable | 72 | 132 |
| BI, Cycle 6 Maintenance — Improved | 69 | 139 |
| S, Cycle 6 Maintenance — Worsened | 16 | 45 |
| S, Cycle 6 Maintenance — Stable | 121 | 242 |
| S, Cycle 6 Maintenance — Improved | 53 | 95 |
| ATD, Cycle 6 Maintenance9 — Worsened | 54 | 117 |
| ATD, Cycle 6 Maintenance9 — Stable | 44 | 101 |
| ATD, Cycle 6 Maintenance9 — Improved | 97 | 179 |
| AS, Cycle 6 Maintenance — Worsened | 22 | 49 |
| AS, Cycle 6 Maintenance — Stable | 106 | 222 |
| AS, Cycle 6 Maintenance — Improved | 70 | 128 |
| PN, Cycle 6 Maintenance — Worsened | 108 | 234 |
| PN, Cycle 6 Maintenance — Stable | 43 | 89 |
| PN, Cycle 6 Maintenance — Improved | 47 | 75 |
| MS, Cycle 6 Maintenance — Worsened | 53 | 127 |
| MS, Cycle 6 Maintenance — Stable | 85 | 164 |
| MS, Cycle 6 Maintenance — Improved | 60 | 107 |
| CSE, Cycle 6 Maintenance — Worsened | 37 | 102 |
| CSE, Cycle 6 Maintenance — Stable | 111 | 200 |
| CSE, Cycle 6 Maintenance — Improved | 50 | 96 |
| HS, Cycle 6 Maintenance — Worsened | 13 | 23 |
| HS, Cycle 6 Maintenance — Stable | 58 | 92 |
| HS, Cycle 6 Maintenance — Improved | 125 | 282 |
| BI, Cycle 9 Maintenance — Worsened | 51 | 99 |
| BI, Cycle 9 Maintenance — Stable | 59 | 130 |
| BI, Cycle 9 Maintenance — Improved | 75 | 130 |
| S, Cycle 9 Maintenance — Worsened | 19 | 40 |
| S, Cycle 9 Maintenance — Stable | 109 | 201 |
| S, Cycle 9 Maintenance — Improved | 51 | 103 |
| ATD, Cycle 9 Maintenance — Worsened | 47 | 89 |
| ATD, Cycle 9 Maintenance — Stable | 39 | 86 |
| ATD, Cycle 9 Maintenance — Improved | 99 | 184 |
| AS, Cycle 9 Maintenance — Worsened | 22 | 38 |
| AS, Cycle 9 Maintenance — Stable | 103 | 198 |
| AS, Cycle 9 Maintenance — Improved | 61 | 125 |
| PN, Cycle 9 Maintenance — Worsened | 91 | 206 |
| PN, Cycle 9 Maintenance — Stable | 52 | 75 |
| PN, Cycle 9 Maintenance — Improved | 43 | 79 |
| MS, Cycle 9 Maintenance — Worsened | 51 | 96 |
| MS, Cycle 9 Maintenance — Stable | 67 | 158 |
| MS, Cycle 9 Maintenance — Improved | 68 | 106 |
| CSE, Cycle 9 Maintenance — Worsened | 39 | 81 |
| CSE, Cycle 9 Maintenance — Stable | 101 | 193 |
| CSE, Cycle 9 Maintenance — Improved | 46 | 86 |
| HS, Cycle 9 Maintenance — Worsened | 7 | 17 |
| HS, Cycle 9 Maintenance — Stable | 52 | 74 |
| HS, Cycle 9 Maintenance — Improved | 126 | 268 |
| BI, Cycle 12 Maintenance — Worsened | 32 | 79 |
| BI, Cycle 12 Maintenance — Stable | 57 | 99 |
| BI, Cycle 12 Maintenance — Improved | 67 | 130 |
| S, Cycle 12 Maintenance — Worsened | 14 | 30 |
| S, Cycle 12 Maintenance — Stable | 86 | 178 |
| S, Cycle 12 Maintenance — Improved | 51 | 85 |
| ATD, Cycle 12 Maintenance — Worsened | 35 | 83 |
| ATD, Cycle 12 Maintenance — Stable | 39 | 59 |
| ATD, Cycle 12 Maintenance — Improved | 82 | 166 |
| AS, Cycle 12 Maintenance — Worsened | 16 | 49 |
| AS, Cycle 12 Maintenance — Stable | 90 | 166 |
| AS, Cycle 12 Maintenance — Improved | 52 | 93 |
| PN, Cycle 12 Maintenance — Worsened | 68 | 164 |
| PN, Cycle 12 Maintenance — Stable | 46 | 73 |
| PN, Cycle 12 Maintenance — Improved | 44 | 71 |
| MS, Cycle 12 Maintenance — Worsened | 44 | 91 |
| MS, Cycle 12 Maintenance — Stable | 59 | 138 |
| MS, Cycle 12 Maintenance — Improved | 55 | 79 |
| CSE, Cycle 12 Maintenance — Worsened | 25 | 66 |
| CSE, Cycle 12 Maintenance — Stable | 95 | 164 |
| CSE, Cycle 12 Maintenance — Improved | 38 | 78 |
| HS, Cycle 12 Maintenance — Worsened | 5 | 6 |
| HS, Cycle 12 Maintenance — Stable | 44 | 68 |
| HS, Cycle 12 Maintenance — Improved | 108 | 231 |
| BI, Cycle 15 Maintenance — Worsened | 40 | 73 |
| BI, Cycle 15 Maintenance — Stable | 54 | 92 |
| BI, Cycle 15 Maintenance — Improved | 55 | 114 |
| S, Cycle 15 Maintenance — Worsened | 18 | 33 |
| S, Cycle 15 Maintenance — Stable | 82 | 162 |
| S, Cycle 15 Maintenance — Improved | 44 | 68 |
| ATD, Cycle 15 Maintenance — Worsened | 26 | 59 |
| ATD, Cycle 15 Maintenance — Stable | 35 | 69 |
| ATD, Cycle 15 Maintenance — Improved | 88 | 151 |
| AS, Cycle 15 Maintenance — Worsened | 22 | 30 |
| AS, Cycle 15 Maintenance — Stable | 86 | 154 |
| AS, Cycle 15 Maintenance — Improved | 42 | 97 |
| PN, Cycle 15 Maintenance — Worsened | 66 | 147 |
| PN, Cycle 15 Maintenance — Stable | 42 | 59 |
| PN, Cycle 15 Maintenance — Improved | 42 | 72 |
| MS, Cycle 15 Maintenance — Worsened | 41 | 80 |
| MS, Cycle 15 Maintenance — Stable | 62 | 116 |
| MS, Cycle 15 Maintenance — Improved | 47 | 83 |
| CSE, Cycle 15 Maintenance — Worsened | 30 | 60 |
| CSE, Cycle 15 Maintenance — Stable | 80 | 144 |
| CSE, Cycle 15 Maintenance — Improved | 40 | 74 |
| HS, Cycle 15 Maintenance — Worsened | 7 | 6 |
| HS, Cycle 15 Maintenance — Stable | 40 | 59 |
| HS, Cycle 15 Maintenance — Improved | 100 | 213 |
| BI, Cycle 17 Maintenance — Worsened | 10 | 15 |
| BI, Cycle 17 Maintenance — Stable | 13 | 32 |
| BI, Cycle 17 Maintenance — Improved | 16 | 35 |
| S, Cycle 17 Maintenance — Worsened | 4 | 10 |
| S, Cycle 17 Maintenance — Stable | 18 | 42 |
| S, Cycle 17 Maintenance — Improved | 16 | 27 |
| ATD, Cycle 17 Maintenance — Worsened | 8 | 16 |
| ATD, Cycle 17 Maintenance — Stable | 6 | 17 |
| ATD, Cycle 17 Maintenance — Improved | 25 | 48 |
| AS, Cycle 17 Maintenance — Worsened | 7 | 9 |
| AS, Cycle 17 Maintenance — Stable | 19 | 38 |
| AS, Cycle 17 Maintenance — Improved | 14 | 36 |
| PN, Cycle 17 Maintenance — Worsened | 19 | 45 |
| PN, Cycle 17 Maintenance — Stable | 7 | 19 |
| PN, Cycle 17 Maintenance — Improved | 14 | 19 |
| MS, Cycle 17 Maintenance — Worsened | 10 | 25 |
| MS, Cycle 17 Maintenance — Stable | 11 | 31 |
| MS, Cycle 17 Maintenance — Improved | 19 | 27 |
| CSE, Cycle 17 Maintenance — Worsened | 7 | 20 |
| CSE, Cycle 17 Maintenance — Stable | 20 | 38 |
| CSE, Cycle 17 Maintenance — Improved | 13 | 25 |
| HS, Cycle 17 Maintenance — Worsened | 1 | 2 |
| HS, Cycle 17 Maintenance — Stable | 10 | 14 |
| HS, Cycle 17 Maintenance — Improved | 28 | 66 |
| BI, Cycle 23 Maintenance — Worsened | 9 | 25 |
| BI, Cycle 23 Maintenance — Stable | 20 | 37 |
| BI, Cycle 23 Maintenance — Improved | 26 | 37 |
| S, Cycle 23 Maintenance — Worsened | 4 | 9 |
| S, Cycle 23 Maintenance — Stable | 36 | 52 |
| S, Cycle 23 Maintenance — Improved | 14 | 31 |
| ATD, Cycle 23 Maintenance — Worsened | 8 | 21 |
| ATD, Cycle 23 Maintenance — Stable | 15 | 20 |
| ATD, Cycle 23 Maintenance — Improved | 32 | 57 |
| AS, Cycle 23 Maintenance — Worsened | 8 | 12 |
| AS, Cycle 23 Maintenance — Stable | 34 | 52 |
| AS, Cycle 23 Maintenance — Improved | 14 | 35 |
| PN, Cycle 23 Maintenance — Worsened | 20 | 50 |
| PN, Cycle 23 Maintenance — Stable | 18 | 17 |
| PN, Cycle 23 Maintenance — Improved | 18 | 32 |
| MS, Cycle 23 Maintenance — Worsened | 18 | 28 |
| MS, Cycle 23 Maintenance — Stable | 25 | 46 |
| MS, Cycle 23 Maintenance — Improved | 13 | 26 |
| CSE, Cycle 23 Maintenance — Worsened | 9 | 21 |
| CSE, Cycle 23 Maintenance — Stable | 28 | 48 |
| CSE, Cycle 23 Maintenance — Improved | 19 | 30 |
| HS, Cycle 23 Maintenance — Worsened | 4 | 6 |
| HS, Cycle 23 Maintenance — Stable | 17 | 17 |
| HS, Cycle 23 Maintenance — Improved | 35 | 74 |
| BI, Cycle 29 Maintenance — Worsened | 13 | 26 |
| BI, Cycle 29 Maintenance — Stable | 18 | 29 |
| BI, Cycle 29 Maintenance — Improved | 20 | 38 |
| S, Cycle 29 Maintenance — Worsened | 5 | 11 |
| S, Cycle 29 Maintenance — Stable | 25 | 46 |
| S, Cycle 29 Maintenance — Improved | 19 | 28 |
| ATD, Cycle 29 Maintenance — Worsened | 8 | 18 |
| ATD, Cycle 29 Maintenance — Stable | 11 | 21 |
| ATD, Cycle 29 Maintenance — Improved | 32 | 55 |
| AS, Cycle 29 Maintenance — Worsened | 9 | 14 |
| AS, Cycle 29 Maintenance — Stable | 30 | 52 |
| AS, Cycle 29 Maintenance — Improved | 12 | 28 |
| PN, Cycle 29 Maintenance — Worsened | 17 | 48 |
| PN, Cycle 29 Maintenance — Stable | 16 | 20 |
| PN, Cycle 29 Maintenance — Improved | 17 | 26 |
| MS, Cycle 29 Maintenance — Worsened | 14 | 24 |
| MS, Cycle 29 Maintenance — Stable | 16 | 45 |
| MS, Cycle 29 Maintenance — Improved | 20 | 25 |
| CSE, Cycle 29 Maintenance — Worsened | 7 | 19 |
| CSE, Cycle 29 Maintenance — Stable | 30 | 54 |
| CSE, Cycle 29 Maintenance — Improved | 13 | 21 |
| HS, Cycle 29 Maintenance — Worsened | 1 | 6 |
| HS, Cycle 29 Maintenance — Stable | 14 | 19 |
| HS, Cycle 29 Maintenance — Improved | 35 | 68 |
| BI, Cycle 35 Maintenance — Worsened | 13 | 19 |
| BI, Cycle 35 Maintenance — Stable | 11 | 35 |
| BI, Cycle 35 Maintenance — Improved | 21 | 31 |
| S, Cycle 35 Maintenance — Worsened | 5 | 12 |
| S, Cycle 35 Maintenance — Stable | 26 | 47 |
| S, Cycle 35 Maintenance — Improved | 13 | 21 |
| ATD, Cycle 35 Maintenance — Worsened | 9 | 20 |
| ATD, Cycle 35 Maintenance — Stable | 11 | 14 |
| ATD, Cycle 35 Maintenance — Improved | 25 | 50 |
| AS, Cycle 35 Maintenance — Worsened | 6 | 15 |
| AS, Cycle 35 Maintenance — Stable | 25 | 48 |
| AS, Cycle 35 Maintenance — Improved | 13 | 23 |
| PN, Cycle 35 Maintenance — Worsened | 14 | 33 |
| PN, Cycle 35 Maintenance — Stable | 19 | 28 |
| PN, Cycle 35 Maintenance — Improved | 12 | 25 |
| MS, Cycle 35 Maintenance — Worsened | 9 | 26 |
| MS, Cycle 35 Maintenance — Stable | 17 | 38 |
| MS, Cycle 35 Maintenance — Improved | 19 | 22 |
| CSE, Cycle 35 Maintenance — Worsened | 10 | 18 |
| CSE, Cycle 35 Maintenance — Stable | 24 | 42 |
| CSE, Cycle 35 Maintenance — Improved | 11 | 26 |
| HS, Cycle 35 Maintenance — Worsened | 2 | 6 |
| HS, Cycle 35 Maintenance — Stable | 15 | 14 |
| HS, Cycle 35 Maintenance — Improved | 28 | 64 |
| BI, Cycle 41 Maintenance — Worsened | 23 | 30 |
| BI, Cycle 41 Maintenance — Stable | 15 | 36 |
| BI, Cycle 41 Maintenance — Improved | 19 | 38 |
| S, Cycle 41 Maintenance — Worsened | 6 | 14 |
| S, Cycle 41 Maintenance — Stable | 30 | 53 |
| S, Cycle 41 Maintenance — Improved | 21 | 34 |
| ATD, Cycle 41 Maintenance — Worsened | 10 | 26 |
| ATD, Cycle 41 Maintenance — Stable | 13 | 21 |
| ATD, Cycle 41 Maintenance — Improved | 34 | 57 |
| AS, Cycle 41 Maintenance — Worsened | 11 | 16 |
| AS, Cycle 41 Maintenance — Stable | 31 | 52 |
| AS, Cycle 41 Maintenance — Improved | 15 | 36 |
| PN, Cycle 41 Maintenance — Worsened | 25 | 52 |
| PN, Cycle 41 Maintenance — Stable | 19 | 27 |
| PN, Cycle 41 Maintenance — Improved | 12 | 24 |
| MS, Cycle 41 Maintenance — Worsened | 18 | 29 |
| MS, Cycle 41 Maintenance — Stable | 19 | 51 |
| MS, Cycle 41 Maintenance — Improved | 19 | 23 |
| CSE, Cycle 41 Maintenance — Worsened | 15 | 20 |
| CSE, Cycle 41 Maintenance — Stable | 26 | 50 |
| CSE, Cycle 41 Maintenance — Improved | 15 | 33 |
| HS, Cycle 41 Maintenance — Worsened | 3 | 9 |
| HS, Cycle 41 Maintenance — Stable | 17 | 17 |
| HS, Cycle 41 Maintenance — Improved | 37 | 77 |
| BI, Cycle 47 Maintenance — Worsened | 14 | 19 |
| BI, Cycle 47 Maintenance — Stable | 18 | 34 |
| BI, Cycle 47 Maintenance — Improved | 15 | 33 |
| S, Cycle 47 Maintenance — Worsened | 6 | 6 |
| S, Cycle 47 Maintenance — Stable | 21 | 46 |
| S, Cycle 47 Maintenance — Improved | 20 | 27 |
| ATD, Cycle 47 Maintenance — Worsened | 7 | 19 |
| ATD, Cycle 47 Maintenance — Stable | 9 | 19 |
| ATD, Cycle 47 Maintenance — Improved | 31 | 47 |
| AS, Cycle 47 Maintenance — Worsened | 10 | 16 |
| AS, Cycle 47 Maintenance — Stable | 28 | 44 |
| AS, Cycle 47 Maintenance — Improved | 9 | 26 |
| PN, Cycle 47 Maintenance — Worsened | 21 | 40 |
| PN, Cycle 47 Maintenance — Stable | 14 | 25 |
| PN, Cycle 47 Maintenance — Improved | 12 | 21 |
| MS, Cycle 47 Maintenance — Worsened | 12 | 24 |
| MS, Cycle 47 Maintenance — Stable | 19 | 43 |
| MS, Cycle 47 Maintenance — Improved | 16 | 19 |
| CSE, Cycle 47 Maintenance — Worsened | 9 | 18 |
| CSE, Cycle 47 Maintenance — Stable | 29 | 44 |
| CSE, Cycle 47 Maintenance — Improved | 9 | 24 |
| HS, Cycle 47 Maintenance — Worsened | 5 | 6 |
| HS, Cycle 47 Maintenance — Stable | 12 | 16 |
| HS, Cycle 47 Maintenance — Improved | 30 | 60 |
| BI, Cycle 53 Maintenance — Worsened | 10 | 14 |
| BI, Cycle 53 Maintenance — Stable | 8 | 20 |
| BI, Cycle 53 Maintenance — Improved | 8 | 20 |
| S, Cycle 53 Maintenance — Worsened | 4 | 5 |
| S, Cycle 53 Maintenance — Stable | 11 | 32 |
| S, Cycle 53 Maintenance — Improved | 11 | 14 |
| ATD, Cycle 53 Maintenance — Worsened | 3 | 12 |
| ATD, Cycle 53 Maintenance — Stable | 5 | 9 |
| ATD, Cycle 53 Maintenance — Improved | 18 | 33 |
| AS, Cycle 53 Maintenance — Worsened | 5 | 11 |
| AS, Cycle 53 Maintenance — Stable | 15 | 33 |
| AS, Cycle 53 Maintenance — Improved | 6 | 10 |
| PN, Cycle 53 Maintenance — Worsened | 7 | 27 |
| PN, Cycle 53 Maintenance — Stable | 13 | 15 |
| PN, Cycle 53 Maintenance — Improved | 6 | 11 |
| MS, Cycle 53 Maintenance — Worsened | 7 | 24 |
| MS, Cycle 53 Maintenance — Stable | 9 | 18 |
| MS, Cycle 53 Maintenance — Improved | 10 | 11 |
| CSE, Cycle 53 Maintenance — Worsened | 4 | 11 |
| CSE, Cycle 53 Maintenance — Stable | 14 | 33 |
| CSE, Cycle 53 Maintenance — Improved | 8 | 9 |
| HS, Cycle 53 Maintenance — Worsened | 4 | 2 |
| HS, Cycle 53 Maintenance — Stable | 8 | 11 |
| HS, Cycle 53 Maintenance — Improved | 14 | 41 |
| BI, Cycle 59 Maintenance — Worsened | 6 | 7 |
| BI, Cycle 59 Maintenance — Stable | 6 | 11 |
| BI, Cycle 59 Maintenance — Improved | 6 | 17 |
| S, Cycle 59 Maintenance — Worsened | 1 | 3 |
| S, Cycle 59 Maintenance — Stable | 9 | 20 |
| S, Cycle 59 Maintenance — Improved | 8 | 11 |
| ATD, Cycle 59 Maintenance — Worsened | 3 | 4 |
| ATD, Cycle 59 Maintenance — Stable | 5 | 6 |
| ATD, Cycle 59 Maintenance — Improved | 10 | 25 |
| AS, Cycle 59 Maintenance — Worsened | 3 | 6 |
| AS, Cycle 59 Maintenance — Stable | 12 | 20 |
| AS, Cycle 59 Maintenance — Improved | 3 | 9 |
| PN, Cycle 59 Maintenance — Worsened | 7 | 15 |
| PN, Cycle 59 Maintenance — Stable | 6 | 12 |
| PN, Cycle 59 Maintenance — Improved | 5 | 8 |
| MS, Cycle 59 Maintenance — Worsened | 5 | 9 |
| MS, Cycle 59 Maintenance — Stable | 6 | 17 |
| MS, Cycle 59 Maintenance — Improved | 7 | 9 |
| CSE, Cycle 59 Maintenance — Worsened | 3 | 6 |
| CSE, Cycle 59 Maintenance — Stable | 10 | 22 |
| CSE, Cycle 59 Maintenance — Improved | 5 | 7 |
| HS, Cycle 59 Maintenance — Worsened | 4 | 3 |
| HS, Cycle 59 Maintenance — Stable | 4 | 6 |
| HS, Cycle 59 Maintenance — Improved | 10 | 26 |
| BI, Cycle 65 Maintenance — Worsened | 3 | 4 |
| BI, Cycle 65 Maintenance — Stable | 4 | 10 |
| BI, Cycle 65 Maintenance — Improved | 5 | 11 |
| S, Cycle 65 Maintenance — Worsened | 2 | 3 |
| S, Cycle 65 Maintenance — Stable | 5 | 12 |
| S, Cycle 65 Maintenance — Improved | 5 | 9 |
| ATD, Cycle 65 Maintenance — Worsened | 1 | 5 |
| ATD, Cycle 65 Maintenance — Stable | 5 | 5 |
| ATD, Cycle 65 Maintenance — Improved | 6 | 15 |
| AS, Cycle 65 Maintenance — Worsened | 2 | 4 |
| AS, Cycle 65 Maintenance — Stable | 9 | 17 |
| AS, Cycle 65 Maintenance — Improved | 1 | 4 |
| PN, Cycle 65 Maintenance — Worsened | 5 | 9 |
| PN, Cycle 65 Maintenance — Stable | 5 | 9 |
| PN, Cycle 65 Maintenance — Improved | 2 | 7 |
| MS, Cycle 65 Maintenance — Worsened | 3 | 6 |
| MS, Cycle 65 Maintenance — Stable | 3 | 14 |
| MS, Cycle 65 Maintenance — Improved | 6 | 5 |
| CSE, Cycle 65 Maintenance — Worsened | 2 | 5 |
| CSE, Cycle 65 Maintenance — Stable | 9 | 14 |
| CSE, Cycle 65 Maintenance — Improved | 1 | 6 |
| HS, Cycle 65 Maintenance — Worsened | 4 | 2 |
| HS, Cycle 65 Maintenance — Stable | 4 | 3 |
| HS, Cycle 65 Maintenance — Improved | 4 | 20 |
| BI, Cycle 71 Maintenance — Worsened | 1 | 3 |
| BI, Cycle 71 Maintenance — Stable | 1 | 6 |
| BI, Cycle 71 Maintenance — Improved | 6 | 4 |
| S, Cycle 71 Maintenance — Worsened | 2 | 0 |
| S, Cycle 71 Maintenance — Stable | 4 | 10 |
| S, Cycle 71 Maintenance — Improved | 1 | 3 |
| ATD, Cycle 71 Maintenance — Worsened | 1 | 2 |
| ATD, Cycle 71 Maintenance — Stable | 1 | 4 |
| ATD, Cycle 71 Maintenance — Improved | 6 | 7 |
| AS, Cycle 71 Maintenance — Worsened | 3 | 1 |
| AS, Cycle 71 Maintenance — Stable | 4 | 11 |
| AS, Cycle 71 Maintenance — Improved | 1 | 1 |
| PN, Cycle 71 Maintenance — Worsened | 2 | 6 |
| PN, Cycle 71 Maintenance — Stable | 4 | 4 |
| PN, Cycle 71 Maintenance — Improved | 1 | 3 |
| MS, Cycle 71 Maintenance — Worsened | 1 | 3 |
| MS, Cycle 71 Maintenance — Stable | 1 | 7 |
| MS, Cycle 71 Maintenance — Improved | 5 | 3 |
| CSE, Cycle 71 Maintenance — Worsened | 1 | 1 |
| CSE, Cycle 71 Maintenance — Stable | 5 | 10 |
| CSE, Cycle 71 Maintenance — Improved | 1 | 2 |
| HS, Cycle 71 Maintenance — Worsened | 3 | 0 |
| HS, Cycle 71 Maintenance — Stable | 2 | 5 |
| HS, Cycle 71 Maintenance — Improved | 3 | 8 |
| BI, Cycle 77 Maintenance — Worsened | 1 | 3 |
| BI, Cycle 77 Maintenance — Stable | 1 | 2 |
| BI, Cycle 77 Maintenance — Improved | 2 | 6 |
| S, Cycle 77 Maintenance — Worsened | 1 | 2 |
| S, Cycle 77 Maintenance — Stable | 2 | 4 |
| S, Cycle 77 Maintenance — Improved | 0 | 5 |
| ATD, Cycle 77 Maintenance — Worsened | 0 | 2 |
| ATD, Cycle 77 Maintenance — Stable | 1 | 1 |
| ATD, Cycle 77 Maintenance — Improved | 3 | 8 |
| AS, Cycle 77 Maintenance — Worsened | 0 | 2 |
| AS, Cycle 77 Maintenance — Stable | 2 | 6 |
| AS, Cycle 77 Maintenance — Improved | 2 | 3 |
| PN, Cycle 77 Maintenance — Worsened | 2 | 6 |
| PN, Cycle 77 Maintenance — Stable | 1 | 1 |
| PN, Cycle 77 Maintenance — Improved | 1 | 4 |
| MS, Cycle 77 Maintenance — Worsened | 0 | 5 |
| MS, Cycle 77 Maintenance — Stable | 0 | 4 |
| MS, Cycle 77 Maintenance — Improved | 4 | 2 |
| CSE, Cycle 77 Maintenance — Worsened | 1 | 1 |
| CSE, Cycle 77 Maintenance — Stable | 2 | 8 |
| CSE, Cycle 77 Maintenance — Improved | 1 | 2 |
| HS, Cycle 77 Maintenance — Worsened | 0 | 3 |
| HS, Cycle 77 Maintenance — Stable | 2 | 1 |
| HS, Cycle 77 Maintenance — Improved | 2 | 7 |
| BI, Cycle 83 Maintenance — Worsened | 1 | 1 |
| BI, Cycle 83 Maintenance — Stable | 0 | 0 |
| BI, Cycle 83 Maintenance — Improved | 2 | 4 |
| S, Cycle 83 Maintenance — Worsened | 1 | 1 |
| S, Cycle 83 Maintenance — Stable | 1 | 0 |
| S, Cycle 83 Maintenance — Improved | 1 | 4 |
| ATD, Cycle 83 Maintenance — Worsened | 0 | 0 |
| ATD, Cycle 83 Maintenance — Stable | 1 | 0 |
| ATD, Cycle 83 Maintenance — Improved | 2 | 5 |
| AS, Cycle 83 Maintenance — Worsened | 0 | 0 |
| AS, Cycle 83 Maintenance — Stable | 2 | 4 |
| AS, Cycle 83 Maintenance — Improved | 1 | 1 |
| PN, Cycle 83 Maintenance — Worsened | 0 | 1 |
| PN, Cycle 83 Maintenance — Stable | 1 | 0 |
| PN, Cycle 83 Maintenance — Improved | 2 | 4 |
| MS, Cycle 83 Maintenance — Worsened | 0 | 1 |
| MS, Cycle 83 Maintenance — Stable | 0 | 4 |
| MS, Cycle 83 Maintenance — Improved | 3 | 0 |
| CSE, Cycle 83 Maintenance — Worsened | 1 | 0 |
| CSE, Cycle 83 Maintenance — Stable | 1 | 2 |
| CSE, Cycle 83 Maintenance — Improved | 1 | 3 |
| HS, Cycle 83 Maintenance — Worsened | 0 | 1 |
| HS, Cycle 83 Maintenance — Stable | 2 | 0 |
| HS, Cycle 83 Maintenance — Improved | 1 | 4 |
| BI, Cycle 89 Maintenance — Worsened | 0 | 0 |
| BI, Cycle 89 Maintenance — Stable | 0 | 0 |
| BI, Cycle 89 Maintenance — Improved | 0 | 2 |
| S, Cycle 89 Maintenance — Worsened | 0 | 0 |
| S, Cycle 89 Maintenance — Stable | 0 | 0 |
| S, Cycle 89 Maintenance — Improved | 0 | 1 |
| ATD, Cycle 89 Maintenance — Worsened | 0 | 0 |
| ATD, Cycle 89 Maintenance — Stable | 0 | 0 |
| ATD, Cycle 89 Maintenance — Improved | 0 | 2 |
| AS, Cycle 89 Maintenance — Worsened | 0 | 0 |
| AS, Cycle 89 Maintenance — Stable | 0 | 0 |
| AS, Cycle 89 Maintenance — Improved | 0 | 2 |
| PN, Cycle 89 Maintenance — Worsened | 0 | 0 |
| PN, Cycle 89 Maintenance — Stable | 0 | 1 |
| PN, Cycle 89 Maintenance — Improved | 0 | 1 |
| MS, Cycle 89 Maintenance — Worsened | 0 | 0 |
| MS, Cycle 89 Maintenance — Stable | 0 | 2 |
| MS, Cycle 89 Maintenance — Improved | 0 | 0 |
| CSE, Cycle 89 Maintenance — Worsened | 0 | 0 |
| CSE, Cycle 89 Maintenance — Stable | 0 | 0 |
| CSE, Cycle 89 Maintenance — Improved | 0 | 2 |
| HS, Cycle 89 Maintenance — Worsened | 0 | 0 |
| HS, Cycle 89 Maintenance — Stable | 0 | 0 |
| HS, Cycle 89 Maintenance — Improved | 0 | 2 |
| BI, End of treatment — Worsened | 45 | 94 |
| BI, End of treatment — Stable | 68 | 109 |
| BI, End of treatment — Improved | 68 | 134 |
| S, End of treatment — Worsened | 21 | 52 |
| S, End of treatment — Stable | 122 | 206 |
| S, End of treatment — Improved | 33 | 66 |
| ATD, End of treatment — Worsened | 65 | 124 |
| ATD, End of treatment — Stable | 43 | 72 |
| ATD, End of treatment — Improved | 72 | 142 |
| AS, End of treatment — Worsened | 45 | 59 |
| AS, End of treatment — Stable | 90 | 186 |
| AS, End of treatment — Improved | 46 | 96 |
| PN, End of treatment — Worsened | 79 | 171 |
| PN, End of treatment — Stable | 52 | 83 |
| PN, End of treatment — Improved | 50 | 85 |
| MS, End of treatment — Worsened | 42 | 97 |
| MS, End of treatment — Stable | 83 | 149 |
| MS, End of treatment — Improved | 56 | 94 |
| CSE, End of treatment — Worsened | 35 | 75 |
| CSE, End of treatment — Stable | 94 | 180 |
| CSE, End of treatment — Improved | 52 | 85 |
| HS, End of treatment — Worsened | 13 | 24 |
| HS, End of treatment — Stable | 45 | 76 |
| HS, End of treatment — Improved | 122 | 240 |
| BI, Safety Follow-up — Worsened | 42 | 94 |
| BI, Safety Follow-up — Stable | 47 | 84 |
| BI, Safety Follow-up — Improved | 52 | 102 |
| S, Safety Follow-up — Worsened | 16 | 42 |
| S, Safety Follow-up — Stable | 90 | 175 |
| S, Safety Follow-up — Improved | 28 | 55 |
| ATD, Safety Follow-up — Worsened | 50 | 111 |
| ATD, Safety Follow-up — Stable | 32 | 67 |
| ATD, Safety Follow-up — Improved | 59 | 103 |
| AS, Safety Follow-up — Worsened | 22 | 55 |
| AS, Safety Follow-up — Stable | 78 | 152 |
| AS, Safety Follow-up — Improved | 43 | 75 |
| PN, Safety Follow-up — Worsened | 72 | 151 |
| PN, Safety Follow-up — Stable | 36 | 70 |
| PN, Safety Follow-up — Improved | 35 | 61 |
| MS, Safety Follow-up — Worsened | 29 | 83 |
| MS, Safety Follow-up — Stable | 67 | 130 |
| MS, Safety Follow-up — Improved | 47 | 69 |
| CSE, Safety Follow-up — Worsened | 29 | 66 |
| CSE, Safety Follow-up — Stable | 77 | 139 |
| CSE, Safety Follow-up — Improved | 37 | 77 |
| HS, Safety Follow-up — Worsened | 15 | 26 |
| HS, Safety Follow-up — Stable | 37 | 52 |
| HS, Safety Follow-up — Improved | 90 | 203 |
| BI, LTFU (EOT + 3 months) — Worsened | 47 | 79 |
| BI, LTFU (EOT + 3 months) — Stable | 46 | 83 |
| BI, LTFU (EOT + 3 months) — Improved | 41 | 81 |
| S, LTFU (EOT + 3 months) — Worsened | 24 | 35 |
| S, LTFU (EOT + 3 months) — Stable | 79 | 157 |
| S, LTFU (EOT + 3 months) — Improved | 25 | 42 |
| ATD, LTFU (EOT + 3 months) — Worsened | 46 | 88 |
| ATD, LTFU (EOT + 3 months) — Stable | 33 | 47 |
| ATD, LTFU (EOT + 3 months) — Improved | 55 | 108 |
| AS, LTFU (EOT + 3 months) — Worsened | 23 | 44 |
| AS, LTFU (EOT + 3 months) — Stable | 68 | 132 |
| AS, LTFU (EOT + 3 months) — Improved | 43 | 67 |
| PN, LTFU (EOT + 3 months) — Worsened | 63 | 135 |
| PN, LTFU (EOT + 3 months) — Stable | 39 | 56 |
| PN, LTFU (EOT + 3 months) — Improved | 32 | 52 |
| MS, LTFU (EOT + 3 months) — Worsened | 27 | 56 |
| MS, LTFU (EOT + 3 months) — Stable | 52 | 108 |
| MS, LTFU (EOT + 3 months) — Improved | 55 | 78 |
| CSE, LTFU (EOT + 3 months) — Worsened | 30 | 67 |
| CSE, LTFU (EOT + 3 months) — Stable | 79 | 116 |
| CSE, LTFU (EOT + 3 months) — Improved | 25 | 60 |
| HS, LTFU (EOT + 3 months) — Worsened | 17 | 25 |
| HS, LTFU (EOT + 3 months) — Stable | 29 | 42 |
| HS, LTFU (EOT + 3 months) — Improved | 86 | 173 |
| BI, LTFU (EOT + 9 months) — Worsened | 36 | 56 |
| BI, LTFU (EOT + 9 months) — Stable | 37 | 56 |
| BI, LTFU (EOT + 9 months) — Improved | 34 | 68 |
| S, LTFU (EOT + 9 months) — Worsened | 13 | 31 |
| S, LTFU (EOT + 9 months) — Stable | 74 | 110 |
| S, LTFU (EOT + 9 months) — Improved | 19 | 31 |
| ATD, LTFU (EOT + 9 months) — Worsened | 42 | 67 |
| ATD, LTFU (EOT + 9 months) — Stable | 17 | 28 |
| ATD, LTFU (EOT + 9 months) — Improved | 47 | 84 |
| AS, LTFU (EOT + 9 months) — Worsened | 18 | 35 |
| AS, LTFU (EOT + 9 months) — Stable | 58 | 86 |
| AS, LTFU (EOT + 9 months) — Improved | 31 | 59 |
| PN, LTFU (EOT + 9 months) — Worsened | 60 | 92 |
| PN, LTFU (EOT + 9 months) — Stable | 24 | 47 |
| PN, LTFU (EOT + 9 months) — Improved | 23 | 41 |
| MS, LTFU (EOT + 9 months) — Worsened | 22 | 38 |
| MS, LTFU (EOT + 9 months) — Stable | 50 | 82 |
| MS, LTFU (EOT + 9 months) — Improved | 35 | 60 |
| CSE, LTFU (EOT + 9 months) — Worsened | 32 | 48 |
| CSE, LTFU (EOT + 9 months) — Stable | 54 | 88 |
| CSE, LTFU (EOT + 9 months) — Improved | 21 | 44 |
| HS, LTFU (EOT + 9 months) — Worsened | 12 | 16 |
| HS, LTFU (EOT + 9 months) — Stable | 26 | 40 |
| HS, LTFU (EOT + 9 months) — Improved | 69 | 123 |
| BI, LTFU (EOT + 15 months) — Worsened | 22 | 42 |
| BI, LTFU (EOT + 15 months) — Stable | 31 | 46 |
| BI, LTFU (EOT + 15 months) — Improved | 23 | 61 |
| S, LTFU (EOT + 15 months) — Worsened | 12 | 26 |
| S, LTFU (EOT + 15 months) — Stable | 43 | 86 |
| S, LTFU (EOT + 15 months) — Improved | 15 | 31 |
| ATD, LTFU (EOT + 15 months) — Worsened | 30 | 54 |
| ATD, LTFU (EOT + 15 months) — Stable | 16 | 33 |
| ATD, LTFU (EOT + 15 months) — Improved | 30 | 61 |
| AS, LTFU (EOT + 15 months) — Worsened | 19 | 23 |
| AS, LTFU (EOT + 15 months) — Stable | 37 | 81 |
| AS, LTFU (EOT + 15 months) — Improved | 20 | 45 |
| PN, LTFU (EOT + 15 months) — Worsened | 43 | 79 |
| PN, LTFU (EOT + 15 months) — Stable | 13 | 40 |
| PN, LTFU (EOT + 15 months) — Improved | 20 | 27 |
| MS, LTFU (EOT + 15 months) — Worsened | 17 | 37 |
| MS, LTFU (EOT + 15 months) — Stable | 41 | 78 |
| MS, LTFU (EOT + 15 months) — Improved | 18 | 34 |
| CSE, LTFU (EOT + 15 months) — Worsened | 19 | 45 |
| CSE, LTFU (EOT + 15 months) — Stable | 41 | 73 |
| CSE, LTFU (EOT + 15 months) — Improved | 16 | 29 |
| HS, LTFU (EOT + 15 months) — Worsened | 7 | 13 |
| HS, LTFU (EOT + 15 months) — Stable | 21 | 34 |
| HS, LTFU (EOT + 15 months) — Improved | 48 | 101 |
| BI, LTFU (EOT + 21 months) — Worsened | 12 | 26 |
| BI, LTFU (EOT + 21 months) — Stable | 18 | 31 |
| BI, LTFU (EOT + 21 months) — Improved | 16 | 39 |
| S, LTFU (EOT + 21 months) — Worsened | 5 | 13 |
| S, LTFU (EOT + 21 months) — Stable | 26 | 62 |
| S, LTFU (EOT + 21 months) — Improved | 13 | 18 |
| ATD, LTFU (EOT + 21 months) — Worsened | 17 | 36 |
| ATD, LTFU (EOT + 21 months) — Stable | 11 | 18 |
| ATD, LTFU (EOT + 21 months) — Improved | 18 | 42 |
| AS, LTFU (EOT + 21 months) — Worsened | 12 | 19 |
| AS, LTFU (EOT + 21 months) — Stable | 25 | 48 |
| AS, LTFU (EOT + 21 months) — Improved | 10 | 29 |
| PN, LTFU (EOT + 21 months) — Worsened | 18 | 53 |
| PN, LTFU (EOT + 21 months) — Stable | 13 | 25 |
| PN, LTFU (EOT + 21 months) — Improved | 15 | 18 |
| MS, LTFU (EOT + 21 months) — Worsened | 12 | 25 |
| MS, LTFU (EOT + 21 months) — Stable | 21 | 44 |
| MS, LTFU (EOT + 21 months) — Improved | 14 | 27 |
| CSE, LTFU (EOT + 21 months) — Worsened | 10 | 25 |
| CSE, LTFU (EOT + 21 months) — Stable | 27 | 50 |
| CSE, LTFU (EOT + 21 months) — Improved | 9 | 21 |
| HS, LTFU (EOT + 21 months) — Worsened | 4 | 11 |
| HS, LTFU (EOT + 21 months) — Stable | 6 | 22 |
| HS, LTFU (EOT + 21 months) — Improved | 37 | 62 |
| BI, LTFU (EOT + 27 months) — Worsened | 10 | 21 |
| BI, LTFU (EOT + 27 months) — Stable | 15 | 22 |
| BI, LTFU (EOT + 27 months) — Improved | 10 | 26 |
| S, LTFU (EOT + 27 months) — Worsened | 6 | 9 |
| S, LTFU (EOT + 27 months) — Stable | 18 | 41 |
| S, LTFU (EOT + 27 months) — Improved | 8 | 16 |
| ATD, LTFU (EOT + 27 months) — Worsened | 16 | 28 |
| ATD, LTFU (EOT + 27 months) — Stable | 7 | 14 |
| ATD, LTFU (EOT + 27 months) — Improved | 11 | 27 |
| AS, LTFU (EOT + 27 months) — Worsened | 5 | 15 |
| AS, LTFU (EOT + 27 months) — Stable | 21 | 38 |
| AS, LTFU (EOT + 27 months) — Improved | 9 | 16 |
| PN, LTFU (EOT + 27 months) — Worsened | 19 | 36 |
| PN, LTFU (EOT + 27 months) — Stable | 9 | 16 |
| PN, LTFU (EOT + 27 months) — Improved | 7 | 17 |
| MS, LTFU (EOT + 27 months) — Worsened | 8 | 17 |
| MS, LTFU (EOT + 27 months) — Stable | 18 | 29 |
| MS, LTFU (EOT + 27 months) — Improved | 9 | 23 |
| CSE, LTFU (EOT + 27 months) — Worsened | 11 | 24 |
| CSE, LTFU (EOT + 27 months) — Stable | 18 | 31 |
| CSE, LTFU (EOT + 27 months) — Improved | 6 | 14 |
| HS, LTFU (EOT + 27 months) — Worsened | 6 | 8 |
| HS, LTFU (EOT + 27 months) — Stable | 7 | 14 |
| HS, LTFU (EOT + 27 months) — Improved | 22 | 47 |
| BI, LTFU (EOT + 33 months) — Worsened | 1 | 12 |
| BI, LTFU (EOT + 33 months) — Stable | 8 | 12 |
| BI, LTFU (EOT + 33 months) — Improved | 7 | 15 |
| S, LTFU (EOT + 33 months) — Worsened | 0 | 6 |
| S, LTFU (EOT + 33 months) — Stable | 13 | 23 |
| S, LTFU (EOT + 33 months) — Improved | 3 | 9 |
| ATD, LTFU (EOT + 33 months) — Worsened | 9 | 15 |
| ATD, LTFU (EOT + 33 months) — Stable | 4 | 6 |
| ATD, LTFU (EOT + 33 months) — Improved | 3 | 18 |
| AS, LTFU (EOT + 33 months) — Worsened | 4 | 7 |
| AS, LTFU (EOT + 33 months) — Stable | 7 | 25 |
| AS, LTFU (EOT + 33 months) — Improved | 5 | 7 |
| PN, LTFU (EOT + 33 months) — Worsened | 8 | 19 |
| PN, LTFU (EOT + 33 months) — Stable | 5 | 12 |
| PN, LTFU (EOT + 33 months) — Improved | 2 | 8 |
| MS, LTFU (EOT + 33 months) — Worsened | 2 | 12 |
| MS, LTFU (EOT + 33 months) — Stable | 8 | 17 |
| MS, LTFU (EOT + 33 months) — Improved | 6 | 10 |
| CSE, LTFU (EOT + 33 months) — Worsened | 4 | 11 |
| CSE, LTFU (EOT + 33 months) — Stable | 7 | 20 |
| CSE, LTFU (EOT + 33 months) — Improved | 4 | 8 |
| HS, LTFU (EOT + 33 months) — Worsened | 1 | 5 |
| HS, LTFU (EOT + 33 months) — Stable | 3 | 11 |
| HS, LTFU (EOT + 33 months) — Improved | 11 | 23 |
| BI, LTFU (EOT + 39 months) — Worsened | 3 | 11 |
| BI, LTFU (EOT + 39 months) — Stable | 6 | 6 |
| BI, LTFU (EOT + 39 months) — Improved | 2 | 10 |
| S, LTFU (EOT + 39 months) — Worsened | 0 | 6 |
| S, LTFU (EOT + 39 months) — Stable | 10 | 18 |
| S, LTFU (EOT + 39 months) — Improved | 1 | 3 |
| ATD, LTFU (EOT + 39 months) — Worsened | 3 | 12 |
| ATD, LTFU (EOT + 39 months) — Stable | 3 | 5 |
| ATD, LTFU (EOT + 39 months) — Improved | 5 | 10 |
| AS, LTFU (EOT + 39 months) — Worsened | 2 | 5 |
| AS, LTFU (EOT + 39 months) — Stable | 6 | 18 |
| AS, LTFU (EOT + 39 months) — Improved | 3 | 4 |
| PN, LTFU (EOT + 39 months) — Worsened | 5 | 14 |
| PN, LTFU (EOT + 39 months) — Stable | 4 | 8 |
| PN, LTFU (EOT + 39 months) — Improved | 2 | 5 |
| MS, LTFU (EOT + 39 months) — Worsened | 4 | 10 |
| MS, LTFU (EOT + 39 months) — Stable | 6 | 10 |
| MS, LTFU (EOT + 39 months) — Improved | 1 | 7 |
| CSE, LTFU (EOT + 39 months) — Worsened | 3 | 8 |
| CSE, LTFU (EOT + 39 months) — Stable | 7 | 14 |
| CSE, LTFU (EOT + 39 months) — Improved | 1 | 5 |
| HS, LTFU (EOT + 39 months) — Worsened | 1 | 3 |
| HS, LTFU (EOT + 39 months) — Stable | 3 | 5 |
| HS, LTFU (EOT + 39 months) — Improved | 7 | 19 |
| BI, LTFU (EOT + 45 months) — Worsened | 1 | 6 |
| BI, LTFU (EOT + 45 months) — Stable | 2 | 5 |
| BI, LTFU (EOT + 45 months) — Improved | 1 | 5 |
| S, LTFU (EOT + 45 months) — Worsened | 1 | 1 |
| S, LTFU (EOT + 45 months) — Stable | 3 | 11 |
| S, LTFU (EOT + 45 months) — Improved | 0 | 3 |
| ATD, LTFU (EOT + 45 months) — Worsened | 3 | 5 |
| ATD, LTFU (EOT + 45 months) — Stable | 0 | 5 |
| ATD, LTFU (EOT + 45 months) — Improved | 1 | 6 |
| AS, LTFU (EOT + 45 months) — Worsened | 0 | 4 |
| AS, LTFU (EOT + 45 months) — Stable | 2 | 10 |
| AS, LTFU (EOT + 45 months) — Improved | 2 | 2 |
| PN, LTFU (EOT + 45 months) — Worsened | 3 | 11 |
| PN, LTFU (EOT + 45 months) — Stable | 0 | 4 |
| PN, LTFU (EOT + 45 months) — Improved | 1 | 1 |
| MS, LTFU (EOT + 45 months) — Worsened | 0 | 6 |
| MS, LTFU (EOT + 45 months) — Stable | 3 | 5 |
| MS, LTFU (EOT + 45 months) — Improved | 1 | 5 |
| CSE, LTFU (EOT + 45 months) — Worsened | 1 | 5 |
| CSE, LTFU (EOT + 45 months) — Stable | 2 | 10 |
| CSE, LTFU (EOT + 45 months) — Improved | 1 | 1 |
| HS, LTFU (EOT + 45 months) — Worsened | 0 | 1 |
| HS, LTFU (EOT + 45 months) — Stable | 3 | 3 |
| HS, LTFU (EOT + 45 months) — Improved | 1 | 12 |
| BI, LTFU (EOT + 51 months) — Worsened | 1 | 1 |
| BI, LTFU (EOT + 51 months) — Stable | 1 | 1 |
| BI, LTFU (EOT + 51 months) — Improved | 0 | 3 |
| S, LTFU (EOT + 51 months) — Worsened | 1 | 0 |
| S, LTFU (EOT + 51 months) — Stable | 0 | 4 |
| S, LTFU (EOT + 51 months) — Improved | 0 | 1 |
| ATD, LTFU (EOT + 51 months) — Worsened | 2 | 1 |
| ATD, LTFU (EOT + 51 months) — Stable | 0 | 2 |
| ATD, LTFU (EOT + 51 months) — Improved | 0 | 2 |
| AS, LTFU (EOT + 51 months) — Worsened | 0 | 0 |
| AS, LTFU (EOT + 51 months) — Stable | 2 | 5 |
| AS, LTFU (EOT + 51 months) — Improved | 0 | 0 |
| PN, LTFU (EOT + 51 months) — Worsened | 2 | 2 |
| PN, LTFU (EOT + 51 months) — Stable | 0 | 2 |
| PN, LTFU (EOT + 51 months) — Improved | 0 | 1 |
| MS, LTFU (EOT + 51 months) — Worsened | 0 | 1 |
| MS, LTFU (EOT + 51 months) — Stable | 2 | 3 |
| MS, LTFU (EOT + 51 months) — Improved | 0 | 1 |
| CSE, LTFU (EOT + 51 months) — Worsened | 0 | 2 |
| CSE, LTFU (EOT + 51 months) — Stable | 1 | 3 |
| CSE, LTFU (EOT + 51 months) — Improved | 1 | 0 |
| HS, LTFU (EOT + 51 months) — Worsened | 0 | 0 |
| HS, LTFU (EOT + 51 months) — Stable | 1 | 2 |
| HS, LTFU (EOT + 51 months) — Improved | 1 | 3 |
| BI, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| BI, LTFU (EOT + 57 months) — Stable | 1 | 0 |
| BI, LTFU (EOT + 57 months) — Improved | 1 | 1 |
| S, LTFU (EOT + 57 months) — Worsened | 1 | 0 |
| S, LTFU (EOT + 57 months) — Stable | 0 | 1 |
| S, LTFU (EOT + 57 months) — Improved | 0 | 0 |
| ATD, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| ATD, LTFU (EOT + 57 months) — Stable | 2 | 1 |
| ATD, LTFU (EOT + 57 months) — Improved | 0 | 0 |
| AS, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| AS, LTFU (EOT + 57 months) — Stable | 2 | 1 |
| AS, LTFU (EOT + 57 months) — Improved | 0 | 0 |
| PN, LTFU (EOT + 57 months) — Worsened | 2 | 1 |
| PN, LTFU (EOT + 57 months) — Stable | 0 | 0 |
| PN, LTFU (EOT + 57 months) — Improved | 0 | 0 |
| MS, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| MS, LTFU (EOT + 57 months) — Stable | 2 | 0 |
| MS, LTFU (EOT + 57 months) — Improved | 0 | 1 |
| CSE, LTFU (EOT + 57 months) — Worsened | 1 | 0 |
| CSE, LTFU (EOT + 57 months) — Stable | 0 | 1 |
| CSE, LTFU (EOT + 57 months) — Improved | 1 | 0 |
| HS, LTFU (EOT + 57 months) — Worsened | 0 | 0 |
| HS, LTFU (EOT + 57 months) — Stable | 0 | 1 |
| HS, LTFU (EOT + 57 months) — Improved | 1 | 0 |
| BI, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| BI, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| BI, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| S, LTFU (EOT + 63 months) — Worsened | 1 | 0 |
| S, LTFU (EOT + 63 months) — Stable | 0 | 0 |
| S, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| ATD, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| ATD, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| ATD, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| AS, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| AS, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| AS, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| PN, LTFU (EOT + 63 months) — Worsened | 1 | 0 |
| PN, LTFU (EOT + 63 months) — Stable | 0 | 0 |
| PN, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| MS, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| MS, LTFU (EOT + 63 months) — Stable | 1 | 0 |
| MS, LTFU (EOT + 63 months) — Improved | 0 | 0 |
| CSE, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| CSE, LTFU (EOT + 63 months) — Stable | 0 | 0 |
| CSE, LTFU (EOT + 63 months) — Improved | 1 | 0 |
| HS, LTFU (EOT + 63 months) — Worsened | 0 | 0 |
| HS, LTFU (EOT + 63 months) — Stable | 0 | 0 |
| HS, LTFU (EOT + 63 months) — Improved | 1 | 0 |
Collected over All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Not Treated | 33/79 (41.8%) | 35/79 (44.3%) | 51/79 (64.6%) |
| Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1) | 106/159 (66.7%) | 63/159 (39.6%) | 158/159 (99.4%) |
| Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | 235/417 (56.4%) | 190/417 (45.6%) | 417/417 (100%) |
| Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) | 430/745 (57.7%) | 405/745 (54.4%) | 745/745 (100%) |
| Event | Not Treated | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1) | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/79 | 2/159 | 25/417 | 31/745 |
| AnaemiaBlood and lymphatic system disorders | 0/79 | 3/159 | 19/417 | 28/745 |
| Intestinal obstructionGastrointestinal disorders | 3/79 | 3/159 | 11/417 | 17/745 |
| Abdominal painGastrointestinal disorders | 2/79 | 6/159 | 10/417 | 25/745 |
| Platelet count decreasedInvestigations | 1/79 | 1/159 | 10/417 | 28/745 |
| Small intestinal obstructionGastrointestinal disorders | 1/79 | 4/159 | 12/417 | 21/745 |
| PyrexiaGeneral disorders | 0/79 | 4/159 | 2/417 | 21/745 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/79 | 2/159 | 6/417 | 20/745 |
| VomitingGastrointestinal disorders | 2/79 | 1/159 | 4/417 | 9/745 |
| SubileusGastrointestinal disorders | 2/79 | 0/159 | 2/417 | 3/745 |
| Event | Not Treated | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1) | Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 11/79 | 70/159 | 269/417 | 485/745 |
| NauseaGastrointestinal disorders | 15/79 | 86/159 | 251/417 | 443/745 |
| ConstipationGastrointestinal disorders | 7/79 | 70/159 | 193/417 | 365/745 |
| Neuropathy peripheralNervous system disorders | 1/79 | 76/159 | 173/417 | 312/745 |
| FatigueGeneral disorders | 6/79 | 61/159 | 151/417 | 346/745 |
| AlopeciaSkin and subcutaneous tissue disorders | 4/79 | 66/159 | 193/417 | 328/745 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/79 | 64/159 | 155/417 | 293/745 |
| DiarrhoeaGastrointestinal disorders | 11/79 | 63/159 | 148/417 | 296/745 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/79 | 22/159 | 164/417 | 263/745 |
| AstheniaGeneral disorders | 8/79 | 53/159 | 158/417 | 254/745 |
All eligible enrolled participants received SOC during the Cycle 1 Chemotherapy Run-In Period before randomization.
| Age, Continuous(YEARS) | All Enrolled Participants |
|---|---|
| Mean | 62.0 ± 10.81 |
| Sex: Female, Male(Participants) | All Enrolled Participants |
|---|---|
| Female | 1400 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | All Enrolled Participants |
|---|---|
| White | 1245 |
| Black or African American | 30 |
| Asian | 29 |
| American Indian or Alaska Native | 8 |
| Unknown | 80 |
| Not Reported | 8 |
Showing the first 100 of 182 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Ran from Oct 2018 to primary completion in Oct 2024, 72 months.
Results were first posted in Dec 2025, 1 year 2 months after primary completion.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 72 months is above that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Niraparib · Dostarlimab